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SUMMARY
An enzymatic and a novel capillary gas-liquid chromatographic assay have been 
developed and compared for the analysis of red blood cell sorbitol concentrations. 
Factors affecting the performance of both assays were investigated and the analytical 
conditions optimised. The enzyme assay was found to be accurate and precise but 
lacked specificity with at least xylitol also acting as a substrate. The capillary GLC 
assay was accurate and precise with the advantage of increased specificity for polyol 
determinations.
The enzyme assay was used to determine the response of erythrocyte sorbitol content 
in a clinical trial of diabetics treated with oral Sorbinil; a novel aldose reductase 
inhibitor. The sorbitol content was reduced and this trend was reversed upon cessation 
of Sorbinil treatment. The capillary GLC method was used to determine the daily 
effect of oral Sorbinil upon erythrocyte sorbitol and myo-inositol concentrations in a 
clinical trial with diabetic subjects. It was found that Sorbinil therapy reduced the 
raised erythrocyte sorbitol by 60% within the first 24 hours of treatment at a lower 
dose than used in previous studies. The erythrocyte myo-inositol content of diabetic 
subjects was not altered by Sorbinil therapy. However, it was found, for the first time, 
that the myo-inositol level in diabetics was found to be significantly different to 
healthy, normal non-diabetic subjects.
The daily variation in erythrocyte sorbitol and myo-inositol in normal non-diabetic 
subjects was investigated. The levels were found to be very consistent both for 
individuals and as a group and were significantly different to the levels found in 
diabetic subjects.
The activity of erythrocyte aldose reductase was found to be greater in diabetics 
compared to normals. Capillary GLC was used to confirm the erythrocyte accumulation 
of sorbitol upon incubation with glucose. The concentration of other components in the 
erythrocyte were seen to change upon glucose incubation. The increase of one 
component was initially identified by its retention as glucosamine. An attempt to 
correlate the erythrocyte aldose reductase activity with the degree of severity of 
subjects with diabetic neuropathy was unsuccessful. Further work is required to 
optimise the assay conditions.
It is concluded that the erythrocyte sorbitol levels can be used in conjunction with 
other tests and clinical observations to manage the long term complications associated 
with diabetes. In particular, the enzyme assay may be of use as a screening test. The 
capillary GLC assay will be of most use in further studies to determine the polyol and 
carbohydrate changes and their role in the onset of neuropathy.
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CHAPTER 1
INTRODUCTION
1.1 General introduction to polvols
Polyols are polyhydric alcohols with the general formula CnH2n+2On which form an 
homologous series starting from the two carbon diol, 1 ,2-ethanediol (ethylene glycol) 
and increasing in molecular weight with ascending carbon number. Polyols are 
commonly refered to as alditols, acyclic polyols or sugar alcohols. They are further 
subdivided on the basis of the number of carbon atoms (or hydroxyl groups) contained 
in the straight chain molecule into tetritols, pentitols, hexitols (which contain 4, 5 and 
6 carbon atoms respectively) and so on. Polyols are highly polar, generally water 
soluble, hygroscopic materials that exhibit moderate viscosity in high aqueous 
concentrations. In general, the melting and boiling points and viscous properties of 
polyols increase with ascending molecular weight. Different polyols have a sweet taste 
ranging from a half to three-quarters that of sugars. Polyols are chemically closely 
related to carbohydrates from which they are naturally and synthetically derived. There 
is also a close biochemical relationship between sugars and polyols which has led the 
latter to be classed as reduced sugars. Xylitol and sorbitol (D-glucitol) are examples 
of the reduction of their respective sugar counterparts xylose and glucose.
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Polyols like sugars contain chiral carbon centres and in solution display optical activity 
in a plane of polarized light. All polyols from the tetritols upward contain more than 
one chiral carbon centre and exist as diastereomers. They follow the rule that the 
number of theoretically possible stereoisomers is given by 2n; where n is the number 
of chiral carbon atoms present in the molecule. Some polyols, for example erythritol, 
xylitol and galactitol (dulcitol) are meso compounds and although they contain chiral 
carbon centres, do not display specific optical rotation. The melting point and the 
specific optical rotation, are the main physical properties used to identify individual 
polyols.
Polyols contain two primary and secondary alcohol groups and their chemical reactions 
include; esterification, ether formation, oxidation, reduction and cyclic anhydride 
formation. Examples of each reaction are; ester formation with acid anhydrides in the 
presence of an acid or base catalyst. Methyl ether formation from dimethyl sulphate 
in the presence of sodium hydroxide base. Oxidation with nitric acid, of the primary 
alcohol groups, producing dicarboxylic aldonic acids. Reduction by periodic acid, of 
adjacent hydroxyl groups, to two shorter chain aldose sugars. The elimination of a 
molecule of water, on heating with dilute sulphuric acid, to produce a cyclic anhydride. 
Many of the above reactions have important uses in the determination of the structures 
of polyols and in industry.
1.2 The natural occurrence of polvols in the plant kingdom
The most abundant naturally occurring polyol in the plant kingdom is the hexitol, 
D-mannitol, which was the first polyol to be isolated from manna of the ash tree in 
1806. D-mannitol is the primary photosynthetic product in brown algae and has since
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been found to be widely distributed in many other plant species, for example; green 
algae, fungi and the higher plants. By contrast L-mannitol is not known to occur 
naturally. Historically, after mannitol perseitol was the next polyol isolated, from 
avocado in 1831, galactitol from melampyrum in 1837 and sorbitol from sorbus in 1872 
(Wallaart, 1980).
The natural sources of the hexitol sorbitol (D-glucitol) in the plant kingdom include 
red algae, the berries of the mountain ash and the fruit of the rosaceae such as apples, 
apricots, pears, cherries, peaches and plums (Dwivedi, 1977). All four pentitols occur 
naturally with ribitol as the major pentitol in plants, based on actual cell content and 
because all organisms require ribitol incorporation into riboflavin (vitamin B2). Ribitol 
is also a major component of some bacterial cell walls (Brimacombe and Webber, 
1972). The five carbon pentitol xylitol occurs naturally in fruits, vegetables, cereals, 
mushrooms, lichens and seaweed (Dwivedi, 1977). The other two pentitols are D- and 
L-arabitol (D- and L-arabinitol, D- and L-lyxitol). The D- form has been reported to 
occur in fungi in varying amounts according to the conditions for growth. There are 
also reports of both D- and L-arabitol occurrence in yeasts and of an L-arabitol 
specific enzyme in tobacco, pea and wheat indicating that L-arabitol may be present 
in these plants as a minor component (Bieleski, 1982).
Of the three possible tetritols two occur naturally, erythritol occurs in algae, lichens 
and grasses and D-threitol occurs in an edible fungi. The remaining tetritol L-threitol 
has not been reported to occur naturally (Brimacombe and Webber, 1972). There are 
three naturally occurring heptitols (seven carbon polyols) and they are known by their 
trivial names as perseitol, volemitol and B-sedoheptitol and the avocado appears to be 
the main source for the first two. The avocado is also the natural source of the only
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known octitol; D-erythro-D-galacto-octitol. To date there are no known naturally 
occurring nonitols or decitols (Brimacombe and Webber, 1972, Bieleski, 1982).
There are two further classes of polyols which occur naturally in the plant kingdom; 
they are derivatives of the straight chain sugar alcohols and the cyclitols. The main 
derivatives of the straight chain polyols are the two anhydro polyols, styracitol 
(1,5-anhydro-D-mannitol) and polygalitol (1,5-anhydro-D-glucitol), and several 
phosphorylated polyols. Examples of the latter are sorbitol-1-phosphate and sorbitol-6- 
phosphate, both of which have been identified in apricot leaves. However, little is 
known about the formation and function of the anhydro or phosphorylated polyols in 
plants (Bieleski, 1982).
The most commonly occuring cyclitol is inositol, which is the generic term used to 
describe, 1,2,3,4,5,6,-cyclohexane hexol. There are 9 possible isomers of inositol of 
which 7 are meso and 2 form a chiral pair. Only four of the inositol isomers are known 
naturally, they are; myo-inositol, scyllo-inositol and the chiral pair D- and L-chiro- 
inositol. The most common natural isomer of inositol is myo-inositol which is present 
as the free cyclitol in virtually all plants (Loewus and Dickinson, 1982). The cyclisation 
of glucose-6-phosphate into lL-myo-inositol-1 -phosphate is the only known route for 
the biosynthesis of inositols in plants. In turn myo-inositol is a precursor to the 
synthesis of the other naturally occuring inositols, for example; the conversion of 
myo-inositol via D-pinitol to D-chiro-inositol. Myo-inositol exists as the glycoside ester 
glucinol (0-J3-D-Glucopyranosyl-l,l-myo-inositol) in sugar cane and beet. Myo-inositol, 
incorporated into phosphatidic acid to produce phosphatidyl-inositol, plays an 
important role in the synthesis and structural integrity of plant membranes. The indole 
acetic acid ester of myo-inositol is believed to act as a plant growth hormone regulator;
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the functions of which have still to be completely understood (Loewus and Dickinson, 
1982).
Like the straight chain polyols inositol exists in various phosphorylated forms, of which 
the most common is the hexa-phosphate, phytic acid. The elements potassium, iron, 
magnesium and manganese are sequestered by the phosphate of phytic acid and are 
stored in seeds.
Research continues into the natural sources of polyols for three main reasons:
i) to further understand plant metabolism,
ii) as an aid to chemical plant taxonomy and
iii) to identify new sources of polyols of possible use to man.
Thus polyols occur widely in the plant kingdom and are ingested as such in the animal 
kingdom, in the diet of many living organisms, forming a food chain which can 
ultimately include man.
1.3 The natural occurrence of polvols in the animal kingdom
The natural occurrence of polyols in the animal kingdom appears to be limited. Polyols 
were first reported to occur, in mammalian physiology, in seminal vesicles and placenta 
(Hers, 1960). The normal occurrence of polyols in the animal kingdom has been 
summarized by Hayman and Kinoshita, (1965) and Touster, (1974) who reported the 
occurrence of sorbitol in sheep foetal blood. The polyols xylitol, galactitol and sorbitol 
were reported to be converted from their corresponding aldose sugars in the lens of 
the eye in experimental sugar cataracts (Kinoshita 1974). The enzyme Aldose 
Reductase, which was believed to be responsible for the conversion of aloose sugars
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to polyols, was first isolated from calf lens by Hayman and Kinoshita (1965). This early 
experimental work was concerned with the normal occurrence of polyols and the 
elucidation of any possible biochemical pathways involving them, rather than any 
pathological role of polyols.
There are several reports of the measurement of polyols in normal human serum, urine 
and cerebro-spinal fluid. The polyols, with their concentrations in parentheses, 
erythritol (0.45), threitol (0.20), ribitol (0.06), arabitol (0.37), xylitol (0.05), mannitol 
(0.41), galactitol (0.15) and sorbitol (0.16) /Jg/ml have been measured in the serum 
of normal subjects (Roboz et al., 1984). The same authors reported that arabitol is the 
only polyol produced in appreciable quantity by the fungus Candida and subjects 
infected with this fungus have correspondingly raised serum arabitol levels. The sorbitol 
content of plasma has been reported to vary with the carbohydrate content in diets 
given to healthy humans (Malaisse et al., 1981). Sorbitol is more slowly absorbed by 
the intestinal mucosa than glucose (Dwivedi, 1977). Therefore ingestion of fruits high 
in sorbitol content, along with the hygroscopic nature of sorbitol, account for their 
laxative effect due to intestinal inhibition of water absorption. The transitory laxative 
effects of sorbitol when given orally to humans has been studied by Koizumi et al., 
(1983). These authors estimated a maximum tolerable oral sorbitol dose of 0.15 g/kg 
body weight for males or 9.7 g for an average 64.4 kg man. By comparison the same 
authors found the maximum tolerable sorbitol dose in women to be 0.3 g/kg or 15.0 
g for an average 50 kg female.
The metabolism of sorbitol and xylitol in man has been reviewed by Froesch and Jacob 
(1974). Upon absorption from the intestine sorbitol and xylitol are rapidly converted 
to glucose, mainly in the liver, in an insulin-independent manner (Forster 1974).
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Sorbitol is metabolised via fructose in the liver, with the first step occurring as 
oxidation of sorbitol to fructose, by the cytosolic enzyme sorbitol dehydrogenase 
(SDH) and the cofactor nicotinic-adenine-dinucleotide (NAD). Xylitol is oxidized to 
D-xylulose, probably by the same or a closely related enzyme that initiates sorbitol 
metabolism and metabolised in the liver by the pentose phosphate shunt. The three 
carbon polyol glycerol, is a normal intermediate in mammalian fat metabolism and 
plasma glycerol levels can be used as an index of fat mobilization, Fenton and Aherne 
(1987).
The polyols, with their excretion concentrations in parentheses, erythritol (63), threitol
(11), arabitol (53), ribitol (10), xylitol (22), myo-inositol (33), galactitol (6), sorbitol 
(23) and mannitol (26) /ig/mg creatinine have been reported to occur in adult human 
urine (Pfaffenberger et al., 1975). A very extensive urinary profiling of polyols and 
other carbohydrates in humans receiving normal diets has been carried out by Jansen 
et al., (1986) who report decreases in the excretion of all polyols examined with 
increasing age from neonates to maturity. Blau (1972) has shown that galactitol and 
mannitol are excreted in urine in raised amounts (above normal) in hereditary 
galactosaemia. Also, Allen et al., (1981) have measured galactitol in amniotic fluid as 
a possible aid in the diagnosis of foetal galactosaemia.
The polyols ribitol, sorbitol and myo-inositol have been reported in normal human 
cerebrospinal fluid at respective concentrations of 3.4, 4.8 and 54 Mg/ml, (Smith et al., 
1984). The same authors reported the presence of 1,5-anhydro-sorbitol at a 
concentration of 37 Mg/ml in cerebrospinal fluid which confirm the results of Pitkanen 
(1973). The origin of the anhydro-sorbitol is unclear but is probably derived from plant 
matter. Of interest is another closely related anhydro polyol, 2,5-anhydro-mannitol,
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which has been shown to be an anti-metabolite, inhibiting glycolysis in bovine 
spermatozoa, carbohydrate stimulated protein synthesis in rat testis and glucose 
synthesis in rat hepatocytes (Dills et al., 1983). The 2,5-anhydro-mannitol has not been 
reported to occur naturally in the plant kingdom but the possibility that it is produced 
by plants in response to abnormal growth conditions, such as environmental pollution 
or hostile climates, has consequences for man which cannot be ignored.
The existence of phosphorylated straight-chain polyols is not known in man. This does 
not preclude the possibility that they are present in some tissues, as transient metabolic 
intermediates, at very low levels which have made their detection difficult.
The existence of the cyclitol myo-inositol, both in the free and phosphorylated form, 
in mammalian metabolism is well documented. Myo-inositol is an essential nutrient in 
the culture of endothelial cells (Lorenzi and Toledo, 1986) and has been shown to be 
important in the control of insulin release from cultured 13-cells of the pancreas (Pace 
and Clements, 1981). Myo-inositol is an important precursor in the synthesis of 
phospholipids (Allen 1982) and plays an integral role in the generation of the 
intra-cellular second messenger (Berridge 1984, Berridge and Irvine 1984). Myo-inositol 
is important in the synthesis and metabolic regulation of phosphatidylinositol in nerve 
tissue (Berry et al., 1983). The maintenance of the cytosolic levels of free myo-inositol 
in the axon is believed to be important in the production of the action potential which 
generates nerve impulses (Simmons et al., 1982). The hexaphosphate of inositol, phytic 
acid, is a common mammalian dietary component and as such is probably another 
precursor source for free myo-inositol. The occurrence of polyols in nature is 
summarised in table 1. The structures of some of the naturally occurring polyols and 
their related sugars are shown in figure 1 .
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In general, there is a lack of data correlating polyol (or abnormal polyol) appearence 
in human tissues with the original amounts in different food sources. There is a need 
to investigate the absorption, distribution, metabolism and excretion of polyols in 
normal human nutrition before comparisons are made with abnormal and pathological 
conditions. The other major physiological significance of polyols in man has come from 
studies of pathological conditions; in particular diabetes which is discussed in more 
detail below (see 1.5).
Table 1 The Distribution of Polyols in Nature
CARBON LENGTH C4 C5 C6 C7 0 7
P L A N T  K I NG DO M  1
A L G A E  ( B l u e ,  G r e e n + + + + +
B r o w n  a n d  R e d )  
L I C H E N S + + + + +
F U N G I + + + ? ?
L I V E R W O R T S ,  MOSSES - - + + ?
P R I M I T I V E  V A S C U L A R  
P L A N T S + ? ?
FERNS - - ? - ?
S E E D - B E A R I N G  P L A N T S - - + + ?
F L O WE R I NG  P L A N T S  
( M o n o c o t y l e d o n a e ) + +
( D i c o t y l e d o n a e ) + + + + ?
A N I M A L  K I NG D OM  2
ACCESSORY
R E P R O D U C T I V E  T I S S U E S +
M A M M A L I A N
P H Y S I O L O G Y + + + ? +
M E T A B O L I C
I N T E R M E D I A T E S + + + ? +
T h e  t h r e e  c a r b o n  g l y c e r o l  o c c u r s  w i d e l y  i n  t h e  p l a n t  a n d  a n i m a l  k i n g d o m s
T h e  m o s t  a b u n d a n t  s i x  c a r b o n  ( C 6 )  p o l y o l  i s  D - m a n n i t o l
O t h e r  i n c l u d e s  b r a n c h e d  a n d  l o n g e r  c h a i n  C 8 ,  C9 a n d  C I O  p o l y o l s
+  =  K n o w n  t o  o c c u r ,  ? =  Q u e s t i o n a b l e ,  -  =  N o t  y e t  e s t a b l i s h e d
1 B i e l e s k i  R . L .  ( 1 9 8 2 ) ,  2 T o u s t e r  0 .  ( 1 9 7 4 )
9
Three carbon
I
HCOH
I
CH20H
D - g l y c e r a l d e h y d e
CHO
HCOH
I
ch2oh
G l y c e r o l
ch2oh
F o u r  c a r b o n
CHO
HCOH
HCOH
I
CH20H
D - e r y t h r o s e
ch2oh
HCOH
HCOH
I
ch2oh
E r y t h r i t o l
( m e s o )
CH20H
HOCH
I
HCOH
I
CH20H
D - t h r e i t o l
F i v e  c a r b o n  
CHO
I
HOCH
I
HCOH
I
HCOH
I
CH20H
D - a r a b i n o s e
CH20H
HOCH
I
HCOH
I
HCOH
I
CH20H
D - a r a b i n i t o l  
( D - l y x i t o l )
CH20H
HCOH
I
HCOH
I
HCOH
CH2OH
R i b i t o l  
( A d o n i t o l )
ch2oh
HCOH
I
HOCH
I
HCOH
I
CH20H
X y l i t o l  
( m e s o )
Figure 1. Structures of Some Naturally Occurring Polyols and Their Related Sugars.
10
S i x  c a r b o n  
CHO
I
HCOH
I
HOCH
I
HCOH
I
HCOH
I
ch2oh
D - g l u c o s e
Figure 1. cont.
HCOH
I
HOCH
I
HCOH
HCOH
I
CH20H
D - g l u c i t o l  
( D - s o r b i t o l ) 
( L - g u l i t o l )
CH20H
HCOH
I
HCOH
I
HCOH
I
HCOH
I
CH20H
A l l i t o l  
( m e s o )
CH20H
OH
J
OH
V f t  OH
rOH 6 /
OH
M y o - I n o s i t o l
OH OH
HOCH
I
HOCH
I
HCOH
I
HCOH
I
CH20H
D - m a n n i t o l
CH20H
HCOH
I
HOCH
I
HOCH
I
HCOH
I
CH20H
G a l a c t i t o l  
( m e s o )
OH
OH
S c y l l o - I n o s i t o l
OH OH
L - c h i r o  ( - )
HOCH
I
HCOH
I
HOCH
I
HOCH
I
CH20H
L - i d i t o l  
( D - i d i t o l  d o e s  
n o t  o c c u r  
n a t u r a l l y )
CH20HI Cm
OH
OH
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HCOH HOCH
I I
HOCH HOCH
I I
HOCH HOCH
I I
HCOH HCOH
I I
HCOH HCOH
I I
ch2oh ch2oh
D - g l y c e r o - D - g a l a c t o -  D - g l y c e r o - D - t a l c
H e p t i t o l  H e p t i t o l
( P e r s e i t o l )  ( V o l e m i t o l )
E i g h t  c a r b o n
CH20H
HCOH
I
HOCH
I
HOCH
I
HCOH
I
HCOH
HCOH
I
CH20H
D - e r y t h r o - D - g a l a c t o -  
o c t i t o l
There are no known naturally occurring Nonitols or Decitols
Seven carbon
ch2oh ch2oh
Figure 1. cont.
1.4 The industrial uses of polvols
The industrial uses of polyols is widespread and has increased with increased world 
production of raw sugar. Starch, raw cane or beet sugar acts as the starting material 
for the industrial producion of some polyols. For example: pure glucose is produced 
from the hydrolysis of starch and known as dextrose, sorbitol is produced by catalytic 
hydrogenation of pure glucose (dextrose) using nickel catalyst and hydrogen at elevated 
temperatures and pressure. When pure fructose is similarly reduced equal quantities 
of sorbitol and mannitol are produced. Sucrose or cane sugar when hydrolyzed yields 
a mixture of glucose and fructose known as invert sugar and also acts as a raw source 
for the production of sorbitol and mannitol. In a similar manner xylitol is produced 
from the catalytic hydrogenation of xylose (wood sugar) which in turn is the hydrolysis 
product of the plant cell wall component, xylan. Historically, in the 60’s, improvements 
to the industrial hydrogenation of glucose were made, initially on a pilot scale, by 
using Raney nickel catalyst (nickel purified from an aluminium-nickel alloy) with 
magnesium as a promoter. The author reported 100% yield of sorbitol from 2000 lb 
dextrose starting material (Phillips 1963).
Attempts have been made on the laboratory scale to produce mannitol in commercially 
acceptable yields from copra meal; a by-product of coconut oil extraction (Saittagaroon 
et al., 1985). This latter example is indicative of the commercial and economic pressure 
to discover and utilize alternative natural sources for polyol production as demand 
outpaces supply of the more usual raw starting material. In recent years molecular 
biology has made an impact on the industrial production of carbohydrates. One such 
example is the simultaneous production of sorbitol from fructose and gluconic acid
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from glucose, by immobilized bacterial cells that contain a specific enzyme complex 
capable of the conversion (Chun and Rogers, 1988). The authors demonstrated 
sustained production of sorbitol and gluconic acid of 7.6 and 7.2 g/l/hr respectively 
for a period of 125 hours on a laboratory scale. The advantages of the last example, 
over the catalytic hydrogenation approach to polyol production, are that the products 
require little further purification, there is no requirement for high temperatures, 
pressures or dangerous gases and that the whole process can be automated. It will be 
of interest to see how soon such a pilot scheme is converted into a large scale
U-
manufacturing process.
Sorbitol is used in the pharmaceutical and food industry as a sweetner, as a humectant 
in the cosmetic industry and in the printing, resin and glue industries (Phillips, 1963). 
The white crystalline solid sorbitol is used in the manufacture of ascorbic acid (vitamin 
C). Sorbitol is also used in the synthesis of the heart drug isosorbide-dinitrate, the 
clinical uses of which have been reviewed by Swedberg (1984). In 1974 Aminoff 
estimated the annual production of sorbitol to be 250,000 tons, of which approximately 
a third ends up in foods. By comparison the 1987 estimate for world sorbitol 
production was 330,000 tons with a world total sugar production in excess of 100 
million tons (Anon, Nestle; see reference under Nestec).
When an acid that contains more than one carboxylic acid group is reacted with an 
alcohol containing more than one hydroxyl group a polyester is produced; one such 
example is the reaction between ethylene glycol and terephthalic acid which produces 
Dacron. There is little doubt that the search for new polyols coincides with the advent 
of new polymers, in what is now a highly competetive and profitable industry.
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Nitric acid esters of polyols have been used as explosives of which the best known 
example is nitroglycerine, the product of nitric acid and glycerol. As a drug 
nitroglycerine has been used for over a century in the treatment of angina and 
myocardial infarction and has been reviewed by Parratt (1979).
As already indicated polyols are used in the food and drink industry as additives, 
particularly sorbitol, mannitol and xylitol. Some of the properties of polyols, which 
include their similar calorific value to sugars, sweetness, insulin independent 
metabolism and non-toxicity, make them ideal candidates as alternatives to sugars in 
processed foods. Their use in the food industry has been reviewed by Griffin and 
Lynch (1972) and their toxicity by Salminen (1982).
The polyols erythritol, arabitol, xylitol, mannitol, sorbitol and inositol occur in sherry 
wines where their presence is believed to account for the smooth tasting texture. The 
concentrations of the polyols in sherry wines vary according to the storage conditions 
but are on average 0.1 g/1 (Estrella et al., 1986). It is interesting that the effect of 
polyols in sherry, the smooth tasting texture, is the very reason why they are added in 
beverages.
More recently, xylitol has attracted much attention as a food additive because of its’ 
additional anti-caries property. The anti-caries action is believed to arise from the 
inability of the normal mouth bacterial enzymes to convert xylitol to an acid which 
attacks the teeth (Scheinin 1980). The use of xylitol as a food additive has been 
reviewed by Hyvonen et al, (1982) who estimated the total world production of 
polyols to be about 345,000 tons in 1978 of which approximately 6000 tons was as
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xylitol and mannitol. It is interesting to compare the 1978 and 1987 estimates for 
industrial polyol production which appear for that decade to be relatively unchanged.
Thus the occurence of polyols has had an enourmous impact on man, from their many 
industrial uses to nutrition, health and disease. Conversely the impact that man has had 
on polyols is also considerable and can be illustrated as follows. Industrial pollution 
of the environment, for example in the form of acid rain, chemical smog or radioactive 
fallout, can have a direct harmful effect on plant photosynthesis (Levitt, 1972). 
Sorbitol is a major photosynthetic product in plum leaves and its fruit (Anderson et al., 
1961) and as such can be affected by adverse environmental conditions, like those 
mentioned above. There becomes then an increased possibility that, under certain 
hostile environmental conditions, the plant produces abnormal polyol derivatives (like 
the anti-metabolite 2,5-anhydro-mannitol refered to earlier) in an effort to relieve the 
man induced stress. In this respect there are at least four research needs which arise 
out of the possible consequences of our actions. They are:
i) to identify polyol changes, especially abnormal polyols, in plants with man induced 
environmental stress,
ii) to determine whether any such changes are suitable for monitoring global pollution,
iii) to determine whether such abnormal polyols are of potential harm to man and
iv) to determine whether these polyols occur in man normally or are related to various 
disease conditions.
To date very little research in this area has been carried out. However, for (i) above, 
Villanueva et al., (1987) have demonstrated the abnormal accumulation of free fructose 
and glucose in the needles of pine trees damaged by air pollution. Therefore, as can
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be seen in the examples above, polyols are a very diversely occurring group of 
compounds and their study is essential to our understanding of them.
1.5 The role of polvols in the long term complications of diabetes
In man carbohydrates constitute a major source of nutritional energy. Carbohydrates 
are broken down in the intestine to their monosaccharides of which the most important 
are the pentoses and hexoses. The physiologically most important pentoses are ribose 
and deoxyribose. Similarily the most important hexoses are glucose, galactose and 
fructose. These sugars are transported from the intestine, via the hepatic portal vein, 
to the liver in an insulin independent manner and are mostly metabolised by the 
hepatocytes.
Insulin is a hormone, produced by the beta cells of the pancreas in response to raised 
blood glucose levels (hyperglycaemia). Insulin induces the hepatic enzyme glucokinase 
and the hexokinase enzyme of other tissues in order to phosphorylate glucose to 
glucose-6-phosphate, the initial step of glucose metabolism in all cells. Insulin also 
stimulates hepatic enzymes to synthesise glycogen, the liver storage product of glucose. 
Any excess glucose, above the hepatic buffering capacity, is transformed into 
triglycerides by the liver and either stored there or in adipose tissue. Further systemic 
glucose is stored as glycogen in muscle or as triglycerides in adipose tissue. The entry 
of glucose into these two tissues is also insulin dependent. Therefore the liver, in 
conjunction with hormonal control, acts as a buffer for glucose and normalises the 
hyperglycaemia during ingestion of carbohydrates. This in turn regulates the blood 
glucose concentration to the rest of the body, especially the brain.
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Glucose can be synthesised in the liver from triglycerides mobilised from adipose 
tissue. At low blood glucose levels (hypoglycaemia) this helps to maintain a regular 
blood glucose concentration. Therefore, even during the temporary hyperglycaemia 
after carbohydrate ingestion or when fasted, the brain under normal circumstances is 
assured of a fairly constant supply of glucose. This is a necessary requirement because 
glucose crosses the blood-brain barrier in a manner which is not dependent on insulin.
Physiologically, in all situations including extreme depletion of hepatic glucose such as 
excessive exercise, starvation or trauma, the brain takes priority in receiving alternative 
souces of energy derived from other tissues. When polyols are ingested in the diet they 
are metabolised as already described and will also contribute to an increase in 
glucose. In the case of poorly absorbed polyols, such as sorbitol, their contribution to 
systemic hyperglycaemia is small.
In diabetes mellitus there is an inability of the beta cells of the pancreas to produce 
appropriate or effective amounts of insulin in response to hyperglycaemia. The post 
prandial blood glucose levels are not maintained at an optimum and the result can be 
sustained hyperglycaemia. In the most severe diabetic case the consequence of 
prolonged hyperglycaemia can lead to coma and death. Fortunately diabetes can be 
treated (in descending order of severity) with replacement insulin by injection before 
eating, by oral therapy which stimulates the beta cells into insulin production or by diet 
control.
A characteristic of diabetes is, that once the condition is diagnosed, it is never resolved 
irrespective of the severity. The causes of diabetes are widespread and include
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auto-immune attack of the beta cells, viral infections, alcoholism, environmental effects, 
genetic factors and various complex interactions which combine all or some of these 
together (Notkins 1979). In the United States diabetes has been estimated to affect 5% 
of the population and account for an economic cost of $5 billion per year (Notkins, 
1979) and in the U.K. at between £260 to £600 million (Gerard et al., 1989).
Another characteristic of diabetes is the appearence of complications which have no 
particular pattern in terms of duration or severity of disease. The complications are 
known as long term because once diagnosed the prognosis is often poor. The long term 
complications of diabetes include retinopathy, cataract formation, nephropathy and 
neuropathy. Retinopathy has a 60-80% frequency in patients with 20-25 years duration 
of diabetes, but the incidence does not reach 100%. Cataract formation in the eye is 
common and often linked to the incidence of retinopathy. The chances of developing 
nephropathy decline after a duration of diabetes of 30 years. Neuropathy is widespread 
in incidence because of the different classifications used to describe the many 
symptoms. Approximately 25% of diabetics who survive indefinitely never develop any 
complications. Other patients develop more than one complication. In the case of 
nephropathy the complication progresses relentlessly to end-stage renal failure, often 
with other complications developing.
Retinopathy is now treated with laser photocoagulation, thereby stopping the micro 
haemorrhages in the eye. Corneal cataracts can be removed surgically under local 
anaesthetic. Nephropathy can be treated with renal dialysis and diabetic renal 
transplant accounts for one-quarter of all renal replacement therapy. Neuropathy, 
however, is an extremely painful and debilitating condition and a difficult complication
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to manage medically. Until recently the only treatment was to control the 
hyperglycaemia in an attempt to relieve the worst symptoms. In the less severe cases 
of neuropathy, such as subjective observations by the patients of numbness or tingling 
sensations in the lower limbs, with improved glycaemic control the symptoms were 
often reduced. It was not suprising that neuropathy was associated with a predominantly 
hyperglycaemic state. As the normal glucose metabolic pathways are blocked or 
reduced in activity in diabetes, alternative pathways for the metabolism of excess 
glucose were sought as a possible biochemical explanation for the aetiology of the 
complications.
Evidence implicating polyols in the long term complications of diabetes has come from 
three main sources. They are:
i) changes in tissue polyol content
ii) tissue distribution of the enzyme aldose reductase (AR) and
iii) clinical trials of aldose reductase inhibitors.
1.5.1 Changes in Tissue Polyol Levels
The first report of polyols occurring in cataractous lens was by van Heyningen (1959a) 
who found that xylose, glucose and galactose, in rats fed these sugars in their diet, were 
converted to their corresponding polyols xylitol, sorbitol and galactitol. Polyols were 
estimated using a semi-quantiative paper electrophoretic method. Dialysed extracts of 
rat lens were found to reduce the sugars if the cofactor NADPH was present. This 
finding suggested that an enzyme was involved in the process. The change in polyol 
levels in the rat lens occurred under experimental conditions and it was not possible
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to conclude that this effect was the cause of the cataract formation. Varma and 
Kinoshita (1974), using packed column gas liquid chromatography (GLC) to separate 
polyol trimethyl silyl ether (TMS) derivatives, showed accumulation of sorbitol in 
diabetic rat lens along with increased fructose. They demonstrated xylitol accumulation 
in isolated normal and diabetic rat lens incubated with 30 mM xylose. The xylitol 
accumulation was significantly higher in the diabetic rat lens than in the non-diabetic 
control.
Malone et al., (1984) demonstrated a high positive correlation between blood glucose 
levels and the sorbitol content in sciatic nerves, lens and erythrocyte of diabetic rats 
with varying degrees of glycaemia. Using an enzymatic assay they demonstrated a 
positive correlation between lens and sciatic nerve levels of sorbitol and the erythrocyte 
sorbitol content. Beyer-Mears et al., (1984) demonstrated that the glomerular sorbitol 
content of streptozotocin induced diabetic rats (after 6 weeks duration of diabetes) was 
significantly raised above normal non-diabetic control rats. In addition, they showed 
significant lowering of glomerular myo-inositol content compared to non-diabetic 
control after 9 weeks duration of diabetes. Polyols from the deprotienised glomerular 
samples were derivatised as the trifluoroacetates and analysed by GLC but no further 
assay details were given.
Willars et al., (1987) studied the sciatic nerve content of sugars and polyols in 
streptozotocin induced diabetic rats. The glucose, sorbitol and fructose levels in sciatic 
nerve, after 3 weeks duration of diabetes, were all significantly raised above 
non-diabetic normal rat. In addition, the myo-inositol content of sciatic nerve was 
significantly lowered in the diabetic group compared to normal control. The same
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authors reported that in rats fed a diet supplemented with 30% galactose, for 5 days, 
the sciatic nerve galactitol content was significantly higher in diabetic rats compared 
to control. In this latter experiment the nerve fructose level was relatively unchanged 
but again the nerve myo-inositol level was depleted in the diabetic group.
Aloia (1973) showed elevated sorbitol levels in the serum of human diabetics; the 
mean serum levels (+_ standard error) for normal and diabetics were 0.24 _+ 0.01 and 
0.59 +. 0.08 mg/100 ml respectively, (n=32). Samples were derivatised by TMS 
silylation and analysed by packed column GLC with flame ionisation detection (FID). 
Additionally, peracetate derivatives of extra samples were prepared to separate 
sorbitol and mannitol. Heath and Galton (1975) showed raised daily urinary excretion 
of glucose, sorbitol and myo-inositol in human diabetics. They reported a linear 
relationship between the 24 hour urinary excretion of glucose and the hexitols. They 
did not find however, increases in fructose, sorbitol or myo-inositol content of human 
diabetic lens. Trimethyl silyl ethers of polyols and sugars were separated isothermally 
at 160°C using a 7 foot narrow bore glass column coated with 3% S.E. 30. Using this 
method the authors reported the detection of an unidentified carbohydrate in adipose 
tissue, which does not appear to have been followed up. Clements et al., (1977) 
reported that urinary myo-inositol excretion was ten fold higher in untreated human 
diabetics compared to normal non-diabetic subjects. Insulin treatment normalised the 
diabetic myo-inositol excretion. Myo-inositol was analysed by a method similar to that 
of Heaf and Galton (1975).
Malone et al., (1980) using their enzyme assay showed that, after an 8 hour fast, there 
was a statistically significant difference between the erythrocyte sorbitol levels in 155
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diabetic children compared to a normal non-diabetic group. The results in nmol/gm 
haemoglobin (+. standard deviation) were 28.0 +. 18.9 diabetic, (n=155) and 10.1 +_ 
12 normal (n=30). Mayhew et al., (1983), using packed column GLC of TMS polyol 
derivatives, showed significantly lower concentrations of free and lipid myo-inositol in 
human diabetic sciatic nerve, removed post-mortem, compared to non-diabetic control. 
The concentrations of glucose, fructose and sorbitol were higher in the diabetic group 
than control.
Popp-Snijders et al., (1984) demonstrated a difference in erythrocyte sorbitol content 
between diabetic and fasting normal non-diabetic human volunteers. They were the 
first to use capillary GLC to separate polyol acetate derivatives extracted from red 
blood cells. The results were in nmol/ml erythrocyte (mean +. standard error of the 
mean, SEM), diabetic 13.1 ±_ 0.9 (n=28), normal 5.2 ±_ 0,3 (n=30). The erythrocyte 
myo-inositol levels were unchanged between the two groups and not statistically 
different. Lapolla et al., (1985), using the enzymatic assay of Malone, obtained similar 
results to those of Popp-Snijders and again demonstrated significantly raised 
erythrocyte sorbitol concentrations in diabetic subjects compared to normal 
non-diabetics.
Finally, a recent report by Akanuma et al., (1988) found the presence of 
1,5-anhydro-D-sorbitol in normal human plasma and its excretion in urine. This 
component was identified by them using GLC with mass spectrometric detection 
(GC-MS) of the acetate derivative but no further details were given. The authors found 
that diabetic patients had lower plasma levels of the anhydro-sorbitol than normal 
non-diabetics. They also showed a significant correlation between diabetic urinary
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anhydro-sorbitol and glucose levels. This correlation was even more apparent during 
a lOOg oral glucose tolerence test in diabetics and normals, where the urinary excretion 
of glucose and the anhydro-polyol were both raised. The significance of this finding is 
not clear, but emphasises the lack of knowledge about the relationship between 
hyperglycaemia and tissue formation and excretion of the less well known polyols.
There does, however, appear to be a distinct relationship between sorbitol and 
myo-inositol which can be sumarised as follows. In rat and human diabetic tissues 
sorbitol is raised and myo-inositol is lowered in content compared to normal 
non-diabetic tissue. The tissues where these changes occur are, most notably those 
tissues affected by the long term complications of diabetes, namely the eye, kidney and 
nerve. These changes can be partly explained by a general biochemical hypothesis that 
has emerged for polyol formation and metabolism, which is as follows.
Aldose reducing sugars are reduced to their corresponding sugar alcohols by the 
enzyme Aldose Reductase (AR) in the presence of the reduced cofactor NADPH. In 
normal circumstances the polyols are further metabolised by the enzyme Polyol 
Dehydrogenase, refered to as Sorbitol Dehydrogenase (SDH), in the presence of 
oxidized NAD cofactor. The resulting sugar may then be further metabolised, as in the 
case of fructose, by phosphorylation and the glycolytic pathway. This series of events 
has become known as the "Polyol pathway" and is represented schematically below, 
with glucose as an example.
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In addition, it has been postulated that tissues freely permeable to glucose (not 
dependent on insulin for transmembrane transport) contain AR which converts the 
glucose to sorbitol in an irreversible step. Evidence for this is supported by the 
observation that in diabetes the levels of NADPH and NADH are higher than normal 
with concomitantly lower levels of NADP and NAD, thus favouring sorbitol formation 
(Varma and Kinoshita 1974). In addition to these favourable conditions for sorbitol 
formation in diabetics the diffusion of this polyol through cell membranes is slow 
(Popp-Snijders et al., 1983). As a consequence of these events it has been postulated 
that sorbitol may undergo intracellular accumulation causing oedema which in turn 
affects the normal function of the cell (Gillon et al., 1986). However, this sequence 
of events does not take into account the role played by the enzyme SDH which further 
metabolises sorbitol to fructose. The activity of this enzyme would have to be 
diminished or non existent for sorbitol to accumulate in those cells that display 
abnormal function.
Three questions have emerged concerning the polyol pathway and the long term 
complications of diabetes:
i) is AR present in those tissues where the long term complications develop,
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ii) what is the tissue distribution of SDH and is this step of polyol metabolism reduced 
in activity, thereby leading to accumulation of polyol and subsequent dysfunction of 
the tissue and
iii) what is the relationship between the polyol pathway and myo-inositol.
In the first instance several workers concentrated on determining the tissue distribution 
of the implicated enzymes AR and SDH and their results are reviewed in section 1.5.2.
1.5.2 Tissue Distribution of Aldose Reductase
Evidence for the reduced-triphosphopyridine nucleotide-dependent reduction of aldoses 
to polyols, in extracts of seminal vesicles and placenta, was first reported by Hers 
(1960) who named the enzyme responsible aldose reductase (AR). Hayman and 
Kinoshita (1965) were the first to isolate AR from calf lens. They purified AR by 
diethylaminoethyl-cellulose (DEAE) column chromatography and characterised the 
properties of the enzyme. They found only one enzyme which had a pH optimum of 
5.5, was stimulated by sulphate ions, had a sulphydryl requirement, reduced aldoses 
and various aldehydes and was inhibited by various glycolytic intermediates; such as 
oxaloacetate, beta-hydroxybutyrate and acetoacetate. In addition, they found this 
enzyme to have the highest Michaelis constant (K J and therefore the lowest affinity 
for glucose. They also found that the enzyme was particularly sensitive to inhibition by 
organic anions, such as beta-ketoglutarate.
Gabbay and O’Sullivan (1968) isolated AR from normal and diabetic rat spinal cord 
and sciatic nerve. They found that the sciatic nerve AR had considerable polyol
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forming ability compared to that from spinal cord. They were the first to report that 
AR was predominantly associated with sciatic nerve schwann cells and that SDH was 
associated with the axon. Clements at al., (1969) partially purified AR from the 
thoracic aorta wall of rabbit and human. They found that incubation of aortic AR with 
5 mM glucose was stimulated approximately three fold by the addition of 5 gg/ml 
adrenalin, whereas nor-adrenalin had no effect. These authors also found SDH to be 
present in rabbit aorta.
Beutler and Guinto (1974) partially purified an enzyme from human erythrocytes which 
was capable of reducing glyceraldehyde to glycerol. They classed the enzyme as an 
L-hexonate dehydrogenase, rather than the AR obtained by Hayman and Kinoshita 
because of the different kinetic characteristics and elution pattern with DEAE 
chromatography. These authors suggested that AR was not present in the erythrocyte.
Ludvigson and Sorenson (1980) raised antibodies in rabbit to AR purified from rat 
seminal vesicles and used immuno-histochemical staining to locate AR in rat tissue. 
They found the presence of AR in numerous cell types of the eye including lens, 
cornea, iris, ciliary body and retina. Retinal capillary endothelium did not contain 
immunoreactive AR. They also found AR in the kidney predominantly in the inner 
medulla. It was also noted that the enzyme location applied to both diabetic and non­
diabetic normal rat tissue. Srivastava et al., (1984) using immunochemical 
characterisation located AR in human aorta, brain, muscle and erythrocyte. They also 
demonstrated the presence of two other enzymes, aldehyde reductase I which was 
present in human kidney, liver and placenta and aldehyde reductase II present in those 
tissues as well as the human lung, brain and erythrocyte. Das and Srivastava (1985a)
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carried out detailed in-vitro kinetic studies of purified human AR and found that the 
enzyme exhibited bi-phasic kinetics. This was explained by the finding that AR existed 
in the activated and inactivated (native) forms. The activated form arises when the 
enzyme is subjected in-vitro to NADPH, glucose and glucose-6-phosphate. It would 
appear that glucose-6-phosphate was an AR activator. The activated enzyme 
subsequently shows a strong affinity for glucose with a lower and less susceptibility 
to inhibition by glycolytic intermediates or AR inhibitors. Furthermore, the authors 
reported that AR purified from normal human lens displayed properties similar to the 
native (inactivated) form of AR, whereas AR purified from clear lens of severely 
hyperglycaemic diabetics displayed AR properties similar to the activated form.
Bagnasco et al., (1988) have shown the existence of AR in an in-vitro cell culture of 
an osmotically resistant cell line from rabbit papillary pelvic epithelium. Using 
SDS-PAGE and scanning densitometry they showed that a gradual decrease in AR 
activity was associated with a corresponding gradual decrease in AR enzyme protein. 
This was the first report that indicated that protein synthesis of AR may be a response 
related to the cellular glycaemic environment.
There is considerable controversy over exactly what form the AR enzyme takes, its 
kinetic characteristics and whether L-hexonate dehydrogenase is the same or a closely 
related enzyme. Nevertheless, the same tissue distribution of AR was observed when 
investigated by several distinctly different techniques. This made the evidence for the 
existence of AR more convincing. Thus AR would appear to be present in human 
tissues which are notably those tissues most affected by the long term consequences 
of diabetes. The AR tissue distribution, in conjunction with the polyol changes that
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occur in those same tissues, support the argument that the long term side effects of 
diabetes may be biochemical in origin. As indicated above the biochemical explanation, 
namely the polyol pathway, only partly explains the polyol changes; which is most 
notably the conversion of glucose to sorbitol. The changes in myo-inositol levels 
observed in diabetes, the lowering of myo-inositol when sorbitol is raised, is not 
explained by the polyol pathway. The exact relationship between these two polyols 
(sorbitol and myo-inositol) has still to be determined.
There are less reports concerning the tissue distribution of SDH. Vaca et al., (1983 and 
1984) showed SDH deficiency in several pig tissues. They also screened several animal 
species for erythrocyte SDH activity and found high activity in hamster, medium 
activity in mouse, guinea pig, rat and dog and low activity in rabbit, sheep, goat, cattle, 
horse and donkey. There was absence of erythrocyte SDH activity in pigs but in human 
erythrocytes the activity was reported to be 17.5 [imo\ product formed per hour per g 
haemoglobin. The pattern of results are in general agreement with those of Agar 
(1979) who found high erythrocyte SDH activity in man, dog, guinea-pig and mouse. 
However the actual activity reported by Agar for human erythrocyte SDH is 5 times 
higher than that obtained by Vaca et al., while Varma and Kinoshita (1974) found the 
activity of SDH in diabetic rat lens to be decreased compared to control.
The role of AR in the development of the long term complications of diabetes has 
been reviewed by Kador and Kinoshita (1985), Greene and Lattimer (1985) and Gillon 
et al., (1986). Further evidence that AR and the associated polyol changes are involved 
in the biochemical aetiology of the complications of diabetes has come from studies 
of AR inhibitors in animal models and man.
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1.5.3 Studies Using Aldose Reductase Inhibitors
The rationale behind the use of aldose reductase inhibitors came from the earlier 
observations of Hayman and Kinoshita (1965) that AR was inhibited by organic anions. 
There was, historically, a need to develop AR inhibitors for three reasons: 
i) to use as probes in elucidating the complex biochemical interactions between 
polyols and AR,
ii) to determine the physiological changes that take place when AR is inhibited; such 
as motor nerve conduction velocity (MNCV),
iii) to determine the potential therapuetic use of AR inhibitors.
The belief was that if AR could be inhibited the formation of sorbitol from glucose 
would not occur. Therefore, the absence of accumulated sorbitol in certain tissues 
would inhibit the onset or continuance of complications. Most of the AR inhibitor 
studies have been carried out in rodents with experimental diabetes and clinical trials 
in man. The structures of the AR inhibitors most commonly under investigation are 
shown in figure 2 .
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CP-45,634, "SORBINIL" BARBITAL
(S-isomer) X=F
CP-43,659 Internal standard for HPLC (Ref Travis et al., 1971)
(racemic) X = Cl 
(Ref Peterson et al., 1979)
ICI 128,436 "STATIL" or "PONALRESTAT" AY-22,284 "ALRESTATIN"
(Ref Stribling et al., 1985) (Ref Dvornik et al., 1973)
Figure 2 . Structures of Some Aldose Reductase Inhibitors
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QUERCETIN, X=OH AY-27/773 "TOLRESTAT"
QUERCITRIN, X=0-L-Rhamnose
(Ref Varma et al., 1975) (Ref Hicks et al., 1984)
s
ONO-2235 
(Ref Asano et al., 1986)
Figure 2 cont. Structures of Some Aldose Reductase Inhibitors
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1.5.3.1 Animal AR Inhibition Studies
Peterson et al., (1979) showed inhibition in-vitro of calf lens AR by the Pfizer novel 
compound CP-45,634 (Sorbinil; d-6-fhioro-spiro[chroman-4,4’-imidazolidine]-2’,5’dione). 
Using GLC analysis of TMS derivatives they found a lack of polyol formation in 
isolated rat sciatic nerve when incubated in-vitro with Sorbinil and 50 mM glucose. 
Furthermore, there was an 85% inhibition of sciatic nerve sorbitol accumulation in 
streptozotocin induced diabetic rats when given oral Sorbinil at 0.75 mg/kg. In a 
similar group of diabetic rats given Sorbinil orally, at a dose of 2.5 mg/kg for 1 week, 
the sorbitol accumulation in nerves and lens was reduced by 90%. At a daily Sorbinil 
dose of 5 mg/kg for 4 weeks galacitol formation was prevented in 90% of galctosaemic 
rats for up to 25 days. At 29 days 50% of the galactosaemic rats had developed 
lenticular opacities. At a Sorbinil dose of 10 mg/kg only 10% of the rats developed 
signs of cataract formation. It appeared that Sorbinil was a potent inhibitor of AR and 
that the effect was dose related.
Finegold et al., (1983) found that oral Sorbinil, dosed at 20 mg/kg daily for 2 weeks, 
completely prevented the fall in nerve myo-inositol and rise in nerve sorbitol in diabetic 
rats, compared to untreated control. Tissue myo-inositol concentrations were 
determined by GLC of the TMS derivative. Sorbinil, in this experiment, did not have 
an effect on diabetic plasma myo-inositol levels.
Gillon et al, (1983) obtained similar results, where Sorbinil was also shown to prevent 
an increase in nerve fructose content and reduced the extent to which motor nerve
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conduction velocity (MNCV) was slowed. Serum myo-inositol (analysed by GLC of the 
TMS derivative) was raised in severely diabetic rats but normalised by treatment for 2 
days with Sorbinil. Yue et al., (1984), using an enzymatic assay, again obtained similar 
results to the above in diabetic rats when treated with Sorbinil. They also showed a 
significant correlation between erythrocyte and nerve sorbitol content. Erythrocyte 
sorbitol was raised in the diabetic rats but was only partially normalised by Sorbinil 
treatment.
Greene and Lattimer (1984) studied the effect of Sorbinil treatment on sodium 
potassium adenosine-triphosphatase activity (Na/K ATPase) in sciatic nerve 
homogenate. They found the activity of this enzyme to be reduced by 25% in untreated 
diabetic rats and that Sorbinil treatment increased the activity towards normal. The 
authors found that Sorbinil prevented the depletion of myo-inositol content in diabetic 
rat sciatic nerve (analysis by GLC) and postulated that the restoration of nerve 
myo-inositol levels had a direct effect on the Na/K ATPase activity. Yeh et al., (1987) 
found that the transport activity of Na/K ATPase in lens from rats with a 2 week 
duration of diabetes was decreased. In these lenses the levels of sorbitol were ten fold 
higher than control with a very depleted myo-inositol content. The daily dose of Sorbinil 
required to restore the ATPase activity to normal was less than that required to 
restore the myo-inositol content to normal. The authors concluded that myo-inositol 
may not be directly linked with the restoration of ATPase activity. A similar result has 
been reported by Lambourne et al., (1988) who compared the restoration of ATPase 
activity with the inhibitors Sorbinil, statil and tolrestat.
34
Stribling et al., (1985) found that the novel ICI compound statil (ICI 128,436, 
(3-[4-bromo-2-fluorobenzyl]-4-oxo-3H-phthalazin-l-yl acetic acid) at a daily oral dose 
of 25 mg/kg completely prevented the development of cataracts in diabetic rats for up 
to 74 days. Statil was found to reduce the elevated sorbitol content in sciatic nerve, 
lens, retina and adrenal cortex of diabetic rats. In addition statil prevented galactitol 
accumulation in erythrocytes of rats receiving a galactose diet and restored the MNCV 
to normal. Tissue polyol levels were analysed by packed column GLC of the TMS 
derivatives.
Hotta et al., (1985) compared the novel Japanese compound ONO-2235, 
(E-3-Carboxymethyl-5-[(E)-2-methyl-3-phenylpropenylidene]rhodamine)with alrestatin 
(Ayerst) in streptozotocin diabetic rats fed a 12% fructose rich diet. They found a 
positive correlation between the sciatic nerve sorbitol content and impaired MNCV. 
Treatment with ONO-2235, at a daily dose of 50 mg/kg for 4 weeks, prevented both 
the nerve sorbitol accumulation and the impairment of MNCV. Using an enzymatic 
assay (similar to that of Malone et al., 1980) these authors found a positive correlation 
between the erythrocyte sorbitol content and the sorbitol content of sciatic nerve and 
retina. A further interesting observation was that diabetic rats receiving insulin 
treatment alone had normal MNCV.
Cameron et al., (1986) demonstrated similar results to those described above with oral 
Sorbinil, given at a daily dose of 25 mg/kg for 6 months, in diabetic rats. They also 
examined the morphology of nerves and found that in untreated rats the axon area was 
reduced by 14% compared to age matched Sorbinil treated rats. They suggested that 
the retarded axon growth could cause the defect in MNCV associated with diabetic
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complications. This is an interesting observation when compared to the results of 
Gabbay and O’Sullivan who had associated AR mainly with the schwann cell and SDH 
predominantly with the axon. The inference from these observations are that schwann 
cell changes predominate over changes in the axon.
Other studies (Bareford et al., 1986, and Robey et al., 1987) have shown that 
erythrocyte deformability is decreased in diabetes and that Sorbinil can improve the 
ability of the erythrocyte to deform. This effect may be linked to the increased polyol 
content and swelling of the erythrocyte. The rheology of osmotically swollen 
erythrocytes suggests that the swollen red blood cell would not pass through the 
capillary vessel bed of tissues, as easily as normal blood cells, thereby decreasing the 
tissue oxygen supply. Lightman et al., (1987) found an increased permeability of 
sucrose across the blood-retinal barrier in long-term galactose fed rats. The 
permeability of sucrose across the blood-retinal barrier was reduced in galactose fed 
rats also given Sorbinil. The relationship between aldose reductase and increased 
sucrose permeability is unclear. However, there is an increase by 200% in the retinal 
capillary basement membrane thickness in the galactosaemic rats. This thickening is 
not seen in control or Sorbinil treated rats.
1.5.3.2 Clinical Observations of AR Inhibition in Man
One of the first studies in humans of an AR inhibitor was that of Gabbay et al., 
(1979). They reported their initial investigation of the Ayerst AR inhibitor alrestatin 
(1,3 dioxo-lH-benz(de)isoquinoline 2(3H) acetic acid) given orally to normal adult 
males and to four adult maturity onset diabetics. The normal adult males given
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alrestatin orally at different doses provided valuable data on the pharmacokinetics of 
alrestatin. The four diabetic patients were characterised by the recent onset of clinically 
severe peripheral neuropathy, which was assessed by subjective observations and by 
decreased motor nerve conduction velocity. The diabetic subjects were given alrestatin 
orally at a dose of 1 g for 30 days. There was no improvement of the motor nerve 
conduction velocity at that dose. Two of the diabetic patients also received alrestatin 
by intravenous infusion. Two days after the infusion some objective benefit was 
reported but no improvement in the MNCV was observed. The authors also commented 
on the lack of a suitable in-vitro test to determine the effect of alrestatin on AR 
inhibition. Handelsman and Turtle (1981) reported no improvement in MNCV in nine 
insulin dependent diabetics with severe painful neuropathy when given alrestatin orally 
at individual daily doses ranging between 3-7 g. There was evidence, in the form of 
photosensitive skin rash, for a poor tolerence to alrestatin at the doses used.
Judzewitsch et al., (1983) studied the effect of oral Sorbinil on nerve conduction, at 
either a daily dose of 250 mg for 9 weeks or a 9 week placebo period, in 39 stable 
diabetic patients without signs of peripheral neuropathy. There was a small but 
statistically significant improvement in MNCV during the Sorbinil treatment period 
which declined upon cessation of Sorbinil treatment.
Popp-Snijders et al., (1984) found that oral Sorbinil, given at a daily dose of 200 mg 
for 12 weeks to 14 diabetic patients, reduced the erythrocyte sorbitol concentrations 
by 75% to within normal non-diabetic levels. A parallel placebo treated group of 
diabetics did not show any changes in erythrocyte sorbitol concentrations. There was 
no change in erythrocyte myo-inositol concentrations between placebo or Sorbinil
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treated diabetics. The study was conducted over 20 weeks with 4 week run-in and 
run-out placebo treated periods. Erythrocyte sorbitol and myo-inositol concentrations 
were determined once every 4 weeks using a modification of their capillary GLC assay.
Fagius et al., (1985) found a small but significant improvement in peripheral nerve 
function in 27 male diabetics given oral Sorbinil, 250 mg daily for 6 months, compared 
to matched placebo treated diabetics. Both placebo and Sorbinil treated groups 
comprised diabetics who had symptoms of symmetrical neuropathy for a least 1 year 
as evidenced by reduced nerve conduction in both legs. The authors noted that the 
Sorbinil treated diabetics who showed the most subjective improvement were the 
patients who had neuropathy symptoms of least duration.
Martyn et al., (1987) found no evidence of improvement in nerve function in 22 
diabetics with abnormal nerve function when given Sorbinil at a daily dose of 125 mg 
for 6 months. Erythrocyte sorbitol was measured (using the method of Popp-Snijders) 
at 3 and 6 months and there was a noticeable 60% decrease to within and below the 
normal non-diabetic range. Guy et al., (1988) found no clinical or neurophysiological 
benefit, in diabetic patients with neuropathy, when treated with Sorbinil at a daily dose 
of 250 mg daily for 1 year.
The pattern that has emerged from studies of AR inhibitors in animals and man is as 
follows. In general, diabetic tissue levels of sorbitol and myo-inositol are respectively 
raised and lowered in content. Inhibition of AR tends to reverse the changes in polyol 
tissue content towards normal. This is especially evident from rodent studies. In man 
AR inhibition normalises the erythrocyte sorbitol content and is believed to be an
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indicator of the same process in less accessible tissues: such as kidney and nerve. The 
normalisation of erythrocyte sorbitol, upon AR inhibition, in rodents and man always 
occurs irrespective of the degree of severity of diabetic complication. Most of the 
erythrocyte sorbitol measurements, in the clinical trials, are made at least one week 
apart. There is a need to establish in-vivo how quickly the erythrocyte sorbitol responds 
to AR inhibition.
Erythrocyte myo-inositol levels do not appear to be affected by AR inhibitor therapy 
in man. In this case the erythrocyte may not reflect the myo-inositol behaviour in less 
accessible tissues. In the relatively simple erythrocyte, myo-inositol will be turned over 
regularly with phosphatidylinositol in the membrane resulting in an average 
intracellular myo-inositol concentration. In other tissues, for example nerve, the role 
of myo-inositol is more specialised. In the nerve there are complicated biochemical 
processes, such as the interaction between myo-inositol and the induction of the ATPase 
protein, specifically designed to generate the action potential.
In diabetes the normalisation of MNCV appears to be dependent on the degree of 
severity of neuropathy. There is noticably much less benefit, for patients treated with 
AR inhibitors, when the degree of severity of neuropathy is increased. This observation 
is supported both clinically (including subjective observations by the patient) and by 
neurophysiological assessment. Patients with only a short duration of neuropathy 
appear to respond best to AR inhibition therapy. This is especially evident from the 
Sorbinil clinical trials in diabetics with varying degrees of complication. The 
biochemical consequences of AR inhibition therapy must also not be overlooked. 
Successful AR inhibition can contribute to hyperglycaemia, which in turn other
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biochemical pathways will attempt to normalise, with subsequent and as yet unknown 
consequences.
However, the major and over-riding benefit of AR inhibition therapy is the relief of 
severe pain that results from diabetic polyneuropathy. Treatment early on at the first 
signs of complications developing may help to inhibit the onset of irreversible 
biochemical changes. To this end alone an in-vivo indication of the efficacy of AR 
inhibition can be obtained by measuring erythrocyte sorbitol levels before and during 
treatment with AR inhibitors. As yet there is no such simple test and it is one of the 
major aims of this thesis to try and establish one. The role of AR in diabetic 
complications of the eye has been reviewed by Kinoshita et al., (1979). Diabetic 
complications and AR inhibition has been reviewed by Clements (1985). Recent 
advances in AR therapy has been reviewed by Greene and Lattimer (1985). AR 
inhibition and nerve conduction has been reviewed by Pfeifer (1985). Sorbinil therapy 
in painful neuropathy has been reviewed by Jaspan et al., (1985).
From all the evidence above it is clear that the polyol pathway exists in animals and 
man. The physiological significance is unclear but the pathway probably exists for 
tissues that require fructose as an energy source. In tissues known to have this pathway 
normally, such as the seminal vesicles, the polyol flux through the activated pathway 
is high and only low levels of polyol are encountered. In some diabetic tissues there 
is a disturbance of the polyol flux through what is essentially a dormant pathway, which 
has been activated by a predominantly hyperglycaemic environment. The evidence that 
the pathway has been activated comes from the observation of changes in polyol 
content in tissues, of which the erythrocyte appears to partially model those changes
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in other tissues. From there on the exact sequence of pathophysiological events which 
cause diabetic complications has still to be determined.
In the case of diabetes the polyol pathway is not the only alternative route for excess 
glucose metabolism. Excess glucose can also undergo non-enzymatic glycosylation of 
proteins, of which the best known example is the glycosylation of haemoglobin, (Bunn 
et al., 1978). Also recent interest has centered around the non-enzymatic glycation by 
glucose of serum albumin and protein, which has become known by the term 
fructosamine, (Johnson et al., 1982). The clinical relevance to diabetes of fructosamine 
has been reviewed by Kennedy and Baynes (1984) and Armbuster (1987).
In many of the above studies the role of chemical analysis has been fundamental to the 
determination of the sometimes subtle polyol changes observed in various tissues. 
Therefore a  reliable method for the determination of polyols in biological matrices is 
essential to onr understanding of the role these compounds have in normal and disease 
conditions.
1.6 The Chemical Analysis of Polyols in Biological Samples
In general, the methods for the determination of polyols in biological samples falls into 
three categories; chemical, biochemical and chromatographic. Some of the chemical 
reactions of polyols can be used for their determination, especially where only one 
polyol is present in a pure solution. An example is the oxidative cleavage of sorbitol, 
by periodic acid, to formic acid and formaldehyde. The formaldehyde can be titrated 
against iodine and the titration value compared to sorbitol standards treated in the
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same way. This sort of analysis is very unspecific when applied to biological samples 
containing other polyols, sugars or compounds which also react. Moreover, wet 
chemical techniques are limited by a lack of specificity when the desire is to measure 
a single component in a complex mixture. There is thus a requirem ent to separate the 
individual polyol components from other interfering compounds present in a biological 
or other complex mixture. However, after appropriate separation procedures, chemical 
reactions can still be employed to visualize the individual polyol and carbohydrate 
components.
An early separation technique for polyols, paper electrophoresis, was first suggested 
by Frahn and Mills (1956) who examined the migration of hexitols and their related 
hexoses in various electrolytes. The migrated hexitols were visualized as pale areas on 
a brown background when the paper was sprayed with potassium permanganate and 
chromium trioxide in sulphuric acid. A  similar electrophoretic system was used by van 
Heyningen (1959b) for the semi-quantitative determination of polyols in cataractous 
rat lens. The major problem with the paper electrophoresis method was one of accurate 
quantitation, which is also a problem with paper chromatography. In order to overcome 
the lack of sensitivity, associated with these techniques, one alternative approach is the 
use of enzyme assays.
1.6.1 Enzymatic Methods for the Determination of Polyols
The advantage of enzyme methods for the determination of polyols over chemical, 
electrophoretic and paper chromatographic methods is speed of analysis and greater 
quantitative power. The principle action of an enzyme is as a biological catalyst in the
42
conversion of a substance (substrate) to a product. The substrate must specifically 
interact with the enzyme, often requiring a cofactor, to form a complex resulting in 
the formation of a product under suitable conditions of tem perature and pH. 
Enzymatic assays are normally optimised so that the end point visualisation is 
dependent upon the substrate concentration.
Polyols are formed in nature by the biological reduction of their respective sugars by 
oxido-reductase enzymes (dehydrogenases) which require pyridine nucleotide cofactors; 
either the cofactor reduced nicotinamide-adenine dinucleotide (NADH2) or the 
phosphorylated form of the latter reduced nicotinamide-adenine dinucleotide phosphate 
(NADPH2). The respective oxidised version of these two cofactors is NAD+ and 
NADP+. The pyridine nucleotide cofactors have absorption spectra with maxima at 340 
nm for the reduced form (NADH, NADPH) and 260 nm for the oxidized form (NAD+, 
NADP+). Oxidoreductive enzyme reactions can be followed by observing the change 
in absorbance, either an increase or a decrease, of the relevant reduced cofactor at 340 
nm in a  spectrophotometer. This fact is one of the most exploited spectral properties 
of the pyridine nucleotide dependent reactions forming the basis of many quantitative 
enzyme assays. The change in cofactor absorbance after a given period of time, or at 
end point of the reaction, is used for the determination of substrate concentration by 
interpolation from calibration standards. In this way many of the natural synthetic 
pathways for polyol formation, reduction of sugars by enzymes, can be exploited in the 
reverse direction, oxidation of polyols to sugars, for their rapid and quantitative 
determination.
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There are different enzyme methods for the determination of a number of polyols. 
Polyols that have reported enzyme methods include ethylene glycol, glycerol, L-threitol, 
xylitol, ribitol, sorbitol, D-mannitol and myo-inositol (Bergmeyer, 1984). An early 
example of the determination of sorbitol using an enzyme method was reported by 
Clements at al., (1969) who used the enzyme sorbitol dehydrogenase (L-iditol: NAD 
oxidoreductase, EC 1.1.1.14) purified from sheep liver to determine the concentration 
of sorbitol in rabbit aorta. The concentration of sorbitol was also determined in-vitro 
by this enzyme method when sections of aorta were incubated with varying amounts 
of glucose. Malone et al., (1980) modified the previous method for sorbitol and used 
it to determine the erythrocyte sorbitol content. The standards in erythrocytes ranged 
from 0.2-9.0 /ig/ml or 1.0-50.0 nm ol/m l with a limit of quantitation of 0.06 Mg/ml. The 
sorbitol was converted to fructose by sorbitol dehydrogenase (SDH) and the NADH 
produced detected fluorimetrically by excitation at 366 nm and emission at 452 nm. 
The fluorimetric detection of NADH adds to the sensitivity of the assay by being more 
specific for NADH than other compounds which increase the background absorbance 
at 340 nm. These authors gave no accuracy or precision data for the erythrocyte 
sorbitol assay but indicated that the enzyme preparation from sheep liver was highly 
specific for sorbitol. The specificity of the enzyme increases the sensitivity of the assay 
because the enzyme specifically converts only the substrate. Thus, highly sensitive and 
specific assays for individual polyols can be obtained by using purified specific enzymes 
along with fluorescence detection of the cofactor for enhanced detection.
The method of Beutler (1984a) for sorbitol determination has the advantage of 
increased specificity. Sorbitol is converted to fructose by SDH and the NADH 
produced is removed by lactate dehydrogenase with the concomitant conversion of
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pyruvate to lactate. Fructose is converted by a series of coupled reactions to 
gluconate-6-phosphate with the production of NADPH. The enzyme phosphoglycerate 
isomerase that converts fructose-6-phosphate to its glucose counterpart is highly specific 
for fructose which is only produced by the conversion of sorbitol; therefore increasing 
the assay specificity for sorbitol. This assay was reported to be linear between 5 and 
180 nm ol/m l sorbitol per assay solution. The detection limit was about 3 nm ol/m l 
which is higher than that reported by Malone et al (1980) and is mainly due to larger 
dilution factors used in the assay and detection of NADPH at 340 nm. The relative 
standard deviation of the assay was determined at two levels; 50 and 120 nm ol/m l and 
were 0.6 and 1.0% respectively. W hen applied to human plasma the range of values 
obtained were 3.7-4.5 nm ol/m l plasma in normal and less than 2.5 nm ol/m l plasma in 
carbohydrate poor diets.
The hexitol mannitol has been determined in fungal spores and pharmaceutical 
preparations using the enzyme D-mannitol dehydrogenase purified from Aspergillus 
oryzae. The products of the enzyme reaction are fructose and NADPH and the assay 
was reported to have a standard deviation of 10% at the detection limit of 1 jumol per 
cuvette. However, the assay is non specific with glycerol, erythritol and galactitol 
reacting with the enzyme (Horikoshi 1984).
The hexahydroxycyclohexane myo-inositol can be determined using an inositol 
dehydrogenase enzyme purified from bacteria. The product of the reaction is 
scyllo-inosose (2,4,6/3,5 pentahydroxycyclohexanone) and NADPH. The method was 
reported to have a limit of detection of 0.01 /rniol but no further assay data was 
available (Weissbach 1984). This method has been adapted by MacGregor and
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Matschinsky (1984) for the determination of myo-inositol in serum and tissues. The 
enzyme myo-inositol dehydrogenase (myo-inositol: NAD* oxidoreductase, EC 1.1.1.18) 
from the bacteria Enterobacter aerogenes converts myo-inositol to scyllo-inosose and 
the NADH produced is removed in a coupled reaction by the concomitant conversion 
of oxalacetate, by malate dehydrogenase, to malate which is determined 
fluorimetrically. This assay was shown to be highly specific for myo-inositol with no 
interference from other polyols, although excess glucose has to be removed to avoid 
interference. This method was reported to be extremely sensitive with detection limits 
as low as 1 pmol in tissues such as rat serum and hampster lens, cortex and pancreatic 
islets.
The three carbon polyol glycerol can be specifically determined by its conversion to 
L-glycerol-3-phosphate by glycerokinase and a coupled reaction that exclusively 
converts the phosphorylated glycerol to dihydroxyacetone phosphate and NADH; with 
the later conversion by the enzyme glycerol-3-phosphate dehydrogenase (EC 1.1.1.8). 
Reference ranges in normal human serum are reported to be between 4-8 Mg/ml with 
assay relative standard deviations between 1-4% (Wieland 1984).
The diol ethylene glycol can be determined by the enzyme alcohol dehydrogenase 
(ADH, EC 1.1.1.1) which in this reaction produces glycolaldehyde and NADH. Other 
volatile alcohols such as methanol and ethanol also react significantly but the polyols 
glycerol, sorbitol and mannitol do not interfere. The relative standard deviations of the 
assay were found to be 5.6 and 3% at levels of 10 and 183 jj,g/m l respectively 
(Eckfeldt and Light 1984).
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Enzymatic methods for the determination of polyol derivatives include a method for 
2,5-anhydro-mannitol (Dills et al., 1983) and sorbitol-6-phosphate (Supp 1984). In the 
case of 2,5-anhydro-mannitol it is phosphorylated by hexokinase and NADH is 
determined by a coupled enzyme reaction in a method that is relatively nonspecific, 
with fructose and other analogues of the anhydro-polyol also reacting. The presence 
of glucose which also interferes can be removed by pretreatm ent of the sample with 
the enzyme glucose oxidase. Validation of this method was carried out by recovery 
studies of anhydro-mannitol spiked into rat serum. It is of interest that no endogenous 
levels of anhydro-mannitol were found in rat serum, indicating that this compound is 
not normally present.
An enzymatic method for sorbitol-6-phosphate has been reported where the phosphate 
group is cleaved from the C6 position by the enzyme alkaline phosphatase and the free 
sorbitol is then converted to fructose by SDH with detection of NADH (Supp 1984). 
Using appropriate blanks any endogenous sorbitol can be accounted for; but the non 
specific alkaline phosphatase will cleave any phosphate group regardless of its position 
on the sorbitol molecule.
The main problem with enzyme assays when used to determine the concentration of 
a substrate is one of specificity. Generally there is no such problem with samples in 
pure solution. Biological matrices, such as tissue homogenate, whole blood or plasma 
contain many other compounds, for example amino acids, carbohydrates, lipids and 
proteins, all of which can potentially interfere by acting as substrates or inhibitors of 
the enzyme. Some of these potential sources of interference can be overcome by their 
removal during sample preparation. For example, proteins can be precipitated by acid
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or base and lipids and fats removed by their extraction with a non-polar solvent. In 
addition, assay conditions can be chosen to favour the maximum efficiency of a 
particular enzyme which has its own optimum for pH, tem perature and ionic 
environment.
The purity of the enzyme preparation, however, is singly the most important factor in 
considering the specificity of enzyme assays. Crude enzyme preparations are more 
likely to contain substantial amounts of other enzymes. So for polyol analysis any 
particular dehydrogenase enzyme preparation should be substantially free of other 
oxidoreductase activity. O ther polyols have been reported to be converted by SDH and 
include xylitol and L-threitol (Beutler 1984b, Goedde and Langenbeck 1984). In this 
case, no m atter how pure the enzyme preparation of SDH, these polyols are still 
converted which has led some workers to rename SDH as Polyol Dehydrogenase.
Overall the advantages of enzymatic methods for the determination of substrates out 
weighs the disadvantages. The advantages include, cost effective, fast analysis times 
with automation for large sample number turnover, good precision and high sensitivity. 
The disadvantages include lack of specificity and only single component analysis. 
Enzyme assays are the method of choice for routine screening of large numbers of 
samples in hospital laboratories. Enzyme assays would be the method of choice if 
pre-purification of the biological sample rendered only the single component of 
interest. It is this latter consideration that in part has led to the use of chromatographic 
separation techniques for the analysis of complex mixtures in general and polyols in 
particular.
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1.6.2 Chromatographic Separation of Polyols
Chromatography is a term  used to describe systems by which components of a liquid 
mixture may be separated. Separations can be achieved by dissolving the mixture in a 
mobile phase, classically a liquid or a gas, and allowing this mobile phase to flow 
through a stationary immobile phase which is either a  liquid or a solid. Separations 
are achieved by the relative affinity of the different solute molecules for the stationary 
phase which retains them  to different extents. Thus, molecules which are retained by 
the stationary phase are separated from those which have more affinity for the mobile 
phase.
In liquid chromatography (LC) the mobile phase is an aqueous solution, organic 
solvent or a mixture of these which carries the solutes over a bed of stationary phase 
which can be in the form of a thin layer or packed in a column. The latter is nowadays 
the most popular form of LC because modern instrumentation, with continuous flow, 
automatic injectors and sensitive detectors, facilitates the on line quantitation of 
solutes as they elute from the column. Such systems together with highly efficient 
columns (available commercially from many sources) have now become known variously 
as high performance, high speed or high pressure liquid chromatography (HPLC).
With paper and thin layer chromatography (TLC) the major drawback has been the 
accurate quantitation of separated components. The situation for TLC is, however, 
changing with the progressive use of this technique coupled to the flame ionisation 
detector (FID) for enhanced quantitation. In addition, when used in combination with 
nuclear magnetic resonance (NMR), TLC can serve as a powerful qualitative method
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for the initial identification of drug metabolites and for screening purposes in forensic 
toxicology.
There are four or five modes of operation of HPLC based upon the principles by 
which components are selectively retained. These modes are adsorption, partition, ion 
pairing, ion exchange and size exclusion. In adsorption chromatography (solid liquid 
chromatography) separation occurs due to interaction between the solutes and the 
surface of the solid porous stationary phase.
The most widely used solid phase in adsoption chromatography is silica which has polar 
silanol groups on its surface. Generally, eluents used for adsorption chromatography 
are non-polar organic solvents and non-polar solutes soluble in the eluent are separated 
by this means; which is often refered to as normal phase chromatography. Polar solutes 
can interact with the free silanol groups of silica which are slightly acidic and hence 
basic groups are very strongly adsorbed often resulting in their complete retention. 
W ater present in such a system is adsorbed by the free silanols. As a result of this the 
irradication of water in the system is essential for the effective elution of non-polar 
compounds. For some applications there is the possibility of adding small amounts of 
water or other polar solvents to the eluent in an attem pt to partially control their 
presence. However, in so doing the nature of the silica surface is altered dramatically 
and the separations obtained can be irreproducible because of competition between 
the partially solvated silanol groups and the solute. It is partly due to this problem 
that much attention has been devoted to partition (liquid:liquid) chromatography as 
an alternative means of separating polar components.
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In partition chromatography, separation is achieved by a liquid stationary phase which 
is immiscible with the eluent. The most common form that this takes is with a non-polar 
stationary liquid phase, such as the octadecyl (ODS, C18) phase and a polar mobile 
phase, such as a m ethanol/w ater mix. W hen used in this form partition chromatography 
is classically used for the separation of polar components which include many drugs 
and their metabolites. This is particularly useful because many modern drugs are low 
molecular weight, non volatile, polar compounds which when metabolised in-vivo 
become more polar to aid their excretion.
Originally in partition chromatography the non-polar phase was coated on either silica 
or some other inert porous particle. More usual now is the attachment of non-polar 
alkyl groups to the free silanols of silica to produce bonded non-polar phases 
containing alkyl chains of various lengths; typically from C5 up to C18. In normal phase 
(adsorption) chromatography the polar components are the last to elute if at all 
whereas in partition chromatography with a polar eluent the polar solutes elute first 
and this has led to the use of the term  reversed phase chromatography. However, the 
advent of bonded phases for HPLC is not confined to non-polar alkyl derivatives. 
There is a vast range of intermediate polarities arising from the bonding to silica of 
other compounds which contain groups such as phenyl, cyano, nitro, amino and 
hydroxyl which are often situated on alkyl moities acting as spacers.
As a consequence of the various stationary phases now available partition 
chromatography can be used in a variety of modes where selectivity is further enhanced 
by modification of the eluent. In drug analysis, for example, the pH  of the eluent and
51
the pKa of the drug are important since in reversed phase HPLC the non-ionised 
species of the drug exhibits greater retention. Thus, acidic drugs show an increase in 
retention as the pH  of the eluent is lowered whereas under these conditions bases 
would show a decreased retention.
An alternative eluent modification is the addition of hydrophobic cations or anions to 
the polar eluent in reversed phase LC. For drugs that have positive or negative charges 
the addition to the eluent of an oppositely charged hydrophobic counter ion results in 
the formation of a neutral ion pair with the drug and an increase in retention. For 
example, the use of sodium salts of alkylsulphonic acids, such as sodium 
octylsulphonate, can be used as an ion-pair for basic drugs. Quaternary ammonium 
compounds, such as tetrabutylammonium salts are used as ion-pairs for acidic drugs. 
This form of LC is known as ion-pairing and generally the concentration of the counter 
ion added to the eluent is between 1 to 5 mM. With prolonged use of eluents 
containing pairing ions or when the ion-pair is present in high concentrations the 
surface of the packing material can become saturated producing a stationary phase 
which can act like an ion exchanger.
Ion exchange is another mode of LC separation which consists of a stationary phase 
containing anionic or cationic groups on the surface to which solutes of opposite charge 
are attracted. There are two types of widely used ion exchange column packings based 
on either ion exchange resins or bonded phase silicas. A  third kind of ion exchange 
column consists of ion exchange micro beads of up to 0.1 gm diameter bonded to 
nonporons resin particles with a uniform radius of approximately 5 gm. The latter type 
of columns (patented by Dionex) have the advantages of rapid diffusion, high efficiency
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and mechanical strength. These columns have been used for a wide variety of 
separations but so far their high cost can be prohibitive.
Size exclusion LC makes use of a stationary phase that has a controlled pore size such 
as rigid minute glass beads or silicas. Alternatively the stationary phase can be 
semi-rigid; made from copolymers such as polystyrene-divinyl benzene. W hen silica of 
controlled pore size is used adsorption effects can occur so these exclusion phases are 
best used as normal phase systems with organic solvents as mobile phase. In size 
exclusion LC solutes are separated according to their molecular size and ability to 
enter the pores. Larger molecules unable to enter the pores elute first and the smaller 
molecules are retained by specific interactions occuring within the pore. The 
introduction of microparticulate packings in size exclusion allows large molecules or 
polymers of molecular weights over 1000 to be separated. As a consequence size 
exclusion has been used as a technique to determine molecular size and weight and 
is especially useful for the characterisation of large biomolecules such as globulins, 
proteins and oligosaccharides.
Separation of solutes in adsorption chromatography is primarily due to hydrogen 
bonding between free silanol groups and the solute. Separation in partition 
chromatography is due to intermolecular forces, which include hydrogen bonding, 
induced dipole interaction, dispersion forces and specific interaction forces. In addition, 
in many separations irrespective of the mode of operation, there are elements of ion 
exchange and size exclusion which also contribute to the separation mechanism. In LC 
a prime requirement is that the solutes are soluble in the mobile phase and a first
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indication of the type of mode to be selected can be summarised in the rule that like 
polarity dissolves like.
The advantage of HPLC is the wide selectivity available by choosing various 
combinations of stationary and simple or modified mobile phases. This is enhanced by 
the use of gradient elution which is particularly appropriate to bonded phase columns 
which are able to equilibrate quickly between the original and final amounts of binary 
or ternary solvent combinations. Furthermore, sensitive on line detectors can be used 
in sequence to add to the selectivity of the technique. The most common detectors 
used in HPLC are the ultraviolet-visible detector, the fluorescence detector, the 
refractive index detector and the electrochemical detector.
The disadvantages of HPLC include the relatively narrow pH  range for bonded phases 
typically between 2 to 8. Non-polar bonded phases can be stripped from the support 
at high pH. A  further disadvantage of HPLC is the lack of a sensitive detector such as 
the highly sensitive and specific electron capture detector (ECD) used in gas liquid 
chromatography. To a certain extent this problem is being overcome by the apparent 
technical feasibility of coupling mass-spectrometry as a detector to HPLC. Once the 
final problem of removing the liquid eluent before it enters the detector is solved then 
HPLC-MS, in terms of selectivity and detection, will be one of the ultimate 
chromatographic techniques limited only by its high cost.
By contrast to HPLC, gas-liquid chromatography (GLC), in more recent times less 
popular, is gaining favour because of the introduction of highly efficient capillary 
columns containing cross-linked and immobilized liquid stationary phases. These phases
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cover a range of polarities from the non-polar methyl silicones to the polar carbowax 
types. However, the most common commercially available phases, obtained already 
immobilised in capillary columns, are of the non-polar to mid-polar variety. This is 
partly due to technical difficulties in bonding polar phases to the internal silica wall. 
The dimensions of capillary columns are typically 10, 25 or 50 metres in length with 
internal diameters of from 0.25 mm (narrow bore columns) to 0.5 mm (mega bore 
columns). The phase thickness, either coated or bonded onto the inside of the 
capillary, are usually thin 0.25 gm in narrow bore columns and anything up to 2 or 3 
gm in mega bore columns. Extra strength is given to fused silica columns by coating 
the outside of the column with a heat resistant polymer such as polyimide.
In capillary GLC the mobile phase is an inert gas, such as helium or nitrogen, which 
carries the gaseous mixture through the column. Separations are carried out by 
injecting the sample into the inlet of the column which is held at a constant 
temperature in an oven. Each component of the mixture is swept towards the detector 
by the carrier gas and the solutes partition between the stationary and mobile phase. 
Molecules with the greatest affinity for the stationary phase spend a longer period in 
it and consequently take longer to reach the detector. The column tem perature can be 
increased by temperature programming, to facilitate the elution of components retained 
in the stationary phase, which is the GLC equivalent to gradient elution in HPLC. The 
commonly used detectors in GLC are the universal flame ionisation detector (FID), 
ECD and mass-spectrometer.
The important difference between HPLC and GLC is the degree of selectivity 
available. In HPLC eluent modification can dramatically alter the selectivity and
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therefore the separation obtained. Whereas in GLC only the stationary phase and the 
temperature have any significant effect on the separation. Although with capillary GLC 
the injection technique is an important factor in obtaining efficient separations. This 
is because it is technically difficult to inject directly onto the top of a capillary column 
particularly those that have narrow internal diameters. This problem does not occur 
with packed GLC columns. With HPLC there is no one universal elution system, 
universal detector or unified retention scale. Whereas GLC has this in the form of low 
polarity phases, the universal FID detector and the retention index scale.
GLC complements HPLC and is used for compounds that are readily volatilised such 
as organic solvents and alcohols. GLC is less suitable for those compounds that are 
thermally labile or of low volatility or compounds that have polar functional groups 
such as many drugs. However, in between these extremes there are drugs that can be 
separated by both chromatographic techniques and the choice depends upon the 
availability of detection and the ability to separate the compounds of interest.
Sample preparation of biological matrices is important in HPLC and GLC 
chromatographic separations. Techniques are used in order to remove sources of 
potential interference, to render the solute in a suitable form for a given application, 
to enhance detection limits, to reduce the time required for an analysis and to reduce 
contamination preserving the working life of the column. Sample preparation 
procedures include protein precipitation with or without pH  adjustment, solvent 
extraction with or without back extraction, derivatisation and sample concentration. 
These can all be used in various combinations depending upon the nature of the 
sample, the chromatographic conditions and the type of detector used to monitor the
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eluting components. Sample preparation procedures in combination with HPLC or 
GLC are extensively used in the determination of drugs in biological fluids as has been 
reviewed by Chamberlain (1985). The use of these techniques for the separation of 
sugars and polyols are discussed below in sections 1.6.2.1 and I.6.2.2.
1.6.2.1 Trace Analysis of Polyols by HPLC
The analysis of polyols by HPLC is complicated by the fact that low concentrations of 
carbohydrates and polyols are difficult to detect by conventional techniques. Many 
drugs contain chromophores or fluorophores which enable them to be detected by 
spectrophotometry or fluorimetry. Simple carbohydrates and polyols, such as those 
already described, do not contain chromophores or fluorophores in the molecule and 
cannot be detected by spectro-fluorometric detectors. In order to enhance polyol 
detection one or more of the hydroxyl groups can be derivitized with a chromophore 
or fluorophore. One approach for the HPLC analysis of trace levels of polyols might 
employ either derivatisation of the sample prior to chromatography or post-column.
The derivatisation of carbohydrates and polyols, including sorbitol, has been described 
by Nachtman and Budna (1977) who prepared the nitrobenzoate derivatives. The 
derivatives of glucose, fructose and sorbitol were prepared in pyridine using 
nitrobenzoyl chloride and separated on a normal phase partition system using a silica 
column with n-hexane-chloroform-acetonitrile (10:3:2.5 v/v) as eluent. Detection of 
the derivatives was by UV at 260 nm with a reported increase in sensitivity of four 
orders of magnitude greater than refractive index. A diabetic confectionary containing 
sorbitol was analysed by this method which had a relative standard deviation of 2.3%.
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The separation of some polyols as their nitrobenzoate derivatives has also been 
described by Schwarzenbach (1977) who used a modified partition system; with a polar 
amino-alkyl modified silica stationary phase and water-acetonitrile (1:4 v/v) as a polar 
eluent. The system was used to separate polyols in apple juice by direct injection of the 
derivatized sample onto the column. The same chromatographic conditions were used 
to separate and measure xylitol from glycerol in a tooth-paste. Petchey and Crabbe 
(1984) have shown that tissue extracts of polyols and glucose, as the nitrobenzoate 
derivatives, can be separated and analysed using normal phase HPLC. They found that 
human cataractous lens contained glucose, sorbitol and inositol at 1.01, 0.35 and 11.74 
m g/g dry weight respectively. They found that ultra filtration of the homogenised tissue 
sample, lens, plasma or erythrocyte, provided a cleaner extract which was more easily 
and fully derivatized. The method was linear over the range 3-60 /ig/ml with a limit 
of detection of 2 ng.
An alternative derivatisation of polyols was used by Dethy et al., (1984) to determine 
tissue concentrations of sorbitol and galactitol. Protein precipitates of rat lens, sciatic 
nerve and erythrocytes and human skin fibroblasts were lyophilised to dryness and 
derivitized with phenylisocyanate. The derivitized samples were diluted with methanol 
and pyridine and injected onto a reversed phase C18 column with acetonitrile 
phosphate buffer at pH  7.0 (60/40%). Detection was with U V  at 240 nm with a limit 
of detection of 3 ng. The method was used to determine the concentrations in human 
skin fibroblasts of sorbitol and galactitol, which were found to be raised, when 
incubated with high levels of glucose or galactitol respectively.
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Recently the polyol myo-inositol has been separated as the anthraniloyl derivative using 
a reversed phase system with a C8 column as stationary phase and acetonitrile- 
phosphate buffer as eluent, Karagacin et al., (1987). The anthraniloyl derivative was 
detected using fluorimetry with a detection limit of 0.1 nmoles (approximately 18 ng).
An example of the post-column derivatisation of carbohydrates has been reported by 
Honda et al., (1984). Carbohydrates were initially separated by gel permeation, ion 
exchange or partition and derivitized post column by 2-cyano-acetamide. 
Electrochemical detection of the carbohydrates was obtained by the ready oxidation 
of the derivatives at a glassy carbon electrode. The limit of detection was given as 20 
pmol for glucose. The cyano-acetamide derivatisation is only applicable to reducing 
sugars and polyols do not react to form derivatives. Therefore, even though polyols 
may be present in the sample, the method is selective for reducing carbohydrates only. 
Other methods for the post column detection of polyols include colorimetric detection 
using a cuprammonium reagent, McKay et a l, (1987) and conductivity detection of the 
ionized polyol-borate complex, Okada and Kuwamoto (1986).
By contrast to partition chromatography Ohsawa et al., (1986) used ion 
chromatography to measure xylitol in human saliva and serum. The method utilizes the 
ionization of polyols and sugars, in strong alkali which is used as the eluent, with 
pulsed amperometric detection. The method was linear between 0.025 and 1.0 4 g/m l 
with a limit of detection of 0.01 /Jg/ml. Using the method peak levels of xylitol were 
found at 30 and 150 minutes in serum and saliva after oral administration of xylitol. 
As yet no further information is available on the specificity of polyol separation in 
other biological matrices with this method.
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With large sample volumes containing relatively high amounts of polyols their 
concentrations can be rapidly determined, without derivatisation, as in the method of 
Dokladalova et al., (1980). The separation of sorbitol from many other polyols and 
carbohydrates was achieved using an Aminex column (amine modified silica) and water 
as the eluent with refractive index detection. Furthermore, the system can be used as 
an initial preparatory separation of monosaccharides from polyols. The disadvantage 
of this system is the inability to separate sorbitol and xylitol which have the same 
retention. A  similar separation has been described by Brandao et al., (1980) in which 
sorbitol was poorly resolved from glucose using water-acetonitrile as eluent. However, 
the advantage of a ternary mobile phase was demonstrated, with the addition of 
ethanol to the eluent, which resolved sorbitol from mono and disaccharides. No other 
polyols were investigated for possible co-elution with sorbitol.
The difficulty of HPLC separations of polyols from carbohydrates has been investigated 
by Shaw and Wilson (1982) who used several different partition systems. The best 
separation was achieved using a carbohydrate column, which resolved glucose, fructose, 
sorbitol, manno-heptulose and sucrose. In addition, the authors demonstrated the use 
of UV detection at 197 nm for the determination of the above components in apple 
juice. Sorbitol was present in freshly pressed apple juice at a concentration of 0.25% 
(w/w) and in pear juice, depending on the type of pear, between 2 and 3%.
In summary, the liquid chromatographic separations of polyols is mostly confined to 
their separation from carbohydrates. Especially noticable is the greater difficulty of 
separating similar polyols from each other; for example, the resolution of hexitols. 
Methods exist where at least two polyols can be separated but with a lack of specificity
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when other polyols of unknown identity are present in the sample. In general, polyols 
and carbohydrates can be modified, by introducing a chromophore into the molecule, 
to enhance their detection and to overcome the lack of sensitivity associated with RI 
detection or the lack of selective detection with low wavelength UV. The HPLC of 
carbohydrates and polyols has been reviewed by Robards and Whitelaw (1986).
In order to overcome problems associated with HPLC separation or detection of polyols 
an alternative approach is the use of gas-liquid chromatography (GLC). GLC 
complements HPLC for a wide variety of applications; in particular in cases where 
volatile compounds are not easily separated, or detected at the desired levels, by HPLC.
1.6.2.2 Trace Analysis of Polyols by Gas-Liquid Chromatography
Almost all volatile organic compounds respond to the flame ionization detector (FID). 
The FID has been used as a general detector in GLC, for a wide variety of compounds 
including alkanes, fatty acids, steroids, pesticides and many types of drugs. 
Consequently the FID can be used to detect most types of organic compound and as 
such is a universal non-selective detector. The major limitation of the FID with packed 
columns is a detection limit, on column, of the order of 50 ng amounts. By contrast, 
the electron capture detector (ECD) is a selective detector responding to electron 
capturing species present in the molecule presented to the detector. The most strongly 
electron capturing compounds are those containing halogens, nitro groups or highly 
conjugated systems. Certain compounds such as chlorinated pesticides and 
polychlorinated biphenyls are highly electron capturing and when extracted from 
biological matrices have on column detection limits at the low picogram level.
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Alternatively compounds can be derivatised with reagents containing electron capturing 
species to enhance sensitivity and their selective detection in the presence of other non 
responding compounds.
The use of MS detection in GLC has been extensive because of the highly specific 
nature of the detector. The detector can be set to monitor a particular ion fragment, 
characteristic of the compound, for absolute specificity. Furthermore, the detector can 
be set to monitor the total ion fragmentation pattern, of components eluting in 
sequence from the GLC, to identify the nature of unknown components in the sample. 
The cost of these detectors does not make them readily available for routine use. 
However, MS detection is used in forensic science, drug metabolism, toxicology and 
medical research with enormous benefit to man.
Polyols require derivatisation in order to make them volatile and amenable to 
gas-liquid chromatographic separation processes. The choice of derivatisation reagent 
in GLC is important and is related to the type of detector at the outlet of the column. 
Derivatisation is achieved by introducing a masking moiety at each hydroxyl group 
producing a volatile hydrocarbon of increased molecular weight. Once carbohydrates 
and polyols have been derivatised the products can often be injected onto the GLC 
column directly, or they can be extracted from the derivatising reagents and further 
concentrated to obtain cleaner samples with a gain in detector sensitivity.
The difficulty of preparing volatile derivatives of polyhydroxy compounds has been 
investigated by Sweeley et al., (1963) who described the rapid derivatisation of this 
class of compounds with silylating reagents. Sugars were treated with hexamethyl-
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dichlorosilazane and trimethylchlorosilane to produce the trimethylsilyl (TMS) 
derivatives. The TMS derivatives were separated on a variety of packed column 
stationary phases and in general where a single anomer was present the elution of a 
single peak was observed. In the case of glucose more than one peak of the TMS 
derivative was observed. The authors also reported that the TMS derivatives of 
pentitols and hexitols were less well resolved. Moreover, the corresponding acetyl 
derivatives could not be separated on any of the stationary phases studied: which 
included a range of polarity from the non-polar SE 52 to the polar Carbowax 1540 
and nitrile silicone, XE 60. An examle of TMS derivatisation applied to a biological 
matrix was reported by Clements and Starne (1975) who analysed myo-inositol from 
human urine as the TMS derivative on a non-polar packed column using methyl- 
mannoside as an internal standard. The method was in good agreement with a yeast 
bio-assay for myo-inositol.
Because of the multiplicity of derivative peaks produced from aldose anomers 
Sawardeker et al., (1965) reduced the aldose sugars to their corresponding alditols by 
sodium borohydride reduction. The alditols were treated with acetic anhydride and 
pyridine to produce the acetates which were found to be more polar than the 
corresonding TMS derivatives. In addition, the alditol acetates could not be eluted 
without their degradation on the polar stationary phase Carbowax 20M. The ideal 
polarity phase was found to be ECNSS-M (a phase consisting of ethylene 
glycolsuccinate chemically combined with a cyanoethyl silicone) and the method was 
reported to have an overall recovery of 98%. The use of silylation to derivatise polyols 
has been reviewed by Poole (1977).
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Szafranek et al., (1973) separated polyols as the acetates using a glass capillary column 
coated with a non-polar phase. Dry sodium acetate was found to be a quicker catalyst 
than pyridine but the analysis time required to separate hexitols was 55 minutes. Other 
catalysts have been used in the formation of acetate derivatives and include; 
methoxylamine hydrochloride in pyridine Mount and Laker (1981) and methyl- 
imidazole Henry et al., (1983). The advantage of some of these catalysts is the 
apparent increased rate of acetylation, above pyridine alone, and their ability to 
catalyse acetylation when traces of water are present in the sample. Acetylation 
procedures for sugars and polyols have been reviewed by Blau and King (1977).
An example of the separation of polyols from a biological matrix is that of 
Popp-Snijders et al., (1983) who separated hexitols extracted from human erythrocytes 
as the acetates on a non-polar capillary column using galactitol as the internal 
standard. The polyol acetate derivatives were reported to be stable for at least three 
months. Furthermore, the identity of the eluted sorbitol hexa-acetate was confirmed 
by mass spectrometry.
In addition, to the use of TMS and acetate derivatisation are the use of electron 
capturing reagents for the preparation of highly volatile derivatives resulting in 
increased selectivity and sensitivity with ECD detection. W hen applied to polyols the 
added advantage of enantiomeric separation, using modified enantiomeric selective 
phases, has become apparent. Leavitt and Sherman (1982) prepared the heptafluoro- 
butanoyl derivative of chiro-inositol and separated the D- and L-enantiomers on a 
capillary chiral column (Chirosil-Val) at an isothermal tem perature of 115°C. In
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addition, Konig and Benecke (1983) prepared the trifluoroacetyl derivatives of polyols 
and were the first to separate the D- and L-enantiomers of mannitol, arabitol and 
fucitol on a modified polysiloxane phase (XE 60-L-Valine-phenylethylamide) where the 
L-enantiomer eluted first, although unfortunately no biological examples were given. 
Previous reports of the non-existence of certain D- or L-enantiomers of polyols in 
plants (section 1.2) may well be due to the lack of suitable separations available at the 
time. In addition, the ability to perform such separations, due to modern column 
technology, demonstrates a further advantage of capillary over packed column GLC.
One of the disadvantages of packed column GLC is inefficiency in separating solutes 
that have increased and similar retentions. With long elution times large carrier gas 
flow rates are required resulting in a high pressure drop along the column. With a 
raised pressure drop the carrier gas flow becomes turbulent which disrupts the partition 
process. These factors in conjunction with finite maximum operating temperatures of 
the phase make some separations difficult to achieve.
W here analyses have long elution times and inefficient separation the problem can 
sometimes be overcome by the use of glass or fused silica capillary columns. Such 
columns are typically 25 metres long with internal diameters of the order of 0.1-0.3 
mm. Glass capillary columns have been superceded by fused silica capillary columns; 
which are drawn from silica at high temperatures using fibre-optic technology, reviewed 
by Tarbet et al., (1988). The advantage of silica capillary columns is in the ability to 
coat the internal wall with intra-molecular crossed linked phases resulting in higher 
maximum working temperatures. Furthermore, Grob et al., (1981) were the first to 
demonstrate that some phases can be immobilized, by chemical linking to residual
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active sites on the fused silica internal wall, resulting in greater thermal and chemical 
stability.
The rationale of using capillary columns is that the efficiency of a column, the height 
equivalent to a theoretical plate, is directly related to the diam eter of the column. For 
a given distribution coefficient of a solute between the gas and liquid phase, which is 
a constant, the smaller the diameter the less the gas volume and hence an increase 
in the partition ratio of the solute between the stationary and mobile phase, Jennings 
(1978). The partition ratio can further be increased by increasing the overall length of 
the column and film thickness of the phase; although any gain in efficiency is cancelled 
by resistance to mass transfer effects for columns with film thicknesses above 1 gm, 
Davies (1988). Thus highly efficient columns can be obtained by decreasing the 
diameter, increasing the length of the column, and or increasing the film thickness of 
the phase. In addition, wall coated capillary columns have negligable carrier gas 
pressure drops along the column because the carrier gas does not flow through a 
packing and the height equivalent to a theoretical plate is unaffected by eddy diffusion 
effects.
The major problem with capillary GLC is one of sample injection. There is greater 
difficulty in introducing the sample onto the top of the capillary column than in the 
wider bore packed columns. As a consequence several different injection techniques 
have been devised to overcome the problem. The major injection techniques currently 
available are; split, splitless (with or without solvent effect), cool-on-column and 
programmable tem perature vaporization (PTV).
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Split injection employs an inert glass liner, which can be heated and through which the 
carrier gas flow can be directed towards the column inlet. A  GLC syringe can be easily 
introduced through a septum to deliver the sample into the vaporizing liner. The 
design of the injector allows the carrier gas to be split so that the majority of the 
incoming carrier gas can be vented through an exhaust without continuing down the 
column. The carrier gas flow rate through the split vent can be adjusted to give preset 
split ratio’s, typically 1 in 100, of flow down the column to flow through the vent. The 
use of split injection technique is its application to relatively concentrated samples for 
semi quantitive analysis; such as volatiles in petroleum. Because the sample is split the 
resultant initial band on the column is very narrow often resulting in very efficient 
separations not affected by carrier solvent. The danger is in attempting to perform 
quantitative analysis for sample components covering a wide boiling point range where 
different components are split to differing extents (Grob K. Jnr 1988). Therefore, for 
quantitation, the use of internal standards is mandatory when using split injection for 
samples containing solutes of widely differing volatility.
Splitless injection is an adaptation of the split technique where the split vent is closed 
during injection and opened at a given time after injection. The exact conditions 
depend upon the application but the technique is often used for samples where split 
injection does not give the desired sensitivity and where solvent effects are minimal. 
Injection using splitless with solvent effect is one of the definitive techniques for 
quantitative capillary GLC analysis. The same injection technique is used as in splitless 
but with the initial column tem perature lower than that of the boiling point of the 
carrier solvent used to introduce the sample. Upon injection the sample vaporizes in 
the injector liner and the solvent condenses on the first one or two metres of the
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column, thereby concentrating the sample onto the column. After a given period the 
split vent is opened to purge any excess solvent vapour and in doing so cleans the 
vaporizing liner. The choice of solute carrier solvent is important in this injection mode 
because some solvents flood the column, which spreads the initial band and leads to 
decreased efficiency. The advantage of the above injection techniques is that automatic 
samplers are commercially available.
Cool-on-column is an injection technique where the sample is introduced directly into 
the column via a capillary needle of smaller diameter than the column. In most cases 
the best results are obtained using the splitless with solvent effect column conditions 
where similar results are observed. However, this type of injection is difficult to 
automate. Parameters affecting the quantitive performance of cool-on-column and 
splitless injection systems have been investigated by Snell et al., (1987). Programmable 
tem perature vaporization is a recent extention to the split and splitless technique and 
when used in those modes offers no advantage. However, the PTV has the distinct 
advantage that low boiling solute carrier solvent, such as chloroform, can be dumped, 
via the split vent, at a vaporizing tem perature well below that of the boiling points of 
the solutes. The split is then closed and the temperature of the injector raised to 
volatilize the solutes. There is the possibility that other low boiling components, which 
could be of interest, will be lost in the initial solvent dumping. However, delitirious 
solvent effects can be reduced to a minimum. The parameters affecting PTV injection 
of n-alkanes have been investigated by Poy (1982).
The problems associated with capillary injection systems has been extensively reviewed 
by Grob K. Jnr (1988) who advocates the use of retention gaps to overcome some of
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the solvent flooding effects observed with various injection conditions, Grob (1982), 
Grob and Schilling (1987). M odern inlets for capillary GLC have been reviewed by 
Hinshaw (1987). Recent fundamental developments in gas chromatography have been 
reviewed by Clement et al., (1986). The use of GLC for the estimation of sugar 
alcohols in biological fluids has been reviewed by Laker (1980). The chromatography 
of monosaccharides and disaccharides has been reviewed by Robards and Whitelaw 
(1986). Table 2 summarises some of the representative uses of GLC for polyol analysis.
The use of GLC and HPLC methods for the separation and determination of almost 
all classes of compounds has had an enormous impact on man. This impact can be 
assessed by the fact that in 1988 there were 1272 GLC and 2487 HPLC abstracted 
publications covering all aspects of the techniques. In terms of health care modern 
chromatographic advances now make it possible to separate and determine, for 
example; individual enantiomers of chiral compounds. This enables the study of 
racemic mixtues, or the individual enantiomers, to be fully investigated before their 
use as drugs so that disasters such as thalidomide may in the future be avoided.
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Table 2 Summary of Some Gas-Liquid Chromatographic Separations of Polyols
YEAR
1963
1965
1971
1972
1973
1973
1974
1975
1978
1981
1981
AUTHOR DERIVATIVE COLUMN MATRIX COMMENT
Sweeley 
et al.
Sawardeker 
et al.
Travis 
et al.
Blau
Szafranek 
et al.
Aloia
Varma and 
Kinoshita
Heaf and 
Galton
Smith 
et al.
Allen 
et al.
Mount and 
Laker
TMS Various
more anomer- packed
isation when in lab
sugars refluxed 
with pyridine
ACETATES 
refluxed
Pure
TMS
TMS and 
ACETATES
ACETATES 
NaAcetate 
as catalyst
TMS and 
ACETATES
TMS
TMS
TMS
ACETATE
AC ETATE
Various 
packed 
10', 3% 
ECNSS-M
12', 15%
glycol
succinate
Various 
packed 
0V1, 0V17 
ECNSS-M
G1 ass 
capillary 
60 m SE30
Pure
Lysed
RBC
Packed Serum
3% SE30 Urine
3% polylOlA
Packed 3% 
SE30
Packed 7'  
3% SE 30
G1 ass 
capillary 
30 m x 0.2 
mm SE52
Packed 
7', 3% 
SP2340
Packed 
2 m, 3% 
XE60
Multiple peaks 
sugar anomers 
polyol acetates 
not resolved
Degradation on 
Carbowax 20M 
75 min analysis 
time
Hexitols
resolved
not
Urine GC-MS
Pure 55 min for 
hexitols 
Split 5:1
Poor hexitol 
resolution 
removal of 
glucose by enz
Rat Sorbitol raised
Lens
Human Hexitols raised
urine Urea removed by
lens urease enzyme
Human GC-MS, 65 min
spinal analysis time
fluid sorbitol elutes
between glucose 
anomers
Amniotic Ion exchange 
fluid removal of 
glucose
Human Hexitols not
urine resolved
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Table 2 (cont.)
YEAR AUTHOR DERIVATIVE COLUMN MARTIX COMMENT
1983 Mayhew TMS 
et al.
Packed Human 
sci atic 
nerve
1983 Popp- ACETATES
Snijders 
et al.
Capillary 
25 m X 0.22 
mm CpSi15
Human GC-MS, 11 min
RBC analysis time
lack of assay 
data
1984 Roboz 
et al.
ACETATES
1984
1986
Johnson & TMS 
Mayersohn
Jansen 
et al.
TMS
Packed and Human 
capillary serum 
50 m OV1701
Capillary 
25 m OV1
Human
plasma
Capillary 
25 m X 0.22 
mm 0V1, 
phase 
split 1:15
Human 
urine 
1 g Washed 
RBC
GC-MS extensive 
validation 
methanol ppt.
Precision and 
recovery 
splitless
25 min analysis 
time per sample 
polyols not lost 
during washing 
methanol ppt. 
Hexane extract 
to remove lipids
Note: TMS = trimethyl silyl derivative, RBC = red blood cell 
enz = enzyme, ppt = protein precipitation
71
1.7 The aims of the present study
The aims of this research are to establish and validate methods for the determination 
of sorbitol and other polyols in biological matrices. To date, no method comparison for 
sorbitol determination has been carried out. A particular aim, therefore, is to set up and 
compare an enzyme and GLC assay for the determination of erythrocyte sorbitol 
concentrations in samples from non-diabetic and diabetic human subjects.
Further aims of this study are to use the analytical methods to determine the 
erythrocyte sorbitol concentrations in diabetic patients taking part in clinical trials of 
the novel aldose reducase inhibitor Sorbinil. Additionally, there is a need to establish 
the rapidity and daily consistancy of the erythrocyte sorbitol and myo-inositol response 
to Sorbinil therapy.
It is anticipated that there will be considerable variation in erythrocyte sorbitol levels 
both in individuals and in response to therapy. Some of the sorbitol levels may be low, 
possibly as a consequence of Sorbinil therapy, and the analytical methods may have to 
be modified to cope with low concentrations. Therefore, a continuing aim of this 
research is to develop improved methods capable of the desired sensitivity. 
Furthermore, it is important that they be fully assessed in terms of performance 
because there is a general lack of information regarding the quality of these methods 
at low sorbitol concentrations.
In humans the daily variation of erythrocyte sorbitol and myo-inositol has not been 
investigated. It is especially important to establish a normal human range for any blood
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param eter before assumptions are made concerning abnormal levels. Therefore, a 
further aim of this research is to determine the daily variation of erythrocyte sorbitol 
and myo-inositol in normal, healthy non-diabetic volunteers and to compare these 
levels with those in diabetic subjects.
A final aim of this research is to attempt to establish an in-vitro incubation system to 
examine the activity of aldose reductase in erythrocytes, from normal and diabetic 
subjects, with a view to its possible use as a diagnostic test. Moreover, to try to 
determine whether there are differences in AR activity between normal and diabetic 
subjects which may support the hypothesis that the underlying cause of diabetic 
complications is biochemical in origin.
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CHAPTER 2
2.1 General Reagents and Compounds
2.1.1 General Reagents
Acetonitrile (J T  Baker, Phillipsburg), chloroform, ethyl acetate and n-butyl acetate 
(BDH, Poole, Dorset), methanol (Fisons, Loughborough) and diethyl ether (May and 
Baker, local supplier) were all of AR grade. Perchloric acid 6% was obtained by 
diluting 60% general reagent grade perchloric acid (BDH, Poole) with water. Distilled 
water was prepared in the laboratory from a Fi-streem water still (Fisons Scientific 
Equipment, Loughborough). Reverse osmosis purified water was obtained using an 
Elgastat Spectrum, (Elga products, Buckinghamshire). All compounds for making 
buffers were obtained in AR grade and used according to the methods in the text. 
Adjustment of buffer pH  was followed using a model PTI pH  m eter (EDT Instruments 
Ltd, Kent). Saline solution (0.85% w /v NaCl) was obtained from Sigma or generated 
in the laboratory using AR grade NaCl dissolved in distilled water to the required 
concentration.
Krebs-Henseleit buffer consisting of 118 mM NaCl, 4.8 mM KC1, 3.2 mM CaCl2, 1.2 
mM M gS04, 1.0 mM KH2P 0 4 , 24 mM N aH C 03, and 1.2 mM HEPES (N-[2-hydroxy- 
ethyl]piperazine-N-[2-ethanesulphonic acid] sodium salt), pH  7.4 was made from AR 
grade reagents supplied by BDH.
MATERIALS AND METHODS
74
2.1.2 Compounds
The following polyols (with their % purities in parentheses) sorbitol (99.0), galactitol 
(99.0), myo-inositol (99.9), d-mannitol (99.6), xylitol (99.0), ribitol, and the sugars 
o;-(+)glucose (94.5 with approximately 5% as the b anomer), galactose (98.2, 0.01% as 
glucose), d-(+)m annose (99.0), d(-)fructose (99.8) and d-( + )xylose (99.0) were obtained 
from Sigma Chemical Co., Poole, Dorset. According to the manufacturers information 
the purity was obtained by packed column gas-liquid chromatography, except for ribitol 
which was found to be one spot by thin-layer chromatography, but no further details 
were available.
D-sorbitol hexaacetate (99.8%), a-d-( + ) glucose pentaacetate (99.0%), a-methyl- 
mannoside (99.9%, GLC), 1-O-methyl-a-d-glucopyranoside (99.0%, GLC) the enzyme 
Sorbitol dehydrogenase (activity units as specified) and ethylenediaminetetraaceticacid 
(EDTA, AR grade) were obtained from Sigma Chemical Co., Poole. Sorbinil, CP- 
45,634 (analytical standard) and CP-43,659; Sorbinil analogue for use as an internal 
standard (analytical standard) were gifts from Pfizer Central Research, Sandwich, Kent. 
Compounds used for calibration standards were accurately weighed using a model 
2024MP five place balance (Sartorius GmbH, Gottingden) and made up to volume 
with appropriate solvent, as specified in the text.
2.1.3 Derivatising Reagents
Acetic anhydride (AR Grade) was obtained from BDH, Poole, Dorset, and stored in 
stoppered dark containers in a desiccator. Pyridine (AR grade) and 4-dimethyl amino 
pyridine (99%) were obtained from Aldrich Chemical Co., Gillingham. Pyridine was
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redistilled before use and stored over KOH (AR grade, BDH) in a dessicator. 1-methyl 
imidazole was obtained from Sigma. Trimethyl silane and hexamethyl disilazane were 
obtained from Pierce Chemical Co., Ond-Beijerland, Holland. Trifluoro-acetic 
anhydride (AR grade) was obtained from Sigma.
Derivatisations requiring heating were carried out in a model BT3 test tube heater 
(Grant Instruments, Cambridge). W here specified, a 2% solution of dimethyl- 
dichlorosilane in 1,1,1-trichloroethane (GPR grade, BDH, Poole) was used to silylate 
glassware.
2.2 Instrumentation
A  Perkin-Elmer LS5 fluorimeter (Perkin-Elmer Corp., Beaconsfield) with sipper cell 
attachment was used for enzyme assays. A thermostated water bath (Grant 
Instruments, Cambridge) was used for incubating the enzyme reactions. For in-vitro 
incubation studies of aldose reductase activity a model UE3 metabolic shaking water 
bath (Grant Instruments, Cambridge) was used.
Packed column gas chromatography was performed on a Pye 104 series GC with FID 
detection (Pye Unicam, Cambridge). Capillary GLC was carried out using either, a 
Sigma 3B capillary GC with FID and ECD detectors, equipped with Grob type and 
cool-on-column injectors, or a model 8320 capillary GC with FID detection and 
Programmable Temperature Vaporiser (both capillary GC instruments supplied by 
Perkin-Elmer Corp., Beaconsfield). The capillary GLC systems used helium (Air 
Products) as carrier gas. Oxygen free nitrogen (OFN) for detector make-up, hydrogen 
and air for FID were supplied by BOC, London. Sample injection was carried out using
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1 or 5 gl plunger in needle syringes (Scientific Glass Engineering, Milton Keynes). The 
syringe needles were cleaned between injections using a syringe cleaner (Scientific 
Glass Engineering, Milton Keynes). A model CR650 chart recorder (JJ Lloyd, 
Southampton) or an SP4270 computing integrator (Spectra Physics, California, USA) 
was used to record the detector output from the packed column and Sigma 3B 
instruments. Capillary GLC columns of various lengths, diameters and phases were 
obtained from SGE, Milton Keynes, or SAC Chromatography, Hertfordshire, and the 
particular type of column used, along with the analytical conditions, are described in 
the text.
2.2.1 Capillary GLC Column Assessment
Capillary columns were installed into the capillary gas chromatgraphs according to the 
instrument manufacturers specifications. The helium carrier gas inlet pressure was 
adjusted to give a linear carrier gas velocity of between 30-35 cm/sec. This was 
approximated by measuring the time taken from the injection point to the emergence 
of the solvent front of a volatile solvent such as chloroform, at an isothermal column 
oven temperature of 130°C.
The efficiency of the columns was measured by making a 1 g\ split injection of an 
activity mix; for example, Activity mix H (SGE) or a mix consisting of C7,8,9,10,12,14 
and 16 n-Alkanes made in the laboratory. The theoretical efficiency was determined 
by measuring the peak width, in mm, at half height for the last eluted component of 
the mix, and the retention, in mm, from the injection point. The number of theoretical 
plates, N, was calculated according to the method of Jennings (1978) as follows:
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( Retention time (mm) \ 2 x 5.54 = N
Peak width at half height (mm)/
The adjusted retention time for a component was approximated by measuring the time, 
in mm, from the injection point to the emergence of the solvent front and subtracting 
this from the component retention. The number of effective plates, n, was then 
calculated as:-
The resultant column efficiencies were used to compare the column manufacturers
metre lengths with 0.32 mm internal diameters with a phase thickness of, typically, 1.0 
gm were used. When tested as described these columns had average N values of 
between 50 to 60 thousand theoretical plates resulting in a height equivalent to a 
theoretical plate of 0.5 mm or less.
2.3 General Laboratory Equipment
For mixing individual samples a vortex mixer (Fisons, Loughborough) was used and 
where large numbers of tubes required simultaneous mixing a model 2601 multitube 
vortexer (SMI, Emeryville, USA) was used. Solvent extraction was performed using a 
home made horizontal shaker, whirlimixing or a rotary mixer (Luckham Ltd, Burgess 
Hill, Sussex). Separation of non miscible layers was carried out in a Mistral 6L 
refrigerated centrifuge (MSE, England). Solvent evaporation was carried out using a 
multi tube solvent evaporator with heated air bath (Robens Institute workshop) with 
OFN to aid solvent evaporation. Occasionally a Buchler vortex evaporator (Buchler
Adjusted retention time (mm) \2 x = n
efficiency specifications obtained under similar conditions. Capillary columns of 25
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Instruments, USA) was used instead. A Modulyo model 4, with high vacuum pump, 
freeze drier (Edwards High Vacuum Co. Ltd., Crawley, Sussex) was used to obtain 
freeze dried samples.
Glass screwneck test tubes 100 X 16 mm with teflon lined screw caps (Corning, New 
York) were used for sample preparation and storage, derivatisation reactions and 
solvent extractions. Glass culture tubes 100 X 16 mm (Corning, New York) were used 
for enzyme assays. Specific precautions taken with the glass ware, such as silylation 
prior to derivatisation, are indicated in the text. Volumetric flasks, volumetric pipettes 
and graduated pipettes (FSA, Fisons Scientific Equipment, Loughborough) of various 
volumes were used for generating aqueous and organic standard solutions and for 
dispensing organic solvents. Aqueous volumes were dispensed using either 5 ml, 1 ml 
or 200 /il adjustable volume hand dispensers (Gilson Medical Electronics, 
Villiers-Le-Bel) which were calibrated on water before use. R epeat dispensing of blood 
or aqueous solutions was done using a repeating dispenser (Eppendorf, Hamburg) or 
a Falcon Pipet-Aid automatic dispenser (Beckton Dickinson, Oxnard, USA).
2.4 Blood Collection
For the generation of plasma or erythrocyte assay standards whole blood from healthy 
volunteers; approximately 500 ml from each donor, was obtained by venepuncture. The 
blood was collected into vessels containing anticoagulant; 0.5 g EDTA dissolved in 
approximately 10 ml of distilled water. The whole blood was separated by 
centrifugation in a Mistral 6L refrigerated centrifuge (MSE Scientific Instruments, 
Crawley) at 2000 r.p.m. and 5°C. Plasma was pooled and stored at -20°C until 
required and the erythrocytes treated according to the following protocol: Erythrocytes
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from healthy volunteers were washed twice with ice cold isotonic saline, centrifuging 
between washes, and the buffy coat removed. The washed erythrocytes were then 
pooled and used to generate standards or for incubation studies. Methods for the 
generation of erythrocyte calibration standards are given in sections 3.1.2, 3.2.2.1 and 
3.2.2.2. The details of the incubation studies are given in section 2.7. Packed cell 
erythrocyte haemoglobin concentration was determined spectrophotometrically by the 
method of van Kampen and Zijlstra, (1961).
Venous blood samples from diabetics, for polyol and Sorbinil determinations, was 
obtained by venepuncture and collected into 10 ml vacutainer tubes containing lithium 
heparin as anticoagulant (Beckton Dickinson, Meyland, France). The tubes were 
immediately placed on ice and processed, as above, as quickly as possible. Plasma was 
stored at -20°C until taken for analysis. Aliquots of washed erythrocytes, 1.0 ml, were 
dispensed into tubes containing ice cold 6% perchloric acid, vortex mixed, capped and 
stored at -20°C until taken for analysis. As a precaution, the erythrocyte sample 
preparation method for all polyol determinations was carried out as quickly as possible 
to minimise any possibility of alterations in the polyol content.
2.5 Determination of Plasma Sorbinil Concentrations bv High Performance 
Liquid Chromatography
Plasma Sorbinil concentrations were determined using an adaptation of the method of 
Foulds et al., (1981) and was as follows: 1.0 ml of plasma sample or standard was 
dispensed into a 10 ml glass screw neck test tube. Using a 1.0 ml Gilson hand 
dispenser 1.0 ml of internal standard (5 gg CP-43,659 per ml phosphate buffer 0.25M, 
pH  7) was added and vortex mixed for 10 seconds. 5 ml of diethyl ether was then
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added and the samples mixed on a rotary mixer for 10 minutes. The samples were 
centrifuged for 5 minutes at 2000 r.p.m. at 15°C and the upper ether layer transferred 
to clean 10 ml culture tubes. The ether was evaporated to dryness in a multitube 
solvent evaporator under a gentle stream of OFN at 37°C. The residue was 
resuspended in 100 ii 1 of eluent and vortex mixed on a whirlimixer for 10 seconds. The 
solution was transferred to a limited volume insert (Chromacol, London) and 50 /d 
injected by a WISP auto sampler (Waters Associates, Milford, Massachusetts) onto the 
HPLC with the following conditions: Column; Spherisorb ODS 5 /Jm, 12.5 cm by 5mm 
(Hichrom, Reading) with a mobile phase consisting of methanol-water-acetic acid, 
35:65:1 % v/v  delivered at 1.0 m l/m inute by an Altex 110A pump (Beckman 
Instruments Inc., San Ramon, California). Detection was by a Pye LC-UV variable 
wavelength detector (Pye Unicam, Cambridge) at 284 nm with the output recorded on 
a JJ Lloyd chart recorder.
Stock solutions of Sorbinil (whether for calibration standards or blind spikes) were 
made by accurately weighing 10 mg into 10 ml volumetric flasks and making up the 
volume with methanol to give 1 mg/ml stock solutions. The working solutions used for 
spiking Sorbinil into plasma were serially diluted from the stock solutions with 
methanol to the required concentrations. Stock solutions of internal standard in 
methanol (1 mg/ml concentrations) were generated in a similar manner and stored at 
4°C. The internal standard stock solution was diluted with phosphate buffer to the 
required concentration on the day.
Plasma calibration standards were prepared in the following way. Pooled, control 
plasma from healthy volunteers was collected as described above. 10.0 ml plasma 
aliquots were accurately dispensed into screw neck test tubes and to each was added
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100 g\ of 100, 200, 300, 400 and 500 Mg/ml Sorbinil in methanol, via a 100 g\ spiking 
syringe (Hamilton Co., Reno, Nevada) to give concentrations of 1, 2, 3, 4 and 5 gg 
Sorbinil per ml plasma. The tubes were capped, mixed well by vortexing and 
approximately 1.2 ml aliquots dispensed into small containers. In this way, eight sets 
of calibration standards were obtained and stored at -20°C until required for analysis. 
Plasma blind spikes, the concentrations of which were unknown to the analyst, were 
generated in the same way as plasma Sorbinil calibration standards. On each day of 
analysis, authentic samples were analysed with a set of calibration standards and blind 
spikes. In addition, approximately 10% of the patient samples were analysed on a 
second day.
2.6 Screening of Diabetic Subjects for Sorbinil Trials
Diabetic subjects for inclusion in the Sorbinil trials were recruited from the diabetic 
out patients clinic at St. Luke’s Hospital, Guildford, by Dr. J. Wright (consultant 
chemical pathologist). Patients were fully informed as to the purpose of the trial and 
a full medical and clinical screening performed.
Routine haematological and clinical biochemistry tests, including glycosylated 
haemoglobin (H bA lc) were performed by the district pathology laboratories of St. 
Luke’s Hospital. Patients with normal results were included in the trial. However, 
patients with histories of heart complaints, high blood pressure, liver disease, alcohol 
abuse or severely poor diabetic control were excluded from participation. W ritten 
consent was obtained from each subject willing to take part in the trial and they were 
free to withdraw at any time. Ethical approval for the trials was obtained from the 
ethical committees of the University of Surrey and St. Luke’s Hospital.
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Diabetic patients taking part in the Sorbinil trials were screened for haematological 
and clinical chemistry parameters regularly throughout the trials: a full blood count and 
heart and liver function tests and a medical examination were performed weekly. Any 
patient with abnormal results or signs of intolerance to the drug were immediately 
withdrawn from the trial. Normal healthy non-diabetic subjects were recruited from 
the Robens Institute volunteer panel. For studies conducted on healthy volunteers they 
were fully informed of the purpose of the study and free to withdraw at any time.
2.7 In-vitro erythrocyte incubation studies
For incubation studies whole blood was collected from volunteers (both diabetic and 
non-diabetic subjects) and the erythrocytes prepared and washed in saline as described 
above (section 2.4). Pooled washed erythrocytes (20 ml) were added to an equal 
volume of Krebs-Henseleit buffer using a Gilson 5 ml hand dispenser. Alternatively, 
small volumes of washed erythrocyte samples (2 ml), obtained from individual 
volunteers, were added to equal volumes of Krebs-Henseleit buffer using a 1 ml Gilson 
hand dispenser. D(+)glucose (AR grade obtained from BDH) was added to 
Krebs-Henseleit buffer in 100 ml volumetric flasks. The volume was made up to the 
mark with reverse osmosis water to give glucose concentrations in the buffer ranging 
from 20-100 mM. A  volume of the Krebs-Henseleit buffer containing glucose was 
added to an equal volume of erythrocytes to give final glucose concentrations in the 
incubation mixture of between 10-50 mM. The particular glucose concentrations and 
the reason for using them in different studies are given in the text.
To one flask containing glucose (100 mM) in buffer was also added Sorbinil to give a 
concentration of 20 /xg/ml. Krebs-Henseleit buffer without glucose or Sorbinil acted
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as the control buffer. For each time point at least two separate erythrocyte samples 
were prepared. For incubation studies a 30 minute equilibration time was allowed, at 
room temperature, followed by incubation of the samples for various times. A ll 
samples were incubated in 10 ml clean glass culture tubes at 37°C  in a shaking water 
bath. After the appropriate incubation time each individual sample was collected, using 
a Gilson hand dispenser, and centrifuged at 4°C, the supernatant was removed and 
checked by eye for any sign of haemolysis. The erythrocytes were then washed twice 
with ice cold saline, centrifuging between washes, and prepared for sorbitol assay by 
adding 1.0 ml of packed erythrocytes to 2.0 ml 6 %  ice cold perchloric acid. The  
samples were mixed by vortexing to ensure protein precipitation which was taken to 
be complete when a smooth brown suspension was obtained. The precipitated 
erythrocyte samples from incubation studies were then stored at -20°C until taken for 
analysis by either the enzyme or capillary G L C  assays. Details of these methods are 
given in the results (chapter 3).
2.8 S tatistical M ethods
The data obtained from these studies was treated using the Minitab (Copyright, 
Pennsylvania University) statistical data base on the Prime mainframe computer of the 
University of Surrey. The data base was used to compute means, standard deviations 
(SD), standard errors of the mean (SEM ), paired and un-paired student t’ tests and for 
obtaining correlation coefficients. Least squares linear regression analysis was performed 
using a Casio scientific calculator (for example, Casio fx-85N) and the equation of the 
line and correlation coefficient (r), were obtained. Other statistical tests, such as %  
difference from the mean, are described in the text. Plots of results were obtained 
using the GrafP programme on the mainframe computer, University of Surrey.
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CHAPTER 3
The results presented in this chapter have been arranged to approximate the order in 
which the work was carried out. However, there was considerable overlap between 
certain studies. Firstly, the enzyme method development and validation are presented 
(section 3.1) followed by the development and validation of a capillary GLC method 
for erythocyte sorbitol (section 3.2). Attempts to improve the capillary GLC assay 
(which was an ongoing aim throughout the project) are then presented (section 3.2.3). 
This is followed by a method comparison between the enzyme and capillary GLC 
assays for erythrocyte sorbitol determination (section 3.3).
For continuity the Sorbinil clinical trials and the polyol normal range trial are 
presented together (section 3.4); although these trials were conducted after the 
respective method validations. Thus, Sorbinil trial No. 1 (using the enzyme method for 
erythrocyte sorbitol determination) was carried out at the end of the enzyme assay 
validation and Sorbinil trial No. 2 at the end of the capillary GLC validation. The 
polyol normal range trial was carried out at a later stage using the capillary GLC 
method with various modifications. Finally, the results from pilot studies to examine 
the feasibility of an erythrocyte aldose reductase assay as a possible diagnostic test for 
diabetic neuropathy are presented (section 3.5).
RESULTS AND DISCUSSION
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3.1 Development of an Enzyme Assay for Ervthrocvte Sorbitol Determination
In order to determine suitable conditions for an enzyme assay for sorbitol the following 
were examined:
i. the specificity of the enzyme sorbitol dehydrogenase (SDH) and 
ii. validation by assessing the linearity, accuracy and precision of erythrocyte 
sorbitol standards and blind spikes both within and between days.
3.1.1 Specificity of Sorbitol Dehydrogenase
The specificity of SDH was determined in the following way: Sorbitol, 282.4 mg, was 
accurately weighed into a boat and the contents transferred to a 250 ml volumetric 
flask. The volume was made up to the mark with distilled water, to give a 6.2 mM 
solution. Aliquots of 100, 200, 400, 600 and 1000 jttl of the stock sorbitol solution were 
spiked into separate 10 ml volumetric flasks and the volume made up to 10 ml with 
distilled water. Sorbitol calibration standards were obtained by spiking 50 /il of each 
of the above dilutions into 0.95 ml of 6% perchloric acid (PCA) to obtain the following 
concentrations 3.1, 6.2, 12.4, 18.6 and 31.0 nm ol/m l with 1.0 ml 6% PCA as the zero 
standard.
A  series of xylitol calibration standards (covering the same molar concentrations as for 
sorbitol) were prepared by transfering 235.9 mg of xylitol into a 250 ml volumetric flask 
and processing the standards as described for sorbitol. Similarily, the sugars xylose, 
fructose, galactose and the polyols ribitol, galactitol, mannitol and myo-inositol were 
prepared as solutions in distilled water so that 50 gl spikes into 0.95 ml 6% PCA gave
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12.4 nm ol/m l solutions. Each sugar and polyol was analysed in duplicate against a 
sorbitol calibration curve.
The method of analysis was as follows: to each 1.0 ml standard or test sample was 
added 2.0 ml 6% PCA and the samples vortex mixed for 5 seconds. An aliquot of the 
sample was transfered to a fresh culture tube and neutralized, by the addition of 3M 
K2C 0 3, till the pH  was between 7 and 9. Typically, for 2.0 ml of 6% PCA, 300 gl of 
3M potassium carbonate was required to bring the pH  to about 8. The samples were 
vortex mixed and centrifuged at 2000 r.p.m. for 10 minutes. Three 0.5 ml aliquots of 
the precipitated supernatant were quantitatively transfered to three separate culture 
tubes; each containing 1.0 ml glycine (50 m M )/ NAD (1.2 mM) buffer, pH 9.4. The 
enzyme SDH was added to two of the tubes, to provide duplicate determinations for 
each sample, and the third tube acted as a blank without the addition of enzyme. The 
samples were pre-incubated for 10 minutes, at 25°C, before the addition of 10 gl of 
enzyme solution; containing 2.5 units of enzyme activity.
[Note: The enzyme sample was diluted with distilled water so that 10 gl contained 2.5 
units of enzyme activity. The actual dilution depended upon the specific activity of the 
enzyme as supplied, but was typically 4.7 units/mg solid, so that 60 mg solid was 
diluted in 1.128 ml of distilled water to provide the required concentration. One unit 
of enzyme activity was described, by the supplier, as the amount of protein required 
to convert 1 /zmole of substrate to product per minute at 25°C and pH 9.]
The samples containing enzyme and their blanks were vortex mixed for 5 seconds, 
stood in a water bath, and incubated at 25°C for 30 minutes. After incubation the two 
samples and relevant blank were read in a fluorimeter (Perkin-Elmer, LS5) using a
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sipper cell for sampling in the following manner. Glycine/NAD buffer was sampled 
into the cuvette using the sipper attachment (a peristaltic pump that can sample 
approximately 0.5 ml when activated by a switch). The fluorescence reading obtained 
from the glycine/NAD buffer was recorded on the digital printer and the value used 
to zero the instrument readout using the autozero facility. Each tube, containing 
enzyme, was then sampled in turn through the sipper into the cuvette and the reading 
recorded on the digital printer. The excitation and emission wavelengths of the 
fhiorimeter were set at 366 and 452 nm respectively with 10 nm slit widths. The fixed 
scale sensitivity of the instrument was usually set to give 60-70% of the maximum 
output (999.9) on the highest concentration standard.
The sample blank, without enzyme, was then read in the same way and the value 
recorded. Thus, the two samples containing enzyme were read followed by their 
relevant blank. The zero was then checked by resampling spare glycine/NAD buffer 
and if necessary re-zeroed. In practice it was rarely found that re-zeroing on the buffer 
was required. The results were calculated by averaging the duplicate fhiorimeter 
readings, of samples containing enzyme, and subtracting the relevant blank value. The 
adjusted fluorescence values obtained for calibration standards were subjected to least 
squares linear regression analysis, using a suitable calculator, and the y intercept, slope 
and correlation coefficient, r obtained. The results for the specificity of SDH, for the 
compounds tested, are shown in table 3. Plots of the sorbitol and xylitol calibration 
standards, in perchloric acid, are shown in figure 3.
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Table 3. Substrate Specificity of Sorbitol Dehydrogenase (SDH)
SUBSTRATE AMOUNT ADDED AMOUNT FOUND
i i i
(nmol/ml) (nmol/ml)
XYLITOL 12.4 12.4 9.9
RIBITOL u 8.7 10.4
GALACTITOL tt 1.0 0.4
MANNITOL n 0.2 0.1
MYO-INOSITOL it ND ND
XYLOSE n 0.8 3.6
GALACTOSE n ND ND
MANNOSE tt ND ND
GLUCOSE n ND ND
FRUCTOSE n ND ND
50 /il of substrate spiked into 0.95 ml of 6% PCA 
i and ii are two separate samples analysed against a 
sorbitol standard curve, in 6% PCA, covering the range 
0-31.0 nmol/ml. ND = none detected.
FL
UO
RE
SC
EN
CE
 
VA
LU
E
nmol/ml 6% p e r c h lo r i c  a c id
Figure 3. Calibration Curves for Sorbitol and Xylitol in 6% Perchloric Acid: Analysis 
by Sorbitol Dehydrogenase Enzyme Assay
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3.1.2 Validation of an Enzyme Assay for Erythrocyte Sorbitol Determination
The performance of the enzyme assay for erythrocyte sorbitol concentrations was 
determined in the following way. Venous blood was taken from healthy volunteers and 
processed as described in chapter 2 to obtain pooled washed erythrocytes. As a 
precaution the red blood cells were maintained on ice throughout the following 
procedure. Erythrocytes were aliquoted, in 0.95 ml amounts, into separate tubes and 
50 nl of sorbitol standards in distilled water spiked to obtain standards covering 0-31.0 
nm ol/m l in exactly the same way as described for the specificity study. In addition, 
erythrocyte blind spikes (the concentrations unknown to the analyst) were generated 
by another operator using the same pool of washed erythrocytes. Four sets of sorbitol 
calibration standards and 36 blind spikes were generated. The erythrocyte protein was 
then precipitated by the addition of 2.0 ml of 6% PCA to each sample, which was 
vortex mixed to obtain a smooth suspension. The erythrocyte calibration standards and 
all the blind spikes were stored at -20°C. On the day of analysis stored samples were 
thawed and maintained on ice, as a precaution, throughout the following procedure. 
Samples were vortex mixed thoroughly and centrifuged at 2000 r.p.m. for 10 minutes. 
Difficulty was found in removing 2.0 ml of the perchloric acid supernatant and 1.8 ml 
aliquots were removed and neutralised by the addition of 3M K2C 0 3; typically 150 /il 
of potassium carbonate being required. From this stage on the enzyme assay adopted 
was exactly as described for the specificity study.
One of the erythrocyte sorbitol standard curves, with a set of similar standards in 
isotonic saline, was analysed on the day of generation. Two of the sets of erythrocyte 
sorbitol calibration standards were analysed, after 1 and 4 days storage at -20°C (called
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day 1 and day 4 respectively), along with half of the blind spikes on each of those 
days. The remaining calibration set was saved for future use.
Fluorimeter readings for each standard and sample were obtained and treated as 
already described. The equation of the curve for calibration standards was used to 
obtain the concentration of sorbitol in unknown samples. Erythrocytes contain a small 
amount of sorbitol already present in the matrix before the addition of known amounts 
of sorbitol to generate calibration standards. The concentration of this amount of 
sorbitol is called the endogenous level and has to be taken into account in the 
calculation of amounts of sorbitol in unknown samples. Therefore the results of 
sorbitol concentrations in unknown samples was adjusted by adding the value obtained 
for the endogenous sorbitol level present in the calibration standards. This latter step 
was unnecessary, when calibration standards were generated in pure aqueous solutions; 
where endogenous sorbitol is not present.
The results of least square linear regression analysis for the calibration standards in 
isotonic saline and erythrocytes gave r values of 0.999 and 0.990 respectively. The 
correlation coefficients for erythrocyte calibration standards, used to analyse blind 
spikes after 1 and 4 days storage (day 1 and day 4 respectively) were 0.994 and 0.998 
respectively. The results for the analysis of calibration standards and a set of blind 
spikes, after 1 days storage (called day 1), are shown in detail in table 4. The 
calibration plot for these results is shown in figure 4. The results obtained for all the 
blind spikes, stored for 1 and 4 days (called day 1 and day 4 respectively), are shown 
in table 5.
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Table 4. Fluorimeter Readings Obtained for Erythrocyte Standards and Blind Spikes 
by Enzyme Assay, after 1 Days Storage (day 1).
SAMPLE READING 1 READING 2 BLANK MEAN - BLANK VALUE
nmol/ml
Standard -E +E
amount added
(nmol/ml)
A 0.0 147.1 167.3 30.2 127.0
B 3.1 276.1 286.8 88.8 192.7
C 6.2 346.1 360.9 98.5 255.0
D 12.4 396.8 441.1 53.7 365.3
E 18.6 564.4 597.1 87.2 493.6
F 31.0 816.2 808.5 169.3 643.1
Blind spike
sample
No.
1 761.2 835.8 121.6 676.9 31.5 40.2
2 522.0 561.8 102.6 439.3 17.4 26.1
3 523.2 553.3 79.3 459.0 18.6 27.3
4 - 689.9 56.8 633.1 28.9 37.6
5 690.5 775.1 52.9 679.9 31.7 40.4
6 291.1 314.3 96.1 206.6 3.6 12.3
7 487.0 482.4 69.9 414.8 16.0 24.7
8 682.1 741.2 50.2 661.5 30.6 39.3
9 312.1 321.8 116.2 200.8 3.3 12.0
10 284.2 309.7 112.8 184.2 2.3 11.0
11 280.5 308.9 103.0 191.7 2.7 11.4
12 663.6 732.9 105.8 592.5 26.5 35.2
13 491.2 530.9 89.2 421.9 16.4 25.1
14 462.9 504.8 66.0 417.9 16.1 24.8
15 259.3 272.0 70.2 195.5 2.9 11.6
16 653.7 664.7 124.4 534.8 23.1 31.8
17 501.1 537.3 100.9 418.3 16.2 24.9
18 269.9 297.3 98.3 185.3 2.3 11.0
Standard B 297.1 312.7 105.9 199.0 3.2
(repeat reading)
NAD/Glycine buffer 21.2 21.5
Mean * mean of reading 1+2
r = 0.994 from least square linear regression of the standards 
E = Endogenous level obtained from 0 standard =8.7 nmol/ml 
Standards and blind spikes were stored for 1 day at -20°C before analysis.
93
700 ,
SDRBITDL nmol/ml e r y t h r o c y t e s
Figure 4. Calibration Plot of Erythrocyte Sorbitol Concentration against Fluorescence 
Value after 1 Days Storage (day 1).
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Table 5. Precision Data for Eiythrocyte Blind Spike Analysis
DAY 1 The endogenous erythrocyte sorbitol level obtained from the calibration 
standards on this day was 8.7 nmol/ml.
Added +
endogenous 11.1 22.7 34.7
Found 12.3 26.1 40.2
12.0 27.3 37.6
11.0 24.7 40.4
11.4 25.1 39.3
11.6 24.8 35.2
11.0 24.9 31.8
Mean 11,6 25.5 37.4
S.D. 0.53 1.02 3,36
C.V. % 4.6 4.0 9.0
Mean recovery % 103 111 108
DAY 4 The endogenous erythrocyte sorbitol level obtained from the 
calibration standards on this day was 6.4 nmol/ml.
Added +
endogenous 8.9 20.5 32.4
Found 9.7 20.6 29.4
9.2 20.2 31.5
8.9 20.5 30.4
9.5 20.0 29.4
9.0 21.1 30.6
9.6 19.9 30.6
Mean 9.3 20.4 30.3
S.D. 0.33 0.44 0.80
C.V. % 3.6 2.2 2.7
Mean recovery % 104 100 94
All results are expressed as nmol/ml erythrocyte
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Results for blind spikes obtained from different calibration standards were determined 
in the following way. Fresh blind spikes in perchloric acid and erythrocytes were 
generated along with a new set of erythrocyte calibration standards from freshly 
collected blood. The standards and blind spikes were generated in exactly the same 
way as described above. These standards and samples were analysed with the 
remaining set of erythrocyte calibration standards; where the latter had been stored (at 
-20°C) for 4 weeks. The correlation coefficients for the "old" and "new" standards were 
0.996 and 0.992 respectively. The results for the blind spike levels, obtained using each 
set of calibration standards, are shown in table 6.
Table 6. Comparison of Blind Spike Results Obtained by two Different Sets of 
Erythrocyte Calibration Standards
"OLD" STANDARDS "NEW" STANDARDS % DIFFERENCE
FROM MEAN
Perchloric 9.9 9.2 3.7
Blind spikes 2.6 2.5 2.0
17.9 16.6 3.8
10.7 9.4 6.5
10.0 9.3 3.6
25.7 23.8 3.8
9.9 8.6 7.0
30.3 29.0 2.2
Erythrocyte 14.4 13.4 3.6
Blind spikes 9.8 9.1 3.7
24.0 22.3 3.7
19.4 18.0 1.6
12.7 11.8 3.7
31.5 29.2 3.8
14.7 13.7 3.5
35.1 32.6 3.7
Results are nmol/ml and include the endogenous level obtained 
from the calibration standards
% difference from the mean is calculated as
higher - lower result
--------------------- X 100
higher + lower result
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3.1.3 Discussion
The SDH used in these studies is a relatively impure, non-specific preparation obtained 
from sheep liver. The non-specific nature of this enzyme has resulted in its’ use to 
determine either sorbitol or xylitol using the relevant substrate calibration standards 
(Beutler, 1984a and b). The slopes of the calibration standards, for the same molar 
concentrations of sorbitol and xylitol, were 10.39 and 8.34 respectively (figure 3). The 
optimum pH  for xylitol assay is 8.6 rather than 9.4, using SDH purified from sheep 
liver, (Beutler, 1984b) and this may account for the difference in slopes obtained. The 
recovery of ribitol, at 12.4 nmol/ml, was 77%. Galactitol, mannitol and xylose were not 
expected to act as substrates for this assay and the finding that they do so may be due 
to these samples containing small amounts of impurities, which are polyols, that do 
act as substrates. Myo-inositol and the other sugars tested did not act as substrates for 
this enzyme assay.
In studies where sorbitol, in biological matrices, is to be analysed by this particular 
enzyme preparation the possible existence of co-substrates, such as xylitol, in the matrix 
will have to be taken into account. In this respect, Travis et al., (1971) found that the 
existence of xylitol in human erythrocytes was limited to less than 2.5 nm ol/m l if at 
all. Alternative analytical techniques, such as chromatographic separations, may have 
to be adopted to overcome the lack of specificity shown by this enzyme.
The use of SDH to determine sorbitol concentrations in biological matrices was first 
reported by Clements et al., (1969) who examined sorbitol levels in rabbit aorta and 
plasma. The method was adapted by Malone et al., (1980) to determine sorbitol
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concentrations in erythrocyte heamolysates, and forms the basis of the method assessed 
here, but no precision data was reported by them.
In the current study the precision and accuracy of sorbitol blind spikes fortified into 
erythrocytes gave the following results. The overall C.V. for blind spikes, after 1 and 
4 days storage, was found to be 4.3% with a mean recovery of 103% (table 5). The 
slopes and correlation coefficients of the calibration curves, on these two days, were 
in close agreement; 16.85 and 17.3, and 0.994 and 0.998 respectively, indicating near 
identical sensitivities. The blind spikes assessed three levels corresponding 
approximately to low, middle and high calibration points. The only other validation 
data for an enzyme method for erythrocyte sorbitol gave a within day reproducibility 
of 6.7% and a between day reproducibility of 13%, but the actual levels determined 
were not specified, Lapolla et al., (1985).
A  limit of detection of 0.3 nm ol/m l for erythrocyte sorbitol was reported by Malone 
et al., (1980) using 1.0-50 nmol/ml calibration standards. The limit of detection for the 
current method is approximately the endogenous level found on the day using the twice 
y intercept method described by McAinsh et al., (1981). However, using half the 
adjusted fluorescence value (mean reading - blank reading) of the bottom standard, 
approximately 65, (see table 4) gives a limit of detection of half the endogenous level; 
approximately 3.0 nmol/ml.
It may be possible to improve the limit of detection for the enzyme assay described in 
this work. The relatively high and variable blank values so far found limits the minimum 
detectable amounts to a value which is clearly above this background noise. Taking the 
data from table 4, for all 25 samples, the mean blank value was found to be 90 with a
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standard deviation of 30 (CV 33%). A value of 3X the standard deviation of the 
background noise added to the mean noise level would give 180 as the cutoff value 
above which a response may be due to analyte. Computing this value into the linear 
regression equation obtained for the standards (table 4) gives a value of 2.0 nmol/ml 
as the limit of detection. This concentration is slightly lower than the value obtained 
by the empirical method of extrapolation from the calibration curve and represents 
approximately one quarter of the endogenous sorbitol level.
The accuracy between different, fresh and stored, standards was assessed by comparing 
the results obtained for them from a series of blind spikes. The following values for 
the slopes, 11.2 and 12.11, correlation coefficients, 0.996 and 0.992, and endogenous 
sorbitol levels, 6.9 and 5.6 (nmol/ml) were found for the old and new calibration 
standards respectively. The mean percent difference from the mean for perchlorate 
and erythrocyte blind spikes was 4.1 and 3.4 % respectively (table 6). When calculated 
using the stored standards, compared to calculation using fresh standards, all the blind 
spikes values were found to be higher with an overall recovery of 108%. Slope 
differences between the two calibration sets were +. 8% and can reflect differences 
between original calibration solutions, pools of erythrocytes, storage effects or any 
combination of these. However, the effect of sample storage has not been fully 
investigated and will require carefull consideration. Sample storage effects were 
investigated by performing a method comparison study and the results are discussed 
below (see section 3.3).
Large sample numbers analyzed over several days requires several sets of calibration 
standards which should be prepared simulaneously using the same pool of erythrocytes. 
Furthermore, the standards should be stored under identical conditions to the real
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samples. The standard curve slopes and endogenous levels can then be monitored to 
give an indication of daily changes in sensitivity and precision at or near to the limit 
of detection. In addition, it is important to carry out checks of standard accuracy 
which may help to determine any sample storage effects.
One of the possible sources of error for the erythrocyte sorbitol enzyme assay was 
considered to be the accuracy of pipetting washed packed erythrocytes. This was 
examined by accurately weighing 1.0 ml aliquots of erythrocytes repeatedly dispensed 
by a plOOO Gilson hand dispenser. The haemoglobin content for each dispensed sample 
was also determined. The mean weight of erythrocytes, for 8 samples, was 1.0516 g 
with a C.V. of 1.9% and the mean haemoglobin content 26.2 g/lOOml with a C.V. of 
1.8%. The respective results in whole blood, for 8 samples, were 1.0325 g, C.V. 1.92% 
and 16.2 g / 100ml, C.V. 2.25%. From these results it would appear that the errors in 
pipetting a viscous matrix account for only a small proportion of the daily variation in 
endogenous sorbitol levels.
The range of standards adopted was based on literature values for human normal and 
diabetic erythrocyte sorbitol levels (Malone et al., 1980, Morrison et al., 1970 and 
Popp-Snijders et al., 1983). In particular, calibration standards are required to cover 
a range that would include high levels, encountered in some diabetic samples, down 
to low levels in normal blood. These levels are anticipated to be of the order of 25.0 
down to 5.0 nmol/ml respectively. Erythrocyte sorbitol results are often expressed in 
terms of the haemoglobin content of washed packed red blood cells where 1 nmol/ml 
equals approximately 3 nm ol/g haemoglobin. Thus the expected range is 15-75 nmol/g 
haemoglobin.
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In general, each batch of enzyme allows for 100 sample analysis, including standards 
and duplicate determinations, with the feasibility of completing that number in a day. 
The enzyme assay was applied to the analysis of erythrocyte samples from diabetic 
patients participating in a clinical trial of the AR inhibitor Sorbinil and the results are 
discussed below, (see section 3.4.1).
3.2 Development of a Capillary Gas-Liquid Chromatographic Assay for 
Ervthrocvte Sorbitol Determinations
3.2.1 Initial GLC Studies
3.2.1.1 Packed Column GLC
Preliminary studies to investigate the GLC separation of polyols were performed using 
packed column systems. Packed column GLC was carried out on a Pye 104 gas 
chromatograph with flame ionisation detection. The retention of sorbitol hexaacetate 
(SHA) was determined for various columns and oven tem perature conditions, with 
oxygen free nitrogen (OFN) as carrier gas. Initially, this was done by dissolving SHA 
in various solvents, eg; chloroform, to give an accurate solution consisting of 1.0 
mg/ml. A 1 g\ injection of this solution onto, for example; a 2 m  x 4 mm ID column 
packed with 3% SP2250 on 80-100 Supelcoport, with carrier gas at 14 m l/m in and an 
isothermal oven temperature of 205°C, resulted in a retention time of 22 minutes for 
SHA. Measurement of the retention and peak width at half height for sorbitol, under 
these conditions, resulted in estimates for the number of theoretical and effective 
plates to be 3,350 and 3,000 respectively.
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Several polyols were derivatised and a retention study, using the above GLC system, 
carried out as follows. Sorbitol, galactitol, mannitol, xylitol, ribitol and glucose were 
acetylated individually, and as a mixture, in the following way. Each compound was 
accurately weighed and prepared as a 1 mg/ml solution in water. Using a Hamilton 
syringe 10 /il spikes of each solution was added to separate tubes; one containing them 
all as a mixture, and the volume made up to 1.0 ml with distilled water. 2.0 ml 6% 
perchloric acid was added and an aliquot (2.0 ml) of the solution neutralised by the 
addition of potassium carbonate as previously described. A 1.8 ml aliquot of the 
neutralised perchlorate was located in fresh tubes and the contents taken to dryness, 
under vaccum at 70°C for 1.5 hours, in a Buchler vortex evaporater. Acetate derivatives 
were prepared according to the method of Popp-Snijders et al., (1983). Samples were 
derivatised, at 70°C for 1 hour, by the addition of 0.25 ml pyridine and 0.25 ml acetic 
anhydride. The reaction was stopped by the addition of 0.5 ml distilled water and 1.0 
ml chloroform was added. The polyol derivatives were extracted into the chloroform 
by vortex mixing for 30 seconds. The samples were centrifuged, for 10 minutes at 2000 
r.p.m., and the chloroform layer taken to dryness, in fresh tubes, under a gentle stream 
of OFN. The samples were resuspended in 100 /tl chloroform and 1 /tl injected onto 
the GC. Results of the packed column separation of acetate derivatives are shown in 
figure 5 and demonstrates imcomplete separation of the alditols.
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Q)10cO
CL
CO0
OC
oQ)
0
Q
1 Ribitol
2 Xylitol
3 and 4 D-Glucose
5 d-Mannitol
6 Sorbitol
7 Galactitol
Key:
Conditions:
Column 2 m X 4 mm (ID) 
3% SP-2250 on 80-100 
Supelcoport with OFN 
carrier at 14 m l/m in and 
205°C isothermal oven 
tem peratu re . FID 
detection at 280°C. GC, 
Pye 104 with Chart 
Recorder at 2 mm/min.
TIME (mm)
Figure 5. Packed Column GLC Separation of Alditol Acetates
Samples were 10 gg of each sugar derivatised and resuspended in 100 gl ol 
chloroform with 1 gl injection onto the column
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A  set of erythrocyte standards, covering the range 0-10 /ig/ml, containing 5 gg a-methyl 
mannoside as internal standard, was taken through the whole procedure; from 
perchlorate precipitation to acetate derivatisation. The resulting correlation coefficient 
for the standards was 0.994. However, the retention study showed that sorbitol, 
galactitol and mannitol could not be completely resolved using various column 
temperature programming conditions. For this method to be applied to pathological 
samples, where changes in hexitols other than sorbitol may occur, a much better degree 
of separation is required.
Packed column GLC of tri-methyl silyl derivatives of polyols was investigated, both in 
perchlorate and erythrocyte suspensions. Extracts containing sorbitol and internal 
standard were prepared and taken to dryness as described above. The method of 
Sweeley et al., (1963) was used to form the TMS-polyol derivatives. The correlation 
coefficients of calibration standards in these extracts were found to be less than 0.94 
and not reproducible.
3.2.1.2 Capillary GLC of Polyols
Packed column GLC of polyols resulted in the problem of inadequate resolution of 
closely related hexitol acetates. Therefore, capillary GLC columns were investigated 
to see if the problem of hexitol resolution could be overcome. Sorbitol hexaacetate 
(SHA) was accurately weighed and diluted to obtain 100 and 50 gg/ml solutions in 
n-butyl acetate (NBA). Elution conditions for SHA were examined by injecting 1 g\ 
onto the GLC.
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An initial retention study was carried out as follows: Polyols and sugars were accurately 
weighed and made up in volumetric flasks to give 1.0 mg/ml solutions in distilled 
water. Aliquots, consisting of 5 gl of each polyol and sugar, were dispensed into 
separate tubes and into a tube containing them all as a mixture. The tubes were taken 
to dryness by vortex evaporation, acetylated, extracted into chloroform and dried down 
under OFN as already described. A tube taken through the whole procedure served 
as a reagent blank. The dried derivatives were resuspended in 100 gl of NBA and 1 
gl injected onto a Perkin-Elmer Sigma 3B capillary GLC with FID detection. Retention 
data is shown in table 7. It was found that repeat injections of the individual sugar and 
polyol samples, as well as injections of the mixtures, gave consistant retention times. 
Separation of the hexitol acetates were almost completely baseline resolved and an 
example, along with the analytical conditions, is shown in figure 6.
Table 7. Retention Data for Some Sugars and Polyols Separated by Capillaty GLC
COMPOUND RETENTION (min) PEAK HEIGHT (mm)
XYLOSE 8.0 & 8.3 36 & 56
RIBITOL 9.3 & 10.0 186 & 16
XYLITOL 9.7 & 10.0 141 & 26
METHYL-«-D-GP 11.0 >200
D(+)MANN0SE 12.2 & 12.6 62 & 34
D(+)GALACT0SE 12.6 59 & 63
D(+)GLUCOSE 12.6 & 12.8 70 (peaks fused)
MYO-INOSITOL 14.3 81
D-MANNITOL 14.6 125
SORBITOL 15.0 102
GALACTITOL 15.3 67
SHA (50 /xg/ml) 15.0 43
Methyl-o-D-GP = 1-0-m ethyl-a-D -glucopyranoside (2 mg/ml so lu tio n )
SHA = so rb ito l hexaacetate
A nalytical cond itions are given in fig u re  6.
Figure 6. Capillary
I and 2 Xylose
3 Ribitol
4 Xylitol
5 a-mGp
6 D + Mannose (2 peaks)
7 D +Galactose
8 and 9 D +Glucose 
10 Myo-inositol
I I  D-Mannitol
12 Sorbitol
13 Galactitol
Qf-mGp = 1-O-Methyl- 
a-D( + )Glucopyranoside
Key:
Conditions:
Column 25 m X 0.32 mm 
(ID) BP1, 1 n phase 
(S.G.E.) programmed from 
110°C for 1 min at 
39.9°C/min to 220°C held 
for 12 min with Helium 
carrier gas at 5.0 ml/min. 
Injector 250°C with the 
split vent opened 0.7 min 
after injection. FID 
detection range XI, 
amplification X16 with JJ 
LLoyd chart recorder 
(lOmv) at 5 mm/min. GC, 
Perkin Elmer Sigma 3B 
with OFN makeup gas. 
(Retention D ata is given 
in table 7.)
GLC Separation of Polyol and Sugar Acetates
Samples were 5 /ig each of compounds derivatised and resuspended in 100 /il 
NBA with 1 /il injected onto the column
106
Calibration standards were generated in perchloric acid and erythrocytes, covering
0-31.0 nmol/ml, and processed to obtain the acetate derivatives as previously described. 
Internal standard (5 g\ of 0.2 m g/m l Methyl-a-D-( + )glucopyranoside in water) was 
added at the beginning of the sample workup procedure. The capillary GLC analytical 
conditions were as for the retention study. The results were calculated by obtaining the 
peak height ratio of sorbitol to internal standard and regressing the values obtained 
for calibration standards against their concentrations. The correlation coefficients were 
0.987 and 0.959 for PCA and erythrocte standards respectively. No interference at 
hexitol retentions was observed in perchlorate or erythrocyte samples. The results 
showed some interference at the internal standard retention; which could explain the 
poor linearity of the standards. In addition, no peak was observed in erythrocytes at 
the galactitol retention which suggested the use of this hexitol as an alternative internal 
standard. From these initial findings a more extensive capillary GLC method 
validation was carried out (see section 3.2.2).
3.2.1.3 Discussion
The packed column separation of alditol acetates was first reported by Sawardeker et 
al., (1965) who reported complete degradation of these derivatives on the polar 
Carbowax 20M column. The best separations were achieved using a 10 foot column 
packed with ECNSS-M (Ethylene glycol succinate chemically combined with cyanoethyl 
silicone) with the hexitols resolving after approximately 75 minutes. Several similar 
packed column separations in biological matrices, such as human urine, serum and 
cerebro-spinal fluid, have been attempted (Blau, 1972, Mount and Laker, 1981, and 
Roboz et al., 1984). Some include the prior removal of glucose b y the enzyme glucose
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oxidase (Aloia, 1973) or by ion exchange (Allen et al., 1981). In most cases the 
resolution of hexitols was poor and incomplete after long retention times (40 minutes 
or more) which makes for lengthy, non cost effective analyses.
In the case of packed column separations of TMS-polyol derivatives difficulty has 
arisen in separating hexitols (Sweeley et al., 1963 and Travis et al., 1971). However, 
Varma and Kinoshita (1974) and Mayhew et al., (1983) have used such separations to 
examine polyol levels in rat lens and human sciatic nerve. As with acetylation some of 
these methods remove potentially interfering compounds present in the matrix, 
particularly glucose in blood, during sample preparation. Another example of matrix 
interference is the presence of urea in urine. Its removal by the enzyme urease, prior 
to TMS ether formation, has enabled H eaf and Galton (1975) to estimate changes in 
hexitol excretion in human urine.
The advent of glass capillary GLC as introduced by Golay in 1958 (Jennings, 1978) has 
led to some previously difficult separations being achieved. Glass capillary separations 
of pure polyol acetates was first described by Szafranek et al., (1973) who achieved the 
complete resolution of hexitols in approximately 55 minutes using a 60 metre column 
coated with SE 30 phase. They reported that fructose forms non-volatile acetylation 
products. The glass capillary separation of TMS derivatives of polyols was reported by 
Smith et al., (1978) who found that sorbitol from human cerebro-spinal fluid eluted 
between the o: and B-glucose anomers without interference from these or other 
constituents.
Glass capillary separations, lengthy in terms of polyol elution times, have generally 
been superseded by the use of fused silica capillary columns. The latter offer the
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additional advantages of greater chemical and thermal stability through immobilised 
and cross-linked stationary phases (Grob et al., 1981).
Various commercial fused silica capillary columns, available in our laboratory, were 
investigated and the initial hexitol separations obtained on a methyl silicone phase 
were encouraging (table 7 and figure 6). Due to the unsuitability of methyl- 
glucopyranoside as an internal standard, galactitol was substituted instead in further 
studies to determine assay performance. Galactitol has the added advantage that on 
the systems so far tested its elution was close to other hexitols and its endogenous 
presence in the matrix was not evident. In addition, factors such as sample preparation, 
column injection technique and derivatisation procedures were investigated to 
determine their influence on the analysis.
3.2.2 Capillary GLC Method Validation for Erythrocyte Sorbitol Determination
3.2.2.1 Sample Preparation using Vortex Evaporation
The aim of this study was to determine the within day and between day linearity, 
accuracy and precision of calibration standards and blind spikes generated in 
erythrocytes. The experimental protocol adopted was similar to that used for the 
enzyme assay validation. Pooled washed erythrocytes were obtained from healthy 
non-diabetic volunteers and prepared as described above, (see section 3.1.). Enough 
erythrocyte calibration standards, covering the range 0-31.0 nmol/ml, were generated 
to provide for 6 days analysis. Blind spikes were generated, in the same pooled 
erythrocytes, by another operator using a separate accurately prepared sorbitol solution. 
Standards and blind spikes were stored at -20°C.
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The capillary GLC sample work up procedure was as already described with the 
exception that on the day of analysis 100 g\ of 20 gg/ml galactitol in water was added, 
as internal standard, to each thawed standard and sample. Neutralised perchloric 
supernatants were taken to dryness by vortex evaporation, then derivatised to form the 
peracetates, extracted into chloroform and taken to dryness. Samples were resuspended 
in 100 /il of NBA and vortex mixed prior to 1 /il injections onto a Perkin-Elmer Sigma 
3B capillary GLC with FID. Peak heights for sorbitol and galactitol were obtained for 
calibration standards and subjected to least squares linear regression analysis. The 
equation of the curve for calibration standards was used to obtain the sorbitol 
concentrations in unknown samples. In total, five standard curves were analysed on 
separate days. Eighteen blind spikes were analysed on each of two days (36 in total). 
In order to obtain an indication of the sorbitol levels in diabetic blood 24 diabetic 
patient samples were randomised, by another operator, and 8 analysed on each of 
three consecutive days. These samples were also analysed by the enzyme assay and 
the results are discussed in detail below (see section 3.3).
The recovery and precision data obtained for blind spikes is shown in table 8, and the 
performance of the standard curves is summarised in table 9. The results are discussed 
below (see section 3.2.2.3). An example erythrocyte sorbitol calibration curve is shown 
in figure 7. The capillary GLC analytical conditions with example chromatograms are 
shown in figure 8.
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Table 8. Recovery and Precision Data for Blind Spikes and Endogenous Erythrocyte 
Sorbitol Level
DAY 1
DAY 2
Endogenous 12.4 nmol/ml 18.6 nmol/ml
level standard standard
found spiked spi ked
% recovery % recovery
3.6 103.5 102.2
2.5 104.7 106.5
3.8 102.4 100.0
3.5 86.5 101.1
4.2 106.5 109.4
3.7 103.5 104.0
MEAN 3.6 101.2 103.9
S.D. 0.57 7.3 3.5
C.V. % 15.8 7.2 3.4
3.1 nmol/ml 6.2 nmol/ml 18.6 nmol/ml
standard standard standard
spi ked spiked spiked
% recovery % recovery % recovery
85.4 97.7 99.0
100.0 110.1 115.8
91.0 88.4 110.5
98.9 124.8 101.0
93.3 93.0 110.5
93.0 107.7
MEAN 93.7 101.2 107.4
S.D. 6.0 13.8 6.3
C.V. % 6.4 13.6 5.9
Day 1 = samples s to red  fo r two days a t -20°C
Day 2 = samples sto red fo r one week a t -20°C
Table 9. Performance of Erythrocyte Sorbitol Standard Curves
NO SLOPE CORRELATION ENDOGENOUS SO
COEFFICIENT FOUND nmol/ml
1 0.0419 0.995 3.4
2 0.0413 0.999 3.7
3 0.0478 0.993 2.4
4 0.0415 0.996 3.7
5 0.0413 0.993 4.2
Mean endogenous e ry th rocy te  so rb ito l level = 3.5 nmol/ml, C.V. % = 19.2 
Mean slope = 0.0427, C.V. % = 6.6
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ERYTHROCYTE SDRBITDL nmol/ml
Figure 7. Example Calibration Curve for Erythrocyte Sorbitol Standards Analysed by 
Capillary GLC
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75 To 5 TNJ
TIME (mm)
Figure 8. Capillary GLC Separations of Eiythrocyte Polyols and Sugars
1 d( + )Glucose (2 peaks)
2 Myo-inositol
3 d-Mannitol
4 Sorbitol
5 Galactitol 
(internal standard)
Key:
Conditions:
All conditions as for figure 
6 but with initial column 
temperature at 110°C for 
1 min and programmed 
at 39.9°C/min to 230°C 
and held for 12 min. 
Samples were resuspended 
in 100 /il NBA and 1 /il 
injected
a) Zero, Endogenous 
Erythrocyte Calibration 
Standard
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As figure 8a).
Conditions: 
As figure 8a).
Key:
15 10 5
TIME (min)
Figure 8 b). Erythrocyte Sorbitol Standard 6.2 nmol/ml
INJ
114
As figure 8a).
Conditions: 
As figure 8a).
Key:
c). Erythrocyte 
Sample from a 
Diabetic Subject
Figure 8 cont. TIME (min)
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3.2.2.2 Sample Preparation using Freeze Drying
The aim of this study was to carry out a method validation, for erythrocyte sorbitol 
determination, using freeze drying to obtain dry samples prior to derivatisation. Enough 
erythrocyte calibration standards were generated so that the between day precision of 
blind spikes, at three different erythrocyte sorbitol concentrations, could be 
determined on 6 different days. In order to facilitate rapid dispensing of calibration 
standards they were prepared in bulk as described below. In addition, freeze drying of 
the neutralised perchlorate supernatants was investigated, as an alternative to drying 
by vortex evaporation, to examine whether this alternative improved either the 
qualitative or quantitative performance of the assay.
Bulk sets of calibration standards were generated in washed erythrocytes from healthy 
volunteers. This was acheived by accurately weighing sorbitol to obtain a 1.0 mg/ml 
solution in distilled water. A  volume of 0.625 ml of this solution was accurately 
transfered to a 250 ml volumetric flask and the volume made up to the mark with 
freshly prepared 6% perchloric acid to give a 2.5 gg/m\ solution. Aliquots of this 
solution were accurately diluted with 6% PCA to obtain 0.25, 0.5, 1.0, 1.5, 2.0 and 2.5 
tig/ml solutions in 100 ml volumetric flasks. Aliquots, 2.0 ml each, of these PCA 
standards were accurately dispensed into separate tubes. To each tube was accurately 
dispensed 1.0 ml of pooled, washed erythrocytes; using an Eppendorf repeating 
dispenser. The zero sorbitol calibration standard consisted of 2.0 ml PCA only; to 
which 1.0 ml erythrocytes were added. In this way erythrocytes were fortified, with PCA 
containing sorbitol, to produce calibration standards equivalent to 0 - 5.0 tig/ml. There 
were enough PCA sorbitol standards to generate up to 40 complete calibration sets. 
Blind spikes were generated using the same pool of erythroctes, by another operator,
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in an analogous manner. Separate sorbitol solutions were used to fortify the blind 
spikes. All the tubes were capped, vortex mixed to obtain a smooth suspension and 
stored at -20°C. Individual sets of calibration standards and blind spikes were analysed 
on each day; 6 in total over a 2 week period.
On the day of analysis samples were thawed and 100 g\ of 25 gg/m\ galactitol in water 
added (to each tube) as internal standard. As on previous occasions the samples were 
maintained on ice as a precaution. Samples were mixed, centrifuged and the perchlorate 
supernatant neutralised as described earlier. Aliquots, consisting of 1.8 ml neutralised 
extracts, were placed in screw neck tubes and the tops covered with gauze bolting cloth 
secured by elastic bands. The samples were frozen at -20°C for at least three hours 
prior to placing them in a freeze drier. The samples were freeze dried overnight with 
the cold trap operating at -55°C. Freeze dried samples were acetylated, extracted, 
dried and resuspended in 100 g\ NBA as already described. Samples were injected onto 
a Perkin-Elmer 8320 GLC equiped with PTV injector, FID detector and automatic data 
handling using a GP2000 plotter. Peak height ratios of sorbitol/galactitol for calibration 
standards were taken from the integrator and subjected to least squares linear 
regression analysis. The equation of the curve, for the calibration standards, was used 
to obtain the sorbitol concentrations in unknown samples. The results for blind spike 
analysis and standard curve performance are shown in table 10, and discussed in section
3.2.2.3. The method was applied to the analysis of erythrocyte samples taken from 
healthy, non-diabetic subjects and these results are shown and discussed in section
3.4.3.
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Table 10. Performance of Blind Spikes and Standards for Freeze Dried Erythrocyte 
Samples Analysed by Capillary GLC.
BLIND SPIKE PRECISION
LEVEL SPIKED 
/xg/ml e ry th rocy te
1.2 (+E) 4.0 (+E) Endog (+E)
DAY
1 1.3 2.6 4.3 5.7 -0 .1 1.2 F
2 1.1 2.3 3 .9 5.1 0.2 1.0 0
3 1.1 2.4 3.9 5.1 -0.1 1.2 U
4 1.2 2.3 4.0 5.2 0.04 1.2 N
5 1.2 2.3 4.2 5.3 0.1 1.2 D
6 1.3 2.6 4.5 5.8 -0 .2 1.2
MEAN 2.4 5.4 1.2
S.D. 0.147 0.307 0.08
C.V. % 6.1 5.7 6.7
STANDARD CURVES
DAY SLOPE r E
1 0.309 0.997 1.3
2 0.352 0.997 1.2
3 0.346 0.997 1.2
4 0.371 0.998 1.2
5 0.359 0.994 1.1
6 0.349 0.997 1.3
MEAN 0.347 1.2
S.D. 0.020 0.075
C.V. % 6.0 6.3
E = Endogenous e ry th ro cy te  so rb ito l level obtained on the  day.
The mean endogenous so rb ito l level o f 1.2 /xg/ml is  equ ivalen t 
to  6.6 nmol/ml.
1 1 8
3.2.2.3 Discussion
The performance of the capillary GLC assay for erythrocyte sorbitol, with sample 
preparation using vortex evaporation or freeze drying prior to acetylation, has been 
assessed. The overall recovery and relative standard deviations for blind spikes were 
101.5%, +_ 8.7% and 101.9% +. 6.2% for the two drying methods respectively (tables 
8 and 10). Both sample preparation methods gave very good linearity with correlation 
coefficients above 0.993 (tables 9 and 10). The relative standard deviation of the slopes 
of the standard curves, for both methods, was approximately +_ 6% indicating
consistant between day sensitivities for the two procedures.
The limit of quantitation was estimated as half the endogenous level between 2 and 
3 nm ol/m l erythrocytes. There is the possibility of improving the limit of detection; 
for example, if more sample was analysed, resuspension in a smaller volume or greater 
detector amplification were employed. However, the limit of detection is dependent 
upon the background noise of the detector. This can be estimated by performing a 
blank mn, temperature programming in this particular application, without injecting 
a sample as described by Knoll (1985). Using this method the largest noise fluctuation 
is measured in a chart interval that is a multiple of the analyte’s chromatographic 
peak width at half height. The concentration for the analyte at the limit of detection 
(CL00) can then be estimated by the following equation:
CL0D = Klod hn Cs /h s
where KL0D is a constant, hn is the largest noise fluctuation observed in the 
measurement interval and Cs is a calibration sample of known concentration resulting
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in a peak height of hs. Knoll has derived values for the constant KL0D which equals 
1.9718 when the peak width multiple is 10. Using this equation the limit of detection 
for the capillary GLC method is estimated to be 0.1 gg/ml. In addition, Knoll has 
derived constants for the estimation of the limit of quantitation which is equal to 3 
times the limit of detection. Thus the limit of quantitation for the current method can 
be estimated to be 0.3 jug/ml which is approximately one tenth the value when 
determined by extrapolation from the calibration curve.
The endogenous erythrocyte sorbitol concentrations, from different pools of washed red 
blood cells, averaged 3.6 and 6.6 nmol/ml by vortex and freeze drying respectively 
(tables 8 and 10). Vortex evaporation gave the greatest imprecision, observed at the 
endogenous level; C.V. 19%, compared to 6.3% by freeze drying. However, the method 
of bulk standard generation may also contribute to the improved precision observed 
for the freeze drying validation study. The importance of using the matrix endogenous 
level as a daily quality control param eter has been stressed by Roboz et al., (1984) who 
found the daily variation in endogenous serum polyols to vary by an average of 9% 
when samples were dried down under OFN after solvent precipitation of the proteins.
The overall recovery of sorbitol at the highest spiked calibration level compared to 
unextracted sorbitol hexaacetate was better than 90% for both sample preparation 
methods. The recovery C.V., assessed by the variation in peak height of galactitol as 
internal standard, was typically 30% for both drying methods and this variation reflects 
all stages of the assay.
Other examples of sample drying of biological matrices include protein precipitation 
with methanol or acetonitrile followed by drying down under OFN (Roboz et al., 1984,
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Johnson and Mayersohn, 1984 and Jansen et al., 1986). Unextracted aqueous polyol 
solutions, at 100 /ig/ml concentrations, taken to dryness directly by vortex evaporation 
were recovered quantitively. And in conjunction with the speed of this drying method 
was felt adequate to determine sorbitol levels in samples from a Sorbinil clinical trial 
(see section 3.4.2). It was noticed that un-neutralised perchlorate supernatants could 
not be taken to dryness within 12  hours of continual vortex evaporation. Whereas 
neutralised perchlorate supernatants could generally be dried within 2 hours. 
Therefore the neutralisation step following perchlorate precipitation is essential in this 
sample workup procedure.
No interference was seen at any of the hexitol retentions and the analysis does not 
suffer from the lack of specificity shown by the enzyme method with xylitol. However, 
the possibility of coelution between naturally occuring chiral polyol enantiomers, for 
example; chiro-inositol with myo-inositol, has still to be examined.
Capillary GLC separations of erythrocyte polyols were first reported by Popp-Snijders 
et al., (1983) using acetate derivatisation with mass-spectrometry detection to confirm 
the identity of eluting hexitols. The current method is partially based on the above 
although there are differences in sample preparation and calibration. Firstly, the 
method of Popp-Snijders splits the original precipitated erythrocyte sample (2.5 ml) 
into three with the third aliquot acting as a blank without the addition of galactitol as 
internal standard. This was particularly useful because very little endogenous galactitol 
(galactitol already present in the matrix) was found by them confirming the choice of 
this polyol for use as an internal standard.
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Their method uses drying down under OFN of the neutralised perchlorate supernatant 
but no further information was given by them. As a consequence two alternative drying 
methods were investigated in the current study in order to determine the effect of this 
stage of sample workup on the assay performance. The evidence would support either 
of the three methods for obtaining dry samples prior to derivatisation. Although it 
would appear that of the two methods investigated in the current study freeze drying 
gave better results.
The division of the original sample into three (as described by Popp-Snijders) in 
conjunction with resuspension of the derivatised extract in 0.5 ml chloroform results 
in a final concentration which is more dilute than that used in the current study. In 
addition, the final resuspended polyol acetate derivatives (in the Popp-Snijders method) 
were injected at an isothermal column temperature held at 180°C. It had been noticed, 
during the initial set up of the current method, that polyol acetates resuspended in 
chloroform gave reduced peak heights with high initial column temperatures and that 
this could effect the ultimate sensitivity of the method. Somewhat surprisingly limits 
of both quantitation and detection were not reported by them. In addition, there 
appeared to be a lack of assay performance data particularly at low levels close to the 
endogenous sorbitol level. As this level is close to the limit of quantitation an indication 
of the assay variation at such low levels is required. This is especially needed if low 
sorbitol levels are expected to be produced as a result of therapy designed to inhibit 
aldose reductase activity.
A further difference between these two capillary GLC methods is the choice of column 
for the separation. The method of Popp-Snijders used a 25 m narrow bore (0.25 mm 
ID) column with the phaf e (Cp sil 5) coated on the inside. The actual phase thickness
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was not quoted by them but as they encountered large predominating glucose peaks 
there is the danger of overloading the phase. Such overloading may affect the 
separation and long term  performance of capillary GLC columns. As an attempt to 
safeguard against deleterious effects occurring due to column overload a wider bore 
column, generally 0.32 mm ID, with a thicker 1 g immobilised phase was used in the 
current studies.
Although there are differences in methodological approach, and considering the data 
available thus far, the two capillary GLC methods agree well with very similar results 
obtained for assay performance in erythrocyte samples. Further experiments to 
determine assay factors, such as capillary GLC injection technique (see section 3.2.3), 
were designed to add data to the capillary GLC method for polyol determination 
already obtained by Popp-Snijders and these validation studies.
The only other example of capillary GLC separations of erythrocyte polyols, that of 
Jansen et al., (1986), used TMS derivatisation with FID detection on a limited number 
of blood samples. They did not examine any performance criteria and no precision data 
was reported. However, these authors found that mannose and glucose but not the 
hexitols, were lost by extensive sample pre-washing with saline.
The range of standards adopted was based on literature values already cited; as for the 
enzyme assay. The overall length of analysis is more time consuming than the enzyme 
method especially with freeze drying overnight. The complete analysis of 30 samples 
would take approximately 2 days from start to finish and is fairly labour intensive. The 
time can be cut down using an automatic injector allowing samples to be run 
unattended. Although taking considerably longer than the enzyme method the capillary
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offers the advantage that other polyols can be determined from each chromtographic 
trace. This was investigated further when the capillary GLC method was used to 
determine erythrocyte sorbitol and myo-inositol concentrations in diabetics participating 
in a clinical trial of the aldose reductase inhibitor, Sorbinil (section 3.4.2).
3.2.3 Further Studies to Optimise the Capillary GLC Method
3.2.3.1 Capillary Column Injection Techniques
Different injection techniques can be used to introduce the sample into the capillary 
column. Several techniques, available in our laboratory, were investigated to determine 
which would be most suitable for the routine analysis of large numbers of polyol 
samples. Furthermore, whichever technique was found to be most appropriate would 
require optimisation.
The techniques available were split or splitless, cool-on-column and programmable 
temperature vaporisation (PTV). All of these techniques were investigated with 
different combinations of column temperature programming and carrier solvents. In 
general, acetate derivatives of blood standards were used to assess the techniques. 
Initially, a 10 m x 0.32 mm ID, BP1, 1 /i phase column was connected to each injector 
in turn and a sorbitol hexaacetate solution (50 /ig/ml NBA) chromatographed under 
isothermal conditions with FID detection. The results are shown in table 11. Capillary 
injection techniques were compared using the same erythrocyte calibration standards, 
firstly resuspended in 100 /il chloroform and subsequently dried down under OFN and 
resuspended in 100 /il NBA. The results are shown in table 12.
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Table 11. Comparison of Capillaiy Column Injection Techniques
TECHNIQUE EFFICIENCY
(E ffec tiv e  plates/m )
SPLIT 2,334
SPLITLESS 2,262
C00L-0N-C0LUMN 1,921
PTV 2,423
REMARKS
Ratio 1:50, autom atable, 
Used fo r  concentrated 
samples, 0.1 /il in je c tio n
Used fo r  d i lu te  samples, 
autom atable, 1.0 /il 
in je c tio n  volumes
D efin itiv e  technique, 
d i f f i c u l t  to  automate,
1-2 /il in je c tio n  volumes
Solvent dumping p o ssib le  
fo r  la rg e  in je c tio n  vol 
probably autom atable
Column 10 m x 0.32 mm ID, BP1, I g phase operated a t 200°C with 
helium c a r r ie r  gas a t 35 cm/sec.
Table 12. The Influence of Solvent Effects on the Results of Erythrocyte Calibration 
Standards
STANDARD SORBITOL GALACTITOL (IS) PEAK HEIGHT RATIO 
/ig/ml Peak height mm S o rb ito l/G a la c tito l
CHC13 NBA CHCfy NBA CHClg NBA
0 1.5 6 9.5 47 0.157 0.127
1 6 15 8 45 0.750 0.333
2 7.5 20 5.5 49 1.363 0.408
3 10.5 28 8.5 47 1.235 0.595
4 8 32 6 38 1.333 0.842
5 6 56 3 55 2.000 1.018
y = 0.366 0.113
Slope = 0.309 0.176
r  = 0.926 0.992
Column 25 m x 0.32 mm ID BP1, 1 g Phase, In je c tio n  volume 1 /il
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The acetate derivative of a 5 gg/ml erythrocyte standard, resuspended in NBA, was 
injected in the split mode (with a split ratio of approximately 1:25) and eluted with 
various initial column temperatures, held for 1 minute, then programmed at 30°C/min 
to a final temperature of 210°C. The column used was a 25 m x 0.2 mm (ID) BP5 
(phenyl methyl silicone) with a 0.25 g phase. This column was chosen because it was 
thought to be a similar column to that used by Popp-Snijders et al., (1983) as already 
discussed (see section 3.2.2.3). The peak height of sorbitol was found to decrease with 
increasing initial column temperature and this effect is shown in figure 9, galactitol 
and myo-inositol were similarily affected.
Cool-on-column injection was performed using a 25 m OV101 column to determine the 
accuracy of this injection technique. A set of erythrocyte standards, without internal 
standard added, was injected and it was found that linear regression analysis of the 
standards gave a correlation coefficient of 0.95. In addition, because galactitol was not 
added any peak elution at this retention could be determined. It was necessary to do 
this because if galactitol was present to any extent the choice of this polyol as internal 
standard would have to be re-examined. No peak was observed to elute at the galactitol 
retention giving further evidence that galactitol may be a suitable choice as internal 
standard. Therefore, the finding by Popp-Snijders of negligible levels of endogenous 
galactitol present in the matrix has been confirmed in this study by the use of an 
alternative phase and injection technique. Example chromatograms are shown in figure 
10 and it would appear that an aqueous solution of sorbitol is chromatographically pure 
eluting as a single peak.
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Figure 9. The Relationship Between Sensitivity and Cold Trapping in the Split Mode
Chromatographic conditions are given in the text and were obtained using 
a Perkin Elmer Sigma 3B capillary GLC with helium carrier gas at 2 m l/m in
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Conditions:
Column 25 m X 0.2 mm 
(ID) OV 101,0.25 n Phase 
(S.G.E. Ltd.) with helium 
carrier gas at 0.6 ml/min. 
Programmed from 120°C 
for 1 min at 39.9°C/min 
to 230°C hold for 10 min. 
FID detection (300°C) 
XI, X16 with JJ LLoyd 
chart recorder (lOmV) at 
10 mm/min. GC, Perkin 
Elmer Sigma 3B with Cool- 
on-Column injecter.
Figure 10. Chromatograms of Standards using Cool-on-Column Injection
a) Sorbitol (2 /xg/100 /xl water) taken to dryness by vortex evaporation, 
acetylated, extracted and resuspended in 100 /il NBA and 1 /xl injected 
onto the column
1 d( + )Glucose
2 Myo-inositol
3 d-Mannitol
4 Sorbitol
5 Galactitol
Key:
Conditions:
As Figure 10a).
L l’ !-trumonis
lli'yfj 'liSiiumRnt?
TIME (min)
Figure 10 b). 5 gg/m\ Erythrocyte Sorbitol Standard Without Galactitol as Internal 
Standard
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Programmable temperature vaporisation (PTV) was assessed using a standard activity 
mix (in n-pentane), with the injector preheated to 250°C in the split mode. The results 
were similar to those obtained for conventional split type injectors with the same 
column. However, when the activity mix was injected with the PTV conditions set to 
dump solvent (initial PTV tem perature 100°C) the lower boiling point volatiles, 
including n-tridecane, were vitually completely lost from the chromatogram (sample 
discrimination). This effect was observed in erythrocyte samples but the hexitols were 
not affected. This injection technique was used for the analysis of a series of polyol 
samples obtained from normal non-diabetic subjects and an example chromatogram is 
given in figure 15, section 3.4.3.
3.2.3.2 Discussion of Injection Techniques
The choice of injection technique used in capillary GLC depends on the type of 
analysis to be performed. Concentrated samples; for example, petroleum, can be 
analysed by making 0.1 gl injections with high split ratio’s. For dilute samples 
containing low concentrations of solutes split injections are not recommended. The 
samples are better transfered completely onto the column using cool-on-column 
injection. However, this technique is not easily automated and requires delicate 
expertise in handling which is considerably labour intensive. Furthermore, applications 
requiring a rapid turnover of large numbers of samples are better injected automatically 
using split or splitless; provided the solutes are not heat labile at high volatilisation 
temperatures. In which case they would have to be injected by cool-on-column or 
possibly solvent dumping using PTV.
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The choice of carrier solvent is important in splitless injection especially when using 
solvent effect. The disadvantage of using chloroform with solvent effect is its low boiling 
point, 70°C. The initial column temperature would have to be about 40°C, to obtain 
the concentration effect onto the column, and this increases the analysis time. Also, 
the recycling time for some gas chromatographs, to return to low initial temperatures, 
prolongs the equilibration time between injections. These factors do not produce a cost 
effective method. Furthermore, chloroform when used in place of n-butyl acetate as 
carrier solvent was seen to affect both the performance of erythrocyte standards, 
producing non-linear calibrations (table 12), and the sensitivity (measurable peak 
height). These effects have not been reported by others.
Butyl acetate is not an ideal solvent for splitless injection (Grob, K. Jr., 1983) because 
it has the disadvantage of spreading through the first m etre or so of non polar 
columns, (Saravalle, et al., 1983). This effect can be overcome by using retention gaps 
at the capillary inlet (Grob, K. Jr., 1982 and Grob, K. and Schilling, B., 1987) but when 
used in this laboratory no advantage was observed for columns of 25 m or more in 
length. Moreover, the large n-butylacetate (NBA) solvent band produced by splitless 
(with solvent effect) did not affect the separation of hexitols; where retentions were 
dependent on the length of column, type and thickness of phase and column 
tem perature programming. The advantages of using NBA are the higher initial oven 
temperature, typically 110°C to obtain the concentration effect, and much reduced 
recycling and equilibration times; which all combine to produce a shorter more cost 
effective analysis. In addition, the performance of the standard curves does not appear 
to be affected by this solvent (table 12).
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The large NBA solvent band obtained by splitless injection is reduced when a split 
injection is made using cold-trapping column temperature programming (column 
programming as for splitless with solvent effect). Split injection, with samples 
resuspened in NBA, resulted in reduced hexitol peak heights, as expected, when 
compared to concentrating the sample with splitless. This effect was even more 
apparent with high initial column temperatures where less cold trapping occurs (figure 
9) even when low split ratios were used. Therefore, split injections with high initial 
oven temperatures should be avoided for analyses requiring trace determinations. The 
results of investigations into capillary GLC injection techniques are summarised below 
in table 13.
Table 13. Siimmaiy of Findings for Capillary GLC Injection Techniques
INJECTION
TECHNIQUE
DECREASED
SENSITIVITY
WITH
INCREASED
SENSITIVITY
WITH
COMMENT
SPLIT High i n i t i a l  column 
tem peratures using 
chloroform and NBA
Low i n i t i a l  column 
tem peratures i f  
using chloroform 
NBA b e tte r
? Low s p l i t  
r a t i o 's  with 
co rre c t 
so lven t
SPLITLESS Chloroform not a 
good choice unless 
very low in i t i a l  
column tem perature
NBA a reasonable 
choice but floods 
non-polar phases 
higher in i t i a l  
column temp
Beware of 
column 
overload 
so lven t 
e f fe c t
COOL-ON-COLUMN As fo r s p l i t l e s s As fo r  s p l i t l e s s Labour
in ten s iv e
PTV Loss of so lu te s  
with NBA and 
so lven t dumping
Chloroform or 
even lower 
b o ilin g  po in t 
so lven ts but 
so lu te s  must be 
so luble  in so lven t
Inaccurate  
tem perature 
contro l when 
programming 
can be used 
fo r normal 
s p l i t / l e s s
Note: s p l i t  and s p l i t l e s s  in je c tio n  techniques are autom atable and very 
r e l ia b le .  Cool-on-column is  now av a ilab le  automated.
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The particular studies envisaged in this work will require as much detector sensitivity 
as possible: because it is anticipated that diabetic erythrocyte sorbitol concentrations 
could be reduced by treatm ent with aldose reductase inhibitors. There is the additional 
requirement of a high turnover of large numbers of samples with the eventual aim of 
providing automated sample injection. Therefore, sample injection using splitless with 
solvent effect is probably a reasonable compromise; resulting in most of the sample 
transfering to the column without undue loss of detector sensitivity.
3.2.3.3 Investigations of Polyol Derivatisation
A  study of the relationship between acetylation and time for the derivatisation of 
sorbitol and galactitol was performed, (acetic anhydride and pyridine, 0.25 ml each was 
used). Individual tubes containing 20 and 10 /xg sorbitol and galactitol respectively were 
incubated at 100°C in an oven for various times; from 0 to 60 minutes up to 6 hours. 
Samples, at each time point, were extracted with chloroform containing myo-inositol 
hexaacetate as unextracted standard. No difference in sorbitol or galactitol recovery 
was found from between 15 minutes up to 6 hours.
Different amounts of pyridine were used to catalyse acetylation of dried PCA extracts 
containing 5/xg sorbitol and 2.5 /xg galactitol. No difference was found, in the peak 
height ratio’s for sorbitol to galactitol, when the reaction was catalysed with either 50, 
100, 150 or 200 /xl pyridine. When biological sample extracts were acetylated as 
already described discoloration was observed. The degree of discoloration, which was 
less when smaller amounts of pyridine was used, had no effect on polyol recovery from 
spiked samples. No difference in recovery was found between new pyridine used
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straight from the bottle and the same pyridine distilled before use. As a precaution, 
however, freshly distilled pyridine, stored over KOH, was used in all studies.
Two peaks were observed, both on packed and capillary GLC, for the acetylated single 
a-D-glucose anomer. Commercialy obtained a-D-glucose pentaacetate gave only one 
peak indicating that mutarotation of a-D-glucose was occuring under the acetylation 
conditions used. Acetylated fructose was observed to break down producing several 
small peaks on the capillary system making quantitation of this sugar impossible, also 
observed by Szafranek et al., (1973).
Single sample extractions with chloroform were found to extract polyols completely. 
Silylating of glassware, prior to their use for reactions, was found to be unneccesary 
there being no qualitative or quantitative differences to clean tubes.
Alternative catalysts for acetylation were examined. These included N-methyl imidazole 
and 4-dimethyl aminopyridine. Acetylation with N-methyl imidazole, using the method 
of Wachowiak and Conners (1979) was not successful. Polyols could not be extracted 
from the dark brown oily residue that resulted. No such problem was reported by 
Henry et al., (1983) who used this alternative catalyst. Acetylation with 4-dimethyl 
aminopyridine (DMAP) was carried out on erythrocyte and plasma samples. Using the 
method of Hofle et al., (1978) it was found that the reaction was complete in 15 
minutes at 40°C with very good recovery. A set of erythrocyte standards acetylated with 
DMAP as catalyst gave 95% recovery with a correlation coefficient of 0.992. In blank 
plasma samples a small peak at the galactitol retention can be seen but sorbitol is 
hardly discernable and example chromatograms are shown in figure 1 1 .
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Figure 11. Capillary Separations of Plasma Polyols and Sugars - Acetylation using 
DMAP Catalyst
1 Unknown from DMAP
2 d( + )Glucose
3 Unknown
4 Unknown
5 Myo-inositol
6 d-Mannitol
7 Sorbitol
8 galactitol
Conditions:
Column, 25 m X 0.32 mm 
(ID) BP1, 2 g phase 
(S.A.C. Ltd.) programmed 
from 110°C for 1 min at 
39.9°C/min to 240°C hold 
for 20 min with helium 
carrier gas at 1.4 ml/min. 
Injector slitless (280°C) 
with vent opened 1 min 
after injection. FID 
detection XI, X8 with JJ 
LLoyd chart recorder 
(lOmV) at 5 mm/min. GC: 
Sigma 3B.
Samples extracted in 0.5 
ml NBA and 1 g\ injected 
onto the column. Sample 
recovery is greater than for 
the same standard injected 
with an initial temperature 
of the column at 160°C (fig 
lib ) .
Key:
a) 1.0 ml plasma standard 
with 5gg each sorbitol and 
galactitol
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column temperature at 160°C
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As Figure 11a)
Conditions:
As Figure l i b )
Acetylation using trifluoroacetic anhydride (TFA) to produce the trifluroacetyl 
derivatives of polyols was attempted. TFA acetylation using the method of Shapira 
(1969) on small amounts of pure polyol was not successful. The method of Ando and 
Yamakawa (1971) was used to produce the hexakis derivative of sorbitol which eluted 
after 5.4 minutes on a non polar capillary column programmed from 110°C for 2 
minutes at 10°C/min to 150°C with FID detection. Some components were seen to 
elute after the sorbitol and when hexitol mixtures were derivatised a considerable 
number of extraneous peaks was observed.
3.2.3.4 Discussion of Derivatisation Procedures
Acetylation of sugars and polyols using acetic anhydride and pyridine, in various 
proportions and under various reaction conditions, has been widely used (Blau and 
King 1977). Pyridine is used because it is an excellent solvent for sugars, polyols and 
their acetate derivatives, and it acts as a base for protons produced by the reaction. 
The production of two peaks for a single anomer of glucose has been reported (Blau 
and King 1977). To avoid this problem sugars are often chemically reduced to their 
corresponding alditols which when acetylated elute as single peaks. This latter 
approach cannot be adopted in the present studies because glucose present in the 
blood would be reduced to sorbitol. An alternative is to carry out the reaction 
overnight at room temperature or for 24 hours on ice - both very time consuming - 
which results in the formation of a single peak. This was unneccesary in this study, 
because no interference between the two glucose peaks and the hexitols was observed 
for any capillary separation so far investigated. This result can be compared to TMS 
derivatisation where sugars are known to produce multiple peaks which can have 
considerably different retentions on the same column, (Smith et al., 1978). There is the
138
possibility of coelution of peaks derived from both polyol and sugars which could affect 
quantitation of the compound under investigation. Furthermore, polyol acetate 
derivatives are more stable than the TMS ethers (Popp-Snijders et al., 1983) and this 
was a further factor in choosing to persue capillary separations of acetates.
Pyridine has male specific toxic effects and its use should be limited and carefully 
carried out. DMAP has been found to be a viable alternative; catalysing acetylation by 
104 times pyridine (Hofle et al., 1978, Wachowiak and Conners, 1979). DMAP was 
investigated for its usefulness as a polyol acetylation catalyst and the initial results were 
encouraging. Another distinct advantage of DMAP is that the reaction time is rapid 
at room temperature and upon completion the reactants can be evaporated off without 
having to resort to solvent extraction. However, before DMAP can be adopted in place 
of pyridine an extensive method validation in biological matrices would have to be 
performed. Dry sodium acetate was used as an alternative to pyridine by Szafranek et 
al., (1973) who reported its faster catalytic action. However, the application was 
performed on pure compounds and its catalytic effect on biological extracts remains 
to be determined.
The trifluoroacetyl derivatives of polyols and sugars are much more volatile than the 
acetates. The reaction was carried out using 0.25 ml each of ethyl acetate and 
trifluoroacetic anhydride. The presence of extraneous peaks, which may interfere with 
hexitol retentions, is probably due to impurities in the solvent and emphasises the need 
to use very pure reagents. Separations of TFA derivatives of hexitols have recently 
been reported for cyanopropyl bonded capillary columns by Haga and Nakajima (1988). 
These authors achieved excellent separations of the pure hexitols with elution times 
of up to 16 minutes. Possible interference from glucose and other components in
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biological matrices was not investigated. Nevertheless, the principle has been 
established that TFA derivatisation could be an alternative approach. This is 
significant if extra sensitivity is required which can be gained using electron capture 
detection instead of FID.
3.3 Method Comparison Between the Enzyme and Capillary GLC Assays for 
Ervthrocvte Sorbitol Determinations
Some samples were analysed by both the enzyme and capillary GLC methods and the 
results compared. Samples were collected from diabetic patients attending the 
out-patients clinic at St. Lukes Hospital, Guildford. The samples were stored on ice 
and treated immediately on arrival back at the laboratory. The red blood cells were 
washed and processed as described previously with the exception that 2.0 ml 
erythrocyte aliquots from each sample were added to 4.0 ml 6% ice cold PCA. Pooled 
normal non-diabetic blood was processed to obtain calibration standards using the 
same volumes of blood and PCA. The samples and standards were stored at -20°C 
until taken for analysis. For the enzyme analysis 1.8 ml aliquots of thawed sample were 
taken and analysed by the method already described for the enzyme validation study 
(see 3.1.1). The remainder of the sample was analysed by the capillary GLC method 
with drying by vortex evaporation as detailed above (see 3.2.2.1). The results are 
shown in table 14 and the correlation betwen them (r value) is not particularly high 
at 0.85. Furthermore, all the capillary results gave lower concentrations than the 
enzyme results. One explanation for this is that the enzyme result gives a falsely high 
value possibly because another component in the matrix also acts as a substrate for the 
enzyme.
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Table 14. Method Comparison Between the Enzyme and Capillaiy GLC Assay on the
Same Sample
ENZYME CAPILLARY
GLC
t  DIFFERENCE 
FROM MEAN 
Enzyme - cap il
9.4 8.3 6.2
14.6 14.4 0.7
14.6 10.3 17.3
10.1 10.0 0.5
14.9 11.3 13.7
19.2 12.9 19.6
12.0 10.7 5.7
9.3 7.5 10.7
13.7 11.7 7.9
10.4 8.1 12.4
19.6 14.4 2.3
R esults are nmol/ml ery th rocy te
% DIFFERENCE FROM MEAN ca lcu la ted  as
Enzyme re s u l t  - C ap illa ry  r e s u l t
--------------------------------------------------  X 100
Enzyme re s u l t  + C ap illary  r e s u l t
A  farther comparison was made on a random selection of diabetic samples left over 
from patients who had participated in an aldose reductase clinical trial. The original 
analysis, by capillary GLC, was performed near to the date of collection. The 
subsequent enzyme assay was performed on duplicate samples which had been stored 
at -20°C for several months. The results are shown in table 15.
The mean % difference from the mean for the method comparison on the same 
sample was + 8.8%, from the enzyme to capillary assay, with the enzyme giving 
consistantly higher results than the capillary assay (table 14). This result is not 
unexpected considering the non-specific nature of the SDH enzyme. The two methods 
are significantly different when tested using student t test, p < 0.07, and are presumed 
to reflect true systematic differences in the assays. The levels found were all between
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approximately 9 and 20 nmol/ml. Furthermore, from the validation studies the 
precision at these levels is better than 5% for both methods. These values are all 
above levels found in normal non-diabetic pooled erythrocytes and are in agreement 
with the diabetic range found by Malone et al., (1980) and Popp-Snidjers et al., (1983).
Table 15. Method Comparison on Duplicate Samples Originally Assayed by Capillary
GLC and Stored Before Enzyme Assay
1st ASSAY 2nd ASSAY % DIFFERENCE
CAPILLARY ENZYME FROM MEAN
GLC C ap illa ry  - Enzyme
12.1 10.6 6.6
15.6 12.8 9.9
5.0 5.1 - 1.0
8.5 9.4 - 5.0
2.7 2.4 5.9
6.0 7.3 - 9.8
6.8 7.2 - 2.9
10.7 9.9 3.9
6.7 6.8 - 0.7
8.3 7.1 7.8
13.8 15.2 - 4 .8
4.8 5.2 - 4.0
6.8 8.6 - 11.7
R esults are nmol/ml ery th rocy te
1st Assay by C ap illa ry  GLC
2nd Assay by Enzyme a f te r  storage a t -20°C
7° DIFFERENCE FROM MEAN ca lcu la ted  as
1st Assay - 2nd Assay
  x 100
1st Assay + 2nd Assay
Method comparison on duplicate clinical trial samples, where the enzyme assay was 
performed after several months sample storage, gave a mean % difference from the 
m ean of -0.5% from the capillary to enzyme assay (table 15). The results obtained by 
both methods were not statistically significant when subjected to student t test (p, > 
0.9) neither does there appear to be any particular bias towards one method.
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The method comparison studies showed that there is a small, systematic difference 
between the values obtained from the same sample by the capillary and enzyme assays. 
However, there appears to be no difference between the results obtained by both 
methods on replicate clinial trial samples. The enzyme analysis of the replicate samples 
was carried out after prolonged storage. In an earlier experiment using the enzyme 
assay the results for freshly generated blind spikes were greater when calculated using 
values obtained from standards stored for a month (see 3.2.1). One possible 
explanation for these results is that there is a component in the matrix which scores 
to about 10% on the enzyme assay. Therefore what is observed is the concentration 
of this component decreasing slighly upon storage. The exact nature of this component 
is unknown but could be a polyol other than sorbitol. A  storage trial, with analysis by 
the capillary method, may help to elucidate whether this phenomena is repeated and 
solely attributed to sorbitol.
To date this is the only method comparison to be carried out on sorbitol analysis and 
it may help to provide useful data, in the future, for determining the choice of assay 
to be adopted in particular studies. The only other literature data on polyol method 
comparisons is that of Soyama and Ono (1988) who investigated plasma D-arabinitol 
by an enzyme and a GLC method. Correlation between the two methods was good 
(0.99) but the enzyme method gave higher results due to mannitol acting as a 
substrate as well as arabinitol.
In summary, it is concluded that the enzyme and capillary GLC methods developed for 
the analysis of erythrocyte sorbitol are suitable to determine this component with a 
reasonable deg ree of accuracy. Both methods have been found to give consistant linear 
calibrations over the expected range of sorbitol concentrations in erythrocytes.
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However, there is a need to determine the reproducibility of the methods when using 
them for the analysis of authentic samples. This was done when both these methods 
were applied to the analysis of erythrocyte samples from diabetic patients taking part 
in clinical trials of the AR inhibitor Sorbinil. The results of these clinical trials and the 
performance of the assays for sorbitol determination are presented in the following 
section.
3.4 Clinical Trials
3.4.1 The Effect of Oral Sorbinil on Erythrocyte Sorbitol Levels in Diabetic Subjects: 
Trial N o.l. Sorbitol Determination by Enzyme Assay
3.4.1.1 Trial Design and Methods
The aim of the study was to determine the effect of oral Sorbinil, 250 mg daily, on 
erythrocyte sorbitol levels in diabetic subjects. The sorbitol levels were determined 
using the enzyme assay and an additional aim was to assess the precision of that 
method.
The trial was a double-blind placebo controlled study over 8 weeks with a two week 
run-in and two week run-out period when patients received placebo. Between these 
periods patients received either Sorbinil 250 mg daily or placebo daily for 4 weeks. 
Thus the study lasted 8 weeks in total. Diabetic patients were recruited from the 
out-patient clinic of St. Lukes Hospital, Guildford.
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Blood samples were taken at the end of each week by venepuncture and separated to 
obtain plasma and washed erythrocytes. Plasma was saved for Sorbinil analysis to 
confirm compliance with medication. Erythrocyte sorbitol concentrations are often 
reported in nm ol/g haemoglobin. Therefore packed cell haemoglobin determinations 
were performed on washed erythrocytes so that their sorbitol concentrations could be 
referenced to the packed cell haemoglobin content. Perchlorate precipitates of 
erythrocytes and plasma samples were stored at -20°C until taken for assay. At each 
time point enough blood was taken and processed so that at least two replicate 
erythrocyte sorbitol samples were generated. In addition, blood was taken each week 
for the determination of haematological and clinical chemistry parameters. The 
percentage of glycosylated haemoglobin (HbAlc) was also determined for each patient 
at each time point. The SDH enzyme assay, as described above (section 3.1.2) for the 
validation study, was used without modification to determine erythrocyte sorbitol 
concentrations. Blind spikes were assayed with every set of samples and standards to 
determine day to day precision.
3.4.1.2 Trial Results
A total of 19 patients were recruited for the trial of which 16 successfully completed 
the protocol and 3 were withdrawn. Of the withdrawn patients one sustained a broken 
leg, another had suspect liver function tests and the third developed signs of an adverse 
reaction to the drug. In all other patients the drug or placebo was well tolerated.
The trial results are shown in figure 12, and show a drop in erythrocyte sorbitol levels 
during weeks 3-6 for the Sorbinil treated group compared to the group recei/ing 
placebo. This drop is significant, p < 0.001, and even more so if two high results from
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a Sorbinil treated patient (No. 7, week 3 and 5) are omitted. However, reassay 
confirmed the two high values found in this individual so they remain included in 
calculations. Therefore, the overall fall in erythrocyte sorbitol, observed in the treated 
group during weeks 3-6, is of the order of 40% from the corresponding placebo level.
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Figure 12. Placebo and Sorbinil Treated Erythrocyte Sorbitol Levels - Clinical Trial 
No.l
Sorbinil was given orally at a daily dose of 250 mg.
*p, < 0.001 between Sorbinil and placebo groups for weeks 3-6 and week 7 
All results are expressed as nm ol/g Haemoglobin
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In all 10 patients recieved placebo and 9 Sorbinil. The three patients withdrawn from 
the study were found to belong to the Sorbinil treated group and none of their 
parameters are included in any calculations. There was no clinical evidence of changes 
in diabetic control during the course of the study. Glycosylated haemoglobin (H bA lc) 
levels were monitored weekly and did not change on Sorbinil treatment. The values 
for all patients (+_ SD) were respectively, 12.0% +. 4% and 11.9% +_ 3% at the start 
and end of the study. However, very poor diabetic control was observed in some 
patients as indicated by high blood glucose and H bA lc values. This was particularly 
evident in the individual with spuriously high sorbitol levels, refered to above, whose 
H bA lc over the 8 week period was 17.5% +. 1.5%.
Sorbitol assays were performed on 9 separate days and the erythrocyte standard curves 
monitored on each of those occasions. The correlation coefficients were all better than 
0.990, the mean slope was 11.6 with a C.V. of 15.8%, and the mean endogenous 
sorbitol level was found to be 6.3 nm ol/m l with a C.V. of 8.5%.
Blind spikes were generated to determine precision at 4 different levels equal to 3.7, 
5.0, 20.5 and 24.8 nmol added /m l erythrocyte and the total number of determinations 
made at each level were 4, 6, 4 and 6 respectively. The precision at these levels gave 
C.V.% values of 17.2, 9.0, 8.8 and 5.9 respectively, and corresponding mean recoveries 
of 118, 100, 107 and 103%. The blind spikes overall gave a m ean recovery of 107% 
with a C.V. of 10.2%. However, when daily differences in endogenous sorbitol levels 
are taken into account the overall blind spike recovery was 105% with a C.V. of 12.8%. 
The overall assay performance is in good agreement with the values obtained in the 
validation study.
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In addition, sorbitol determinations were carried out on two different days on 
approximately 14% of the samples. The overall % difference from the mean between 
the two assays was found to be 13%. This value includes one sample near to the limit 
of detection (values below the endogenous level) and one sample where the two 
determinations were above the upper range of the standard curve. If the duplicate 
results for these two samples are excluded then the overall % difference from the 
m ean was found to be 9.7%. However, these two results are not excluded from any 
calculations.
Compliance with medication was confirmed by analysis of the plasma samples from all 
Sorbinil treated patients. The average value for the treatm ent period was found to be
14.2 +. 0.8 Mg/ml (result +_ SEM). The Sorbinil levels in the treated group fell to a 
m ean value of 1.9 ±_ 0.6 /Jg/ml at week 7, when treatent had ceased, with trace levels 
detectable in some patients at the end of the study. The Sorbinil method gave good 
linear correlation coefficients for each day of analysis and the precision was found to 
be J i  9.4% by repeat sample analysis with a limit of detection of 0.2 jug/ml.
3.4.1.3 Discussion of Results
The compound Sorbinil, CP-45,634, has been found to be a potent inhibitor of aldose 
reductase in human placental tissue and various diabetic animal models (Peterson et 
al., 1979, Finegold et al., 1983, Gillon et al., 1983 and Yue et al., 1984). The 
pharmacokinetics of Sorbinil in non-diabetic humans was first investigated by Foulds 
et al., (1981) who found it to be rapidly absorbed, with peak serum levels strongly 
correlated with dose, and a long biphasic half life of elimination of 38-51 hours. After 
oral administration of 250 mg daily for 10 days to healthy subjects the mean peak
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serum concentration was found to plateau at 10.6 gg/ml. Similar results were found in 
the present study where the level of Sorbinil was found to average 12.6 /ig/ml after 7 
days oral administration to diabetics at the same dose level. In addition, detectable 
levels of Sorbinil were found in some diabetics, after the two week washout period, 
confirming a long half life for the drug. However, it still remains to be determined if 
there is any significant difference in Sorbinil pharmacokinetic profiles between normal 
non-diabetic and diabetic subjects.
Previous clinical trials of Sorbinil in diabetics has concentrated on its effect upon 
motor nerve conduction velocity. Sorbinil was found to improve motor nerve 
conduction velocity to a small extent in 39 stable diabetics where the beneficial effect 
was seen to be diminished upon cessation of treatm ent (Judzewitsch et al., 1983). This 
effect has been observed, at the same dose (250 mg daily), by Fagius et al., (1985) and 
Guy et al., (1988) who both conclude that the benefit of Sorbinil is less in diabetic 
patients with established neuropathy.
The effect of Sorbinil on human erythrocyte sorbitol levels in a clinical trial of 
diabetics was first reported by Malone et al., (1984) who used a modification of the 
enzyme assay of Clements et al., (1969) to monitor sorbitol levels. They demonstrated 
a suppression of erythrocyte sorbitol of approximately 50% from placebo levels on 
treatm ent with 250 mg oral Sorbinil daily. The results obtained by them are in very 
good agreement with our findings. However, in the current study, diabetics were 
recruited irrespective of their degree of glycaemic control; which in some cases was 
very poor. Whereas, in the Malone study all the diabetic volunteers were males with 
very good glycaemic control; with a mean H bA lc of 10%. Thus the 40% suppression 
of sorbitol levels, observed in our study, may be a reflection of an overall poorer level
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of glycaemic control which in turn increases the chances of excess glucose conversion 
to sorbitol.
One criticism of the Malone Study is the complete absence of any assay data for the 
erythrocyte sorbitol determinations. Assay performance is crucial to the interpretation 
of experimental results obtained from the analytical method used. The performance 
of the enzyme assay was examined in the current study to give an indication of its 
suitability to this type of clinical trial. In general the performance of the enzyme assay 
was found to be the same as obtained in the validation study (see section 3.1.2). The 
day to day precision of the endogenous level was found to be 8.5% which is acceptable 
for these low levels which tend towards the limit of quantitation. Accuracy standards, 
fortified by another operator (blind spikes), gave an overall accuracy to within 5% of 
the expected levels. The greatest imprecision of these standards was found at low 
concentrations close to the endogenous level. The mean lowest sorbitol levels in the 
Sorbinil treated group corresponded to about 7.4 nm ol/m l and the precision at this 
level was found to be 9%. The precision above this level was found to be the same or 
better. In addition, the day to day reproducibility was found to average 13%. 
Consequently, it is believed that the performance of the enzyme assay was reliable 
enough to indicate that the fall in erythrocyte sorbitol (observed in the Sorbinil treated 
group and not seen in placebos) was due to inhibition of the AR enzyme and not 
attributable solely to variations in the analytical method.
The fact that two independent laboratories obtained similar clinical trial results (our 
study and that of Malone et al.) could be interpreted as further evidence for the 
sorbitol hypothesis. However, whether the erythrocyte sorbitol model tritely reflects 
biochemical events in less accessible tissues remains unclear. To elucidate the
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erythrocyte model further requires the analysis of other intracellular components; in 
particular myo-inositol. This could be achieved by using capillary GLC which has the 
potential for measuring several components in the sample. This technique was used in 
a second clinical trial where diabetic patients were given a reduced daily dose of oral 
Sorbinil. The reason for using a lower Sorbinil dose was the finding, in some studies 
(for example Jaspan et al., 1985) including our own, of poor drug tolerance by 
approximately 11% of treated diabetic patients. Therefore the polyol hypothesis, and 
the erythrocyte sorbitol model in particular, could be further tested by both a lower 
dose of Sorbinil and by the use of an alternative analytical technique to measure the 
response of polyols to the decreased dosing regimen.
3.4.2 The Effect of Oral Sorbinil on Erythrocyte Sorbitol and Myo-inositol Levels in 
Diabetic Subjects: Trial No.2. Analysis by Capillary GLC
3.4.2.1 Trial Design and Methods
The aim of the study was to determine the effect of oral Sorbinil given at two doses 
on erythrocyte sorbitol and myo-inositol concentrations in diabetic subjects. The 
sorbitol and myo-inositol levels were determined by capillary gas-liquid chromatography 
and a further aim was to determine the accuracy and precision of that method. An 
additional aim was to establish a range for erythrocyte sorbitol and myo-inositol 
concentrations in healthy, normal non-diabetic subjects.
The trial design was a double blind placebo controlled study consisting of a one week 
run-in, followed by a two week treatment, and a final one week run-out period. During 
the treatm ent period patients received either, oral Sorbinil 125 mg daily for the first
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week stepped up to 250 mg daily for the second week, or placebo throughout. All 
patients received placebo during the run-in and run-out periods. The trial lasted 28 
days with a further sample taken on day 35 for the determination of residual drug 
levels. Diabetic patients were recruited from the out patient clinic at St. Lukes 
Hospital, Guildford.
Blood samples were taken at the begining of the study (day 0) and every week day 
during the treatm ent period (days 7-11, 14-18) and at the start (day 21) and end of the 
run-out period (day 28). At each time point enough blood was collected by 
venepuncture to generate duplicate samples for the capillary GLC assay. Additional 
blood was taken each week for the determination of haematological and clinical 
chemistry parameters. In addition, H bA lc was determined in each patient at the start 
and end of the study. On sample days patients attended the Robens Institute, 
University of Surrey, where the blood was collected and immediately processed to 
obtain plasma and erythrocyte perchlorate precipitates. Plasma samples were saved for 
Sorbinil determinations to confirm compliance with medication. In addition, blood 
samples were collected from healthy, normal, non-diabetic volunteers to establish a 
normal range for erythrocyte sorbitol and myo-inositol. These samples were processed 
in exactly the same way as for diabetic samples. All samples were stored at -20°C until 
taken for assay.
Sorbitol and myo-inositol acetate derivatives were analysed by the capillary GLC 
method following vortex evaporation to obtain dry samples. The method, as described 
for vortex drying in the validation study, was used without modification with the 
exception that myo-inositol was added to the sorbitol calibration standards in the 
following way. Accurate solutions of myo-inositol in water covering the concentrations
152
0-100 Mg/ml were prepared and 100 gl spikes of each concentration added to the 
erythrocyte sorbitol standards, in ascending order, to give 2-10 /xg/ml levels. In this way 
the highest sorbitol calibration standard was also the highest myo-inositol standard. 
Zero standards contained 1.0 ml erythrocytes and 2.0 ml 6% PCA only. Erythrocyte 
blind spikes were generated containing sorbitol and myo-inositol; the concentrations 
of which were unknown to the analyst. Erythrocyte standards and blind spikes were 
stored at -20°C until taken for analysis. Packed cell haemoglobin determinations were 
made on all washed erythrocyte samples. A  random selection of these samples were 
determined in duplicate and the overall within day precision found to be +. 2 %.
3.4.2.2 Trial Results
A  total of 13 patients were recruited to the trial and 11 completed the protocol 
successfully. Two patients were excluded from the trial because of significant deviations 
from the protocol. A  total of 8 patients received Sorbinil and 3 placebo. No evidence 
was found of any adverse reaction to Sorbinil and both drug and placebo were well 
tolerated. The results for erythrocyte sorbitol and myo-inositol levels in the treated 
group are shown in figures 13a and b and are given in detail in table 16.
The results show a drop in erythrocyte sorbitol levels, from 26.6 to 10.2 (nm ol/g Hb) 
between day 7 and 8, for patients who recieved a single 125mg oral dose of Sorbinil 
(table 16). This drop is highly significant, p < 0.0001, representing a fall of 
approximately 62% and has not been demonstrated in previous Sorbinil trials. There 
was a further fall in sorbitol levels to the lowest mean value of 5.7 found on day 17 
after three consecutive doses of 250 mg Sorbinil. There was no significant difference
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in the overall m ean sorbitol levels for the Sorbinil treated group between the first and 
second week of active therapy, p > 0.35.
30.
X 28. 
_JJO
+. 26- 
Z  24-<Z
^ 22.
-2 20. X
CD 18.
1  »■ e
_i 14- =i
5 12- 
M 10.DO
LJ I—
□CX 4 X I—>- 2
^ 0
/ / / / / / / / / / / / / /  w w w w w w w
Sorbinil I25ng dally Sorbinil 250ng dally
1 i I I I I I I I 1 i7 a 9 10 11 14 1516 17 18 21
DAY
Figure 13 a. Daily Eiythrocyte Sorbitol Levels in Sorbinil Treated Diabetics
DAY
Figure 13 b. Daily Erythrocyte Myo-inositol Levels in Sorbinil Treated Diabetics
154
Ta
bl
e 
16
. 
So
rb
in
il 
Tr
ia
l 
No
.2 
Er
yt
hr
oc
yt
e 
So
rb
ito
l 
an
d 
M
yo
-in
os
ito
l 
Le
ve
ls 
in 
So
rb
in
il 
Tr
ea
te
d 
D
ia
be
tic
s
LD OJ O  i—i LD i—i i—i ■—i
CO • • rH CO d" rft i—1CD CO i— i
OJ
CO CO CO 1—I 00 LD i—lOJ • * f—1 CVl i—i .—i
co r—1CVI
r—I •X CD CO to. 1—1 O  to COOJ • • OJ COto. I—t t—1
CO * id to. CO 00 LD i—t 00i—i « « r—ft CO i—1to. OJ i—itor--■ r—
CO
to. * to CD CO “O to. LD CO COi—i ♦ . i—l CVI
LO T—1 CD i—1
=
O
LO
ID * r—1 CO to. CV) LD CD CD toT~ft . . i—1 i—l
CO *—I i— 1 1■I—
S.■j—1
X)LO to cvi co — LD OJ OJ 00rH . . 0 I—1 CO r-lID r-l oo rH
to O  CD to O  i—i to.I—1 » « i—; CO •—1LD rH 1—1
I—1 to to- LO CO l—H LD CD 00i—1 • . i—1 OJ00 i—i to ■—lr—■r—
fd
*o>> >> o to O  r-H 00 o d-OOO1-- 1--' 1-I • * CD T—ft OJ r-H■1— -I— O  t—< rHre! co r—i
■O "O ID
OJCD CD-to i—ft
C E  E 3 CD to r-H O  00 CD CD to 00•r— O ♦ • ,— rH1 LO O  I O  r-H -,— t-Hc w in  c t-H z=5 1—1 CVJ =J •p-. i—i
S- S~ -Q DOf— 1— «— S OO *i— *i— O z: CO to CVI i—i 00 C5 _l 00 O  00 CO-Q C C -Cl i—i • • OO CD COCl) ’ I— ■[— QJ CQ O  r-H O i 40 -0 -0  0 O i—1 s:rd to to fO _1 LUi— O O i— CJ3Q- oo OO Q- O rns: to LD CO r—t to. O  CVI rft► ■ ► UJ • * r*l o d* '—1 rftlo m o if l «=c LO CO N i—11—1 CVJ CO z: OJ —I
OI I I I CT z
O  to. r—( —i o CO LO O c* O r-H CO Or-l OO o • • t—1 '—1 l—1
s: to OJ _J I—ft
>-> to, >> >•> c: OJ ocd co co as — h-Q  O  Q  Q ►—1_i ooo oI— Z li—i H—CQ
QC to- <c s:
ic >- Z<  zO < LU LU > <c LU LU00 Q Z  OO C s. Q Z  (/) c
155
Da
ys
 
0, 
7, 
28 
and
 
35 
in
cl
ud
e 
pl
ac
eb
o 
va
lu
es
 
and
 
are
 
co
m
pa
re
d 
to 
da
ys
 
8-
21
 
wh
ere
 
* 
p 
< 
0.
00
01
No significant drop in erythrocyte sorbitol levels was observed in any of the three 
patients receiving placebo. The lowest individual placebo level was 15 with an overall 
m ean value (+. SD) of 38.1 +_ 17.6 nm ol/g Hb. The two patients that were excluded 
from the trial, because of deviations from the protocol, were found to belong to the 
placebo group. Consequently, the actual number of placebo treated patients is small 
and it is unfortunate that not enough patients were recruited to the trial to protect 
against such exclusions occurring.
The erythrocyte myo-inositol concentrations were not altered by Sorbinil treatm ent at 
either dose and there was no significant difference between treated and placebo 
groups. However, a true comparison can only be made if there were more subjects 
belonging to the placebo group. Consequently only the average myo-inositol levels can 
be examined. The overall m ean myo-inositol level (+_ SEM), for all diabetics, was 
found to be 138 ± 3 .0  nm ol/g Hb. The % haemoglobin in the glycosylated form was 
found to be unchanged from the start to finish of the study. The values (+_ SEM) 
were 10.6% +.1.1%  and 10.0% +_ 0.7% and not significantly different p > 0.6.
In order to obtain an indication of the erythrocyte sorbitol and myo-inositol 
concentrations in healthy, non-diabetic subjects whole blood was collected by 
venepuncture from 11 volunteers. A  small portion of the blood was separated for 
glucose determinations and all the subjects were found to have normal glucose levels 
except for one individual who was found to have an abnormally low level of blood 
glucose. (Subsequent clinical investigation of this subject confirmed the low blood 
glucose level for which no cause has so far been found). The blood was treated to 
obtain the perchlorate precipitates as already described and analysed with trial 
samples. Results for the erythrocyte sorbitol and myo-inositol levels in normal, healthy
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non-diabetic volunteers is summarised in table 17. However, not enough samples were 
taken to establish a full normal range for non-diabetics and this was examined in more 
detail in a separate study (see section 3.4.3).
Table 17. Normal Range for Erythrocyte Sorbitol and Myo-inositol in Healthy 
Non-diabetic Subjects
SORBITOL MYO-INOSITOL 
nmol/g Hb
MEAN 20.0 114
SEM 1.4 5.2
n 11 11
Analysis of plasma for Sorbinil showed compliance in the treated group where levels 
were found to rise steadily from the onset of therapy. The mean Sorbinil levels are 
compared in figure 14, to the corresponding mean erythrocyte sorbitol level and there 
was a negative correlation of -0.86 between the two. No residual Sorbinil was detected 
in any sample at day 35. The capillary GLC assay was assessed by the daily 
performance of the standard curves, blind spikes and repeat analysis and these results 
are summarised in table 18. Example chromatograms from a Sorbinil treated diabetic 
subject are shown in figure 15 and compared to a chromatogram from a healthy, normal 
non-diabetic subject.
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Figure 14. Comparison of Mean Erythrocyte Sorbitol and Mean Plasma Sorbinil in 
Diabetic Subjects
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Table 18. Performance of Capillary GLC Assay for Erythrocyte Sorbitol and 
Myo-inositol Determination.
STANDARD CURVES SORBITOL MYO-INOSITOL
SLOPE r E SLOPE r E
MEAN 0.042 0.996 5.26 0.257 0.995 25.80
S.D. 0.003 0.002 0.71 0.020 0.002 4.45
C.V.%
n=ll
7.1 0.2 13.5 7.8 0.2 17.2
BLIND SPIKES
MEAN RECOVERY % 100.6 98.0
C.V. 
n=l 1
% 11.8 10.7
REPEAT ASSAY
OVERALL % DIFFERENCE 
FROM MEAN , n=9
10.9 9.0
r  = C orre la tion  c o e f f ic ie n t from le a s t  squares l in e a r  reg ression  
E = Endogenous level in nmol/ml e ry th rocy te
Key:
1 d( + )Glucose
2 Myo-inositol
3 d-Mannitol
4 Sorbitol
5 Galactitol 
(internal standard)
Conditions:
Column 25 m X 0.32 mm 
(ED) BP1,1 g (S.G.E. Ltd.) 
programmed from 110°C 
for 1 min at 39.9°C/min 
to 230°C hold for 11 min 
with helium as carrier gas 
at =4 ml/min. Injector 
(275°C) with the split vent 
opened 0.7 min after 
injection. FID detection 
(300°C) XI, X8 with data 
recording using a Spectra 
Physics SP4270 computing 
integrator at 5 mm/min. 
GC: Sigma 3B.
Figure 15. Example Chromatograms of Erythrocyte Polyols from a Diabetic Patient
Treated with Sorbinil and a Healthy, Normal Non-diabetic Subject
a) Normal non-diabetic subject. Notice th^ shape of the myo-inositol peak 
(peak number 2) in this normal blood compared to the diabetic 
Samples resuspended in 100 g\ NBA and 1 g\ injection volume
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Key:
Conditions:
As Figure 15 a).
As Figure 15 a).
Figure 15 b). Diabetic patient day 21 after the last day of Sorbinil treatment
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As Figure 15 a).
Conditions:
As Figure 15 a).
Key:
Inj 5 10
Time (min)
15
Figure 15 c). Same diabetic patient (as in b above) at day 35 two weeks after the end 
of Sorbinil treatment
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3.4.2.3 Discussion of Trial Results
Due to the adverse reactions to Sorbinil observed in about 10% of diabetic patients 
Martyn et al., (1987) investigated the extended use of 125 mg oral Sorbinil daily over 
a 6 month period. Their study was primarily designed to observe changes in peripheral 
nerve function but no improvement was seen during treatm ent with Sorbinil. 
Furthermore, measurement of erythrocyte sorbitol levels, after 3 and 6 months of 
Sorbinil therapy, had fallen to within and below the normal non-diabetic range; with 
average values of 3 nmol/ml. Erythrocyte sorbitol was only determined at these two 
time points and no information was available on the speed of erythrocyte sorbitol 
response or its daily variation with respect to either Sorbinil or placebo therapy.
The second Sorbinil trial conducted at the Robens Institute was designed to address 
the latter questions of the initial and subsequent daily response of erythrocyte sorbitol 
and myo-inositol to Sorbinil therapy at lower doses. Myo-inositol was specifically 
included to see whether its response changed upon therapy in any way which might 
reflect the pattern of events in less accessible tissues.
The results of this second trial showed that erythrocyte sorbitol levels in Sorbinil 
treated diabetics fell after the first day of drug administration (table 16). Exactly how 
quickly within the first 24 hours this occurs has not yet been established. Myo-inositol, 
however, was unchanged upon Sorbinil treatment but significantly different to the 
levels observed in normal non-diabetic subjects. The difference was significant, p< 
0.001, and approximately 20% greater for diabetics (mean 138 nmol/gHb) than normal 
non-diabetics (mean 114 nmol/gHb, table 17). The myo-inositol levels in diabetic
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erythrocytes might reasonably have been expected to be lower before the onset of 
Sorbinil therapy (first week run-in period with placebo treatm ent) and rising to a 
higher level during Sorbinil therapy. If this had occurred then the erythrocyte polyol 
changes would model the polyol changes observed in animal models, particulary the 
streptozotocin induced diabetic rat. However, the evidence from this trial does not 
appear to support that hypothesis. A  similar conclusion was reached by Popp-Snijders 
et al., (1984) who measured the erythrocyte sorbitol and myo-inositol changes in 
diabetics receiving 200 mg oral Sorbinil daily.
The capillary GLC analysis was carried out on 11 different days and found to perform 
very well. Standard curves for calibration standards for sorbitol and myo-inositol gave 
excellent linearity with r values for both polyols greater than 0.993. The precision of 
the endogenous level was found to have a C.V. of 7 and 17% for sorbitol and 
myo-inositol respectively. The endogenous levels of myo-inositol are quite high 
approximately five times the endogenous sorbitol level. Detection at the high 
endogenous myo-inositol levels is not a problem and does not account for the 
imprecision seen. The accuracy was assessed by blind spikes generated at several 
concentrations and the recoveries for sorbitol and myo-inositol were found to be 100 
and 102% respectively. Reproducibility was found to give mean % differences from the 
mean of 11 and 9% for sorbitol and myo-inositol respectively. All the repeat diabetic 
samples were found to have values for sorbitol and myo-inositol close to the respective 
endogenous levels found in healthy, non-diabetic erythrocytes.
For sorbitol the accuracy is slightly better than the SDH enzyme assay with comparable 
linearity, precision and reproducibility. For myo-inositol the capillary GLC assay is 
accurate and reproducible but imprecise at the endogenous level. Further validation
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of the myo-inositol assay is required particularly to determine factors that may affect 
precision.
During this trial attempts were made to establish a normal range for erythrocyte 
sorbitol and myo-inositol. However, the number of determinations made on normal 
blood was small. Furthermore, only single samples were taken; so that no information 
could be gained on the daily variation of these levels in normal non-diabetic subjects. 
In order to be more specific about the daily variation of erythrocyte sorbitol and 
myo-inositol in normal non-diabetic subjects a trial was carried out on blood taken 
from healthy volunteers.
3.4.3 The Daily Variation of Erythrocyte Sorbitol and Myo-inositol in Healthy. Normal 
Non-diabetic Subjects
3.4.3.1 Trial Design and Methods
The trial was designed to collect approximately six samples each, on different days 
spread over two weeks, from healthy, normal non-diabetic volunteers. Participants in 
the trial were instructed to continue with their normal daily activities. These activities 
were recorded by completing a proforma on each day that a sample was taken 
indicating, diet (including alcohol consumption), exercise and feelings of well being. 
On each day that samples were taken volunteers attended the Robens Institute in the 
morning and whole blood was drawn by venepuncture. Samples for erythrocyte polyol 
determination were maintained on ice and prepared in duplicate as already described. 
The plasma glucose level was determined for each volunteer on the first day and in
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all cases the values were found to be normal. Therefore, no individual was excluded 
because of a possible tendancy towards hyperglycaemia.
Erythrocyte sorbitol and myo-inositol were measured using capillary GLC, after freeze 
drying and acetate derivatisation, as described above in section 3.2.2.2. Myo-inositol 
concentrations were determined by response factors for a 10 /ig/ml myo-inositol 
standard (with galactitol as internal standard) taken through the whole procedure. 
Derivatised samples were injected onto the capillary column using a PTV injector. The 
PTV was programmed at an initial temperature of 100°C with the split vent opened 
for 30 seconds. The split vent was then closed and the injector temperature increased 
to and held at 300°C. The split vent was then re-opened at 1.5 minutes after injection 
to clear any residual solvent from the injector lining. The aim with this particular PTV 
injector programme was to dump the solvent, through the split valve, immediately when 
the sample was injected. The method performance was assessed by blind spikes and 
repeat analysis of approximately 30% of the samples.
3.4.3.2 Results
A total of 8 volunteers, 3 males and 5 females with an average age of 31 years, 
completed the trial successfully and one volunteer withdrew because of influenza. The 
results are shown in table 19, and the overall mean erythrocyte sorbitol was found to 
be 1.03 with a standard deviation of +_ 0.3 gg/ml The overall mean erythrocyte 
myo-inositol was found to be 9.3 with a standard deviation of +_ 1.7 Mg/ml. These mean 
values are equivalent to 5.7 and 51 nmol/ml for sorbitol and myo-inositol respectively. 
The normal packed cell haemoglobin concentration is approximately 0.3 g/ml so that 
the mean sorbitol and myo-inositol concentrations referenced to their haemoglobin
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content are 19 and 170 nmol/gHb respectively. An example separation, obtained by 
the capillary GLC using the PTV injector programmed to dump solvent, is shown in 
figure 16 and it is noticable that there is considerable loss of the earlier eluting 
components (sample discrimination).
Table 19. Daily Variation in Normal Non-diabetic Eiythrocyte Sorbitol and 
Myo-inositol
VOLUNTEER A B C D F G H J
male/female m f m m f f f f
SORBITOL
DAY 1 0.8 1.1 1.0 1.0 0.8 1.1 1.0 1.9
2 0.9 0.8 1.0 1.0 1.0 1.0 1.0 2.0
3 1.1 1.1 1.0 1.3 0.6 1.0 0.7 1.7
4 0.8 0.8 1.0 1.1 0.9 0.8 1.0 1.5
5 1.0 1.0 0.9 1.0 1.0 0.8 1.2 1.5
6 0.8 0.9 1.0 0.4 0.9 1.1 --
MEAN 0.92 0.93 0.97 1.07 0.78 0.93 1.00 1.72
SD 0.13 0.15 0.05 0.12 0.24 0.12 0.17 0.23
C.V.% 14 16 5 11 30 13 17 13
MYO-INOSITOL
1 11.5 7.8 12.0 9.9 7.5 10.3 8.0 9.7
2 10.8 7.9 9.1 8.1 7.9 10.5 8.0 11.0
3 12.4 8.6 8.3 11.2 8.3 12.6 5.5 12.0
4 9.4 7.5 10.6 9.9 8.7 9.7 9.4 12.6
5 10.0 8.3 6.0 7.1 8.6 9.6 9.2 10.2
6 -- 7.8 7.5 7.7 9.3 10.7 9.8
MEAN 10.8 8.0 8.9 9.0 8.4 10.6 8.3 11.1
SD 1.2 0.4 2.2 1.6 0.6 1.1 1.6 1.2
C.V.% 11 5 24 17 8 10 19 11
All resu lts  are /zg/ml red blood ce lls
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1 d( + )Glucose
2 Unknown
3 Myo-inositol
4 d-Mannitol
5 Sorbitol
6 Galactitol 
(internal
standard)
Conditions:
Column, 25 m X 
0.32 mm (ID) 
immobilised OV1, 
1 g phase (S.A.C. 
Ltd.) programmed 
from 110°C for 1.5 
min at 30°C/min 
to 220°C then at 
1.5°C/min to 225°C 
hold for 10 min 
with helium carrier 
gas at 0.7 ml/min. 
In jec to r PTV 
programmed from 
100°C for 0.5 min 
then split closed 
and temperature 
to 300°C with split 
vent opened 15 min 
after injection. GC: 
Perkin Elmer 8320 
with FID detection 
(300°Q and GP2000 
printer plotter at 10 
mm/min.
Figure 16. Capillary GLC Separation of Polyols from the Blood of a Normal
Non-diabetic Subject, Volunteer D Day 6.
Sorbitol equivalent to 1.0 Mg/ml erythrocyte.
[Note: Chromatogram reduced by x 0.75]
168
The samples were analysed over 5 separate days and the standard curves, obtained 
from the sorbitol calibration standards on each of these occassions, gave correlation 
coefficients > 0.99 with the C.V. of the slopes equal to 5.6%. The erythrocyte sorbitol 
blind spikes, generated by another operator, consisted of samples prepared at levels 
corresponding to endogenous, middle and high calibration points. The precision of the 
blind spikes at these levels were found to be 11, 9 and 9% respectively. This precision 
is slighly poorer compared to an average 6% precision obtained at similar levels during 
the validation of this method. However, the validation study was performed using 
splitless with solvent effect injection without programmable temperature vaporisation.
Replicate analysis was carried out on a different day for approximately 30% of the 
samples and the mean % difference from the mean was found to be 10% for sorbitol. 
Out of the 14 samples that were repeated at random 4 of them had values greater than 
10%. However, the actual concentrations determined in all cases (average 1.0 /xg/ml) 
are low approaching the limit of quantitation, at or near the endogenous level, where 
the precision was found to be 1 1 %.
By comparison, an overall % difference from the mean of 36% was found for 
myo-inositol concentrations in the replicate samples. The actual levels determined are 
high (average 9 /xg/ml), where detection is not a problem, so that the lack of 
reproducibility may be attributed to daily variations in the response factor standards 
and storage effects. Analysis of the response factor standards show that they vary from 
day to day by 18% and by 15% within day so that this variation accounts for 
approximately half of the imprecision. Storage effects for erythrocyte myo-inositol have 
not been studied and contributions of this effect on imprecision, if any, are not known.
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The reproducibility of myo-inositol determinations was previously found to be 18% (for 
the % difference from the mean, second Sorbinil trial) where calibration was obtained 
by myo-inositol standards spiked into the matrix; which in addition, gave very good 
recovery and precision for blind spikes. The generation of many supposedly identical 
replicate response standards, although possibly easier, has little advantage over 
creating calibration standards in the matrix. However, the advantage of using response 
standards is that several components can be quantified by this method. Therefore, if 
response standards are to be used for quantitation several must be generated and their 
variation determined for each analysis with every batch of samples.
3.4.3.3 Discussion
The daily variation of erythrocyte sorbitol and myo-inositol concentrations in normal 
non-diabetic subjects has not been previously investigated. This study was primarily 
designed to determine the daily variation both in individuals and in the group as a 
whole. In individuals there is little variation in the daily sorbitol levels with the 
average daily variation being 15% from the mean or 1 +_ 0.15 jug/ml. The individual 
variation for myo-inositol levels averaged 13%; equivalent to 9 ±  1.2 gg/ml The 
overall group range (mean J l  SEM) for sorbitol and myo-inositol levels were found 
to be 1.03 J l 0.04 and 9.3 J l 0.3 Mg/ml respectively.
There was no pattern between the sorbitol and myo-inositol levels and any of the 
subjective observations made by the volunteers. The subjective observations of diet, 
exercise and well being showed that out of the 8 subjects, 3 females had a vegetarian 
diet. The rest had a mixed diet with one female taking multivitamin tablets. Five out
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of 8 subjects led sedentary lives with little or no exercise and 3 subjects reported 
feeling unwell with cold symptoms at some time during the two week period. The most 
eratic day to day sorbitol levels was found in the one individual who smoked (volunteer 
F, C.V. 30.7%). However, from this study no conclusions can be made concerning the 
daily variation in individual polyol levels or the factors affecting them. A systematic 
study would have to be designed to investigate factors such as smoking, diet or stress.
Considering the relatively narrow daily sorbitol range found in these normal subjects 
it can be reasonably expected that for diabetics to behave in a similar way the levels 
would be comparable. This is clearly not the case when just the placebo values for all 
diabetics (days 0, 7, 28 and 35 obtained from the second Sorbinil trial, table 16) are 
compared with the erythrocyte sorbitol levels found in normal non-diabetic subjects. 
These levels were found to average 26.7 and 5.5 nmol/ml in diabetics and normals 
respectively. By comparison the average placebo erythrocyte sorbitol values in 
diabetics, when analysed by the enzyme method (in the first Sorbinil trial) were found 
to be even higher at 43 nmol/ml. Consequently, the erythrocyte sorbitol levels in 
diabetic subjects compared to healthy non-diabetic subjects are raised by a factor of 
approximately five.
To be able to state that Sorbinil treatment lowered erythrocyte sorbitol in diabetics to 
within the normal range requires knowing that range and its daily variation and this 
has now been established. The second Sorbinil trial sorbitol levels, especially during 
the second week of therapy (days 11-18) are within, and very similar in variation to, 
the normal non-diabetic range found in this study. This result is very encouraging 
showing that Sorbinil therapy can normalise high sorbitol concentrations in diabetics 
to the levels encountered in normal subjects. Moreover, this reversal to normal is
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consistent during the therapy period but upon cessation of treatment diabetic sorbitol 
levels are seen to revert to increased concentrations.
The situation with myo-inositol has been found to be different. The erythrocyte 
myo-inositol in normal subjects was found to be greater in normal than diabetic 
subjects (average 170nmol/g haemoglobin with a daily variation of +_ 5 and in 
diabetics 138 +_ 3nmol/gHb). Therefore, the erythrocyte polyol pattern would appear 
to be raised sorbitol and lower myo-inositol in diabetics (before Sorbinil treatment) 
compared to the reverse in normal subjects. This pattern is consistant with the 
hypothesis that the erythrocyte models the polyol levels in non accessible tissues. 
However, the exception is that myo-inositol levels in diabetics when treated with 
Sorbinil were not increased towards normal.
One way that may prove useful for examining erythrocyte polyol changes, and the 
factors affecting them, is by incubating red blood cells with glucose. The aim of such 
an experiment would be to try to mimic hyperglycaemic conditions encountered in 
diabetes. Sorbitol, polyols, and other sugars, could then be determined by the enzyme 
and capillary GLC assays in an attempt to determine these changes. In addition, such 
studies may help to elucidate the role of AR in the fate of glucose through the polyol 
pathway.
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3.5 In-Vitro Aldose Reductase Assay
The Sorbinil clinical trials showed that a drop in erythrocyte sorbitol concentrations 
was observed in all diabetics treated with this inhibitor. This effect is believed to be 
due to inhibition of the erythrocyte AR enzyme by the drug. An in-vitro live cell assay 
for erythrocyte AR may be a suitable system to investigate the role of this enzyme in 
the intracellular accumulation of sorbitol. Moreover, the intracellular sorbitol 
accumulation in some diabetics compared to normals could be due to an increased 
AR activity. Therefore, the aim is to develop such an assay and determine if there is 
any difference in AR activity between healthy, normal non-diabetic and diabetic 
subjects. Furthermore, it would be especially useful to determine whether there is a 
correlation between increased AR activity and subjects diagnosed as suffering from an 
increased degree of diabetic complication. If such a correlation does exist then there 
is the possibility of using an assay for AR activity as a diagnostic tool. The eventual 
aim would be to produce a diagnostic assay in kit form which would be readily 
available for use in routine hospital laboratories. This is especially needed because no 
such diagnostic kit is currently available.
One possible approach to assay AR activity is by incubating erythrocytes in a suitable 
medium, substituted with or without glucose, and follow the production of sorbitol with 
time. In the first instance, for pilot studies, it is more feasible to determine the 
erythrocyte sorbitol levels using the enzyme assay; which is a cheaper and more rapid 
method. However, should the in-vitro incubation system be shown to work, further 
confirmatory studies could be conducted using the more specific capillary GLC assay.
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3.5.1 Sample collection
Blood samples (10 ml) were taken from diabetic patients, chosen at random, attending 
the out patients clinic at St. Luke’s Hospital, Guildford. In addition, samples of whole 
blood were taken by venepuncure from five healthy, normal non-diabetic volunteers 
and the erythrocytes washed and pooled as already described. The blood was 
immediately prepared for incubation studies as described in the methods (chapter 2). 
A group of diabetic subjects with various degrees of neuropathy was selected from 
those attending the out patients clinic of Dr. P. Wise at the Charing Cross Hospital 
Medical School, London. Blood was taken from these patients, stored on ice and 
immediately transported back to the Robens Institute, where the erythrocytes were 
prepared for incubation studies. The assessment of neuropathy in these patients was 
performed at Charing Cross Hospital and the degree of severity of diabetic 
complication, or any other clinical information, was not made available to the analyst 
until after the analysis stage of the study was completed.
3.5.2 Results
Figure 17 shows the results of an incubation with 50 mM glucose of pooled normal 
erythrocytes, with sampling points at 0, 0.5, 1 , 2 and 3 hr. Sorbitol concentration in the 
incubated erythrocytes can be seen to rise with time. The increase in sorbitol after two 
hours is inhibited by 70% (in the same pooled erythrocytes) when incubated in the 
presence of 10 /xg/ml Sorbinil. There is no assay interference between Sorbinil and 
the SDH enzyme method. Therefore, the in-vitro lowering of erythrocyte sorbitol levels 
is due to inhibition of AR by Sorbinil, This can be compared to the result of the
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second clinical trial where an average 5 Mg/ml plateau Sorbinil plasma concentration 
reduced the sorbitol concentration by 60% (figure 14).
Figure 17. Erythrocyte Sorbitol Levels in Response to In-vitro Incubation with 50 mM 
Glucose
Each resuh is the mean of two separate determinations and the % difference 
for each sample was 5% or less. The incubation was carried out in washed, 
pooled erythrocytes collected from 5 non-diabetic volunteers
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A comparison was carried out using pooled erythrocytes from both a group of diabetics 
and normals. These results are shown in table 20. Pooled erythrocytes from diabetics 
averaged a 33% greater accumulation of sorbitol than normal, non-diabetic pooled red 
blood cells.
Table 20. In-vitro Incubation of Erythrocytes with 50 mM Glucose
TIME NORMAL CONTROL DIABETIC CONTROL
(Hr.) * #
0 11.0 7.8 15.8 10.8
.5 25.6 8.4
1 40.2 7.4 49.9 10.7
2 59.2 5.4 87.2 15.7
3 71.5 3.9 93.5 4.7
0 3.2 5.0
.5 17.2
1 32.8 39.2
2 53.8 71.5
3 67.6 88.8
"esults are nMol/ml Diff = incubated - control
* Slope for incubated normal = 20
# Slope for incubated diabetic = 27
Erythrocytes were washed and pooled from 5 non-diabetic and 10 
diabetic subjects
The in-vitro incubation system was used to determine the increase in sorbitol in blood 
samples from individual diabetics. The results are shown in table 21 and at least two 
subjects appeared to accumulate sorbitol to a considerably greater extent than the rest 
(shown by *).
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Table 21. Etythrocytes from Individual Diabetics Incubated with 50 mM Glucose for
2 hours
TREATMENT BASAL + 50 mM 
GLUCOSE
%
INCREASE
Insulin 15.6 73.7 372
Insulin 8.2 60.7 640
Insulin 36.3 123.5 240
Insulin 8.2 66.0 *705
Oral 18.1 81.2 349
Oral 10.4 73.3 605
Oral 11.1 65.2 487
Oral 10.2 79.4 678
Oral 15.4 77.1 400
Insulin 16.1 134.2 *734
Basal and incubated values are nMol/ml. * ? High
% Increase = Incubated - Basal x 100
Basal
In collaboration with Dr. P. Wise and his colleagues at Charing Cross Hospital Medical 
School, London, blood samples were taken from two groups of age matched diabetics. 
One group with diabetic complications, assessed by degree of retinopathy, and the 
other group without any obvious sign of diabetic complications. The glucose 
concentration chosen for this experiment was 25 mM rather than 50 mM because it 
was thought to be a concentration that would not disprut the viability of the red blood 
cells during incubation. In addition, 25 mM glucose was thought to be a concentration 
that may be more usually encoutered in diabetics. The results are shown in table 22 
and there appears to be no correlation between the degree of severity of diabetic 
complication and erythrocyte aldose reductase activity.
177
Table 22. Incubation of Erythrocytes from Diabetics with Varying Degrees of 
Neuropathy Incubation with 25 mM Glucose for 2 hours
BASAL + 25 mM % DEGREE OF
GLUCOSE INCREASE C0MPLICAT
10.5 11.2 7 NONE
12.2 22.6 85 NONE
18.7 38.3 105 MAJOR
14.1 29.5 109 NONE
15.3 36.9 141 MINOR
8.8 22.6 157 MINOR
7.3 19.9 173 MAJOR
9.1 25.6 181 MINOR
5.0 14.3 186 MINOR
12.7 39.1 208 NONE
8.4 28.3 237 MINOR
12.8 43.5 240 MINOR
11.4 39.1 243 MAJOR
6.4 23.3 264 NONE
5.2 21.8 319 MINOR
10.5 45.7 335 MINOR
5.5 32.1 484 MAJOR
All resu lts  are nmol/ml.
The % increase in normal pooled non diabetic erythrocytes at 
25 mM glucose for 2 hours is approx 250%
The capillary GLC method for polyol analysis was used to analyse normal erythrocyte 
samples incubated for 2 hours with 25 mM glucose. The purpose was to confirm the 
sorbitol increase found using the enzyme method and to assess any other qualitative 
changes that may be observed from the chromatogram. An example of the capillary 
chromatogram obtained is shown in figure 18. Two peaks which elute after the galactitol 
are quantitatively doubled (using galactitol as internal standard), from their basal 
level, after 2 hours incubation with glucose. One of the peaks (number 7 in figure 18) 
has been initially assigned as glucosamine by its retention. However, mass-spectrometry 
is needed to confirm the true identities of these peaks.
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1 Unidentified
2 Unidentified
3 Glucose
4 Unidentified
5 Unidentified
6 Unidentified
7 Myo-inositol
8 Mannitol
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10 Galactitol
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Figure 17. Capillary GLC Separation of Normal Erythrocytes Incubated with 25 mM 
Glucose for 2 Hours
The erythrocyte sorbitol concentration corresponds to 4 /xg/ml equivalent to 
21.8  nmol/ml.
Conditions: Column 50 m x 0.32 mm (ID) BP1, 2 g (S.G.E. Ltd.) programmed from 
120 C for 1 min at 30 C/min to 230°C hold for 35 min with helium carrier gas at =1 5 
ml/min. Injector 275°C, FID detection (300°C) xl, xl6 with JJ Lloyd chart recorder at 
5 mm/min. GC: Sigma 3B. [Note: Chromatogram reduced x 0.75]
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3.5.3 Discussion
In-vitro incubation of erythrocytes was first reported by Travis et al., (1971) who 
demonstrated increased sorbitol accumulation in blood obtained from healthy males 
incubated with 50 mM glucose. Sorbitol was found to accumulate to a concentration 
of 90 nmol/ml after 2 hours incubation. Sorbitol accumulation in erythrocytes from 
diabetics was not investigated by them. By comparison the present study found sorbitol 
to accumulate to approximately 54 nmol/ml in pooled erythrocytes from healthy 
volunteers and by 33% more, to 72 nmol/ml, in blood from diabetics (table 20).
Sorbinil at a 10 /xg/ml concentration was seen to inhibit the in-vitro sorbitol 
accumulation by 70% in pooled erythrocytes obtained from 5 healthy subjects (figure 
16). This is a similar inhibition to that seen in the second Sorbinil clinical trial. The 
in-vitro Sorbinil inhibition, however, does not lower the sorbitol level completely to 
pre-incubation basal levels although it would appear to do so in the clinical trial (table 
16). This is probably because of the falsely high glucose concentration used for the 
in-vitro incubation. This is not seen in the Sorbinil clinical trials because the diabetic 
subjects still received their normal therapy to control the blood glucose level. This has 
to be the case because if hyperglycaemia were allowed to occur in diabetics they 
would risk severe acute ketoacidosis, shock and coma. Consequently, the only ethical 
way of investigating hyperglycaemia in diabetics is by in-vitro techniques. This was the 
reason for studying pooled and individual erythrocytes from diabetic subjects.
The erythrocytes from both normal and diabetic subjects when incubated with various 
glucose concentrations appear to remain viable. There was no evidence of haemolysis 
at up to 50 rnM glucose concentrations for 3 hours. Bareford et al., (1986) have
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confirmed this by showing no appreciable change in erythrocyte mean cell volume, 
haemoglobin concentration or morphology when incubated with 50 mM glucose. In 
addition, Travis et al., have demonstrated that the glucose utilisation by erythrocytes 
is unchanged from normal glucose levels (5 mM) when incubated in hyperglycaemic 
conditions up to 50 mM. However, as a precaution, for the assessment of AR activity 
in erythrocytes from diabetics 25 mM glucose concentrations were used in later studies.
Initially, in-vitro assessment of AR activity was carried out on a few individul samples 
from diabetics to determine the feasibility of the technique and any individual 
variations in them (table 21). Approximately half of the diabetics accumulated sorbitol 
with a percentage change from basal of 600% or more. The percentage change from 
basal in normals was found to be approximately 440% (table 20) and the remaining 
diabetics were within this range. As some of the diabetics appeared to accumulate 
sorbitol to a greater extent than others the question was whether this was correlated 
with clinical evidence for increased symptoms of neuropathy. This was investigated in 
a blind trial using diabetic patients drawn from the very extensive case histories kept 
at the outpatients clinic at Charing Cross Hospital Medical School, London. A total 
of 17 diabetic subjects, with long term complications varying from none to minor to 
severe, were assessed for their AR activity. There was no evidence of any correlation 
between the degree of severity of complication and AR activity (table 22).
This is .the first time that attempts have been made to correlate the degree of severity 
of neuropathy with a biochemical marker. The failure to show any such correlation, 
although disappointing, can be partially explained. Firstly, the assay as such was 
subjected to considerable logistic difficulties (not least the delay in transporting the 
samples back to the laboratory). The assay requires extensive washing of the
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erythrocytes both before and after incubation. There is at least two hours incubation 
with glucose followed by the time required for the sorbitol assay by the enzyme 
method. This would total probably 5 to 6 hours. If the capillary GLC with freeze drying 
method was used, instead of the more rapid enzymatic assay, then the whole procedure 
would take two days to complete. As a consequence the AR assay, whichever method 
is used to determine sorbitol, is long and tedious and certainly not a rapid method 
readily applicable for use in a routine hospital laboratory. A possible alternative would 
be to assess erythrocyte AR activity in haemolysed erythrocyte samples which could 
result in a more rapid and simple assay. Such methods already exist for the 
determination of other enzymes in haemolysate for screening purposes, for example, 
the determination of erythrocyte glucose-6-phosphate dehydrogenase deficiency, as 
described by Beutler (1983). It is recommended that such an approach is investigated 
because there is a real need for some sort of test which may be of diagnostic value.
Secondly, the accumulation of sorbitol must be a reflection of both the in-vivo AR 
activity and the metabolism of sorbitol by the enzyme sorbitol dehydrogenase (SDH). 
The existence of AR has been reported to be increased (as the activated form of the 
enzyme) when partially purified from the clear lens of human diabetics compared to 
non-diabetic, Das and Srivastava (1985a). It is not known whether this is the case with 
erythrocyte AR. Therefore, it would be worth attempting to examine the activity of 
purified erythrocyte AR using their methods. Furthermore, as attempted in this study, 
correlations would have to be performed between activity and degree of severity of 
diabetic complication. However, considerable expertise is required in enzyme 
purification and the resulting method would be expensive and not suitable for routine 
clinical diagnostic use.
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Thirdly, the sorbitol flux through the polyol pathway depends upon the activity of SDH. 
This activity is almost completely unknown and has not been investigated in relation 
to diabetes and the associated long term complications. It is possible that the 
accumulation of sorbitol is controlled by the next step in the polyol pathway; 
metabolism by the enzyme SDH. One possibility, therefore, is to determine the activity 
of SDH in normal and diabetic subjects in a manner analogous to that attempted 
herein for aldose reductase. There is the possibility that the activity of SDH is lowered 
in diabetics compared to normals thus favouring accumulation of sorbitol. Furthermore, 
that the SDH activity is lowered more so in diabetics and correlated with neuropathic 
symptoms. If this is not the case then no such correlation will exist as already found 
for AR. This question is fundamental to the understanding of the polyol pathway in 
relation to the long term complications of diabetes and thus far has been completely 
overlooked. Thus, if neither enzyme is implicated then some alternative biochemical 
mechanism for the aetiology of neuropathy (possibly still involving sorbitol) may exist.
The problem of predicting which diabetics are most prone to the long term 
complications has been found clinically to be virtually insoluble. The results obtained 
in this study typify the problem. For example, some diabetics have no evidence of 
diabetic complication but appear to accumulate sorbitol to a great extent. Similarity 
very poorly controlled diabetics that may be expected to develop complications 
clinically never do so. The reverse is also seen both in the clinic and in our assessment 
of AR activity; with high levels of sorbitol accumulation in some individuals who do 
not show signs of developing the complications. The results of the work of this thesis 
and the methods developed to study the role of polyols in the management of diabetes 
are further discussed in chapter 4.
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CHAPTER 4
GENERAL DISCUSSION AND CONCLUSIONS
Diabetes is classified into two broad categories according to treatment. These 
categories are type I, insulin dependent diabetes mellitus, (IDDM) and type II, 
non-insulin dependent diabetes mellitus (NIDDM). Type I diabetes requires daily 
injections of insulin to help control the blood glucose level. Therapy is usually self 
administered before meals. Type II diabetes does not require insulin but may be 
treated by oral antihyperglycaemic agents, diet control, and sometimes insulin, self 
administered and controlled by the patient. In both cases the co-operation of the 
patient, in coming to terms with, and continuing to regulate their daily activities and 
diet, is fundamental to the medical management of their condition. Needless to say 
such imposed self therapy is widely differing in success. The factors affecting this 
success are very diverse and include; duration of diabetes before and after clinical 
diagnosis, insulin and drug intolerance, psychological and socio-econonmic 
considerations, and the appearance of complications. The latter factor, long term 
complications, are a very painfull and debilitating series of conditions, manifested in 
a variety of ways, all of which require extensive clinical management.
The long term complications of diabetes appear with equal frequency in both diabetic 
types. There is little evidence of any genetic predisposition to the long term 
complications developing in certain types of diabetic (Leslie et al., 1989 and Taylor
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1989). However, studies in twins and long term familial retrospective surveys may help 
to clarify any genetic markers and or, tendancies towards the development of 
complications.
The elevated glycosylated haemoglobin and blood glucose levels have been found to 
be strongly associated with diabetic neuropathy (Boulton et al., 1984). Furthermore, 
the duration of diabetes is considered to be a major risk factor in the development of 
the long term complications. Consequently hyperglycaemia and glycosylation, a direct 
effect of the duration of diabetes, predominate even in the presence of daily 
temporary measures to control them. It is this predominance along with the increased 
activity of the polyol pathway that points to the aetiology of diabetic complications 
being metabolic in origin. The early detection of the onset of these complications gives 
the physician the best chance of managing the condition in an effort to prolong the life 
of the patient. This work has attempted to establish analytical methods that may be of 
use in investigating some of these metabolic interactions with an ultimate aim of 
obtaining a simplified assay that could be of diagnostic value.
In the first instance for any pathological change to be attributed to a causative agent 
requires the latters’ reliable quantitation in the affected tissue. In the case of diabetic 
complications sorbitol is believed to be a major factor in the pathogenesis of 
neuropahy. The increases in sorbitol that occur in the less accessible tissues affected 
by neuropathy are directly correlated with similar changes in the red blood cell. 
Consequently much of the analytical methodology of this work has centered on the 
analysis of sorbitol in erythrocytes.
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Ideally, a reliable method should produce accurate determinations which are 
reproducible, within day and from day to day, with good linearity and the required 
detector sensitivity. Furthermore, the method should be robust, easily used by other 
operators, and capable of some degree of automation to enhance its cost effective use. 
In addition, a method should be capable of a certain degree of selectivity so that 
potentially interfering components are avoided; by either sample preparation 
procedures or the use of selective detectors. Of special relevance to the routine 
hospital laboratory a method, as far as can be ascertained, should be free from any 
drug test interaction. Rarely do all these factors combine together in any one method.
This work has shown that the sorbitol enzyme assay meets most of the above criteria. 
The assay was accurate to within +_ 5% for blind spikes compared to calibration 
standards. Reproducibility, by repeat sample analysis on a different day, was found to 
give a result generally within 10% of the previous determination. The assay was found 
to be consistently linear over the calibration range with linear regression correlation 
coefficients greater than 0.993. The limit of quantitation was found to be approximately 
0.5 Mg/ml, detection below this level is restricted because of high fluorescence values 
for sample blanks. The method is robust in the sense that it was unaffected by different 
batches of enzyme preparation. Therefore, the assay should yield similar results in 
different laboratories if the same commercial preparation of the SDH enzyme and 
analytical conditions are employed.
With appropriate autosamplers or slight modifications to the procedure the method 
could become semi-automated. No interference was observed for the method when 
Sorbinil was present in the assay mix. Other drug test interactions were not tested for 
and cannot be ruled out. However, no sample interference was observed in any of the
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Sorbinil trial diabetic patients receiving oral antihyperglycaemic agents such as 
Tolbutamide.
There are reservations regarding the specificity of the method and sample storage. 
Xylitol acts as a substrate for this particular preparation of SDH. Xylitol is metabolised 
in the erythrocyte to a small extent (Travis et al., 1971) and it is possible that this 
accounts for the small change in sorbitol levels observed upon prolonged storage of 
erythrocyte samples. The more specific capillary GLC assay would be very useful to 
measure erythrocyte xylitol levels and any storage effects. In addition, the apparent lack 
of specificity may be overcome by the use of a new purified SDH preparation, free of 
polyol dehydrogenase, which has just become commercially available. This assumes 
that the new SDH preparation is highly specific for sorbitol and that other polyols and 
sugars do not interfere or act as substrates. It is recommended that this new enzyme 
preparation should be substituted in the assay and compared with the results already 
obtained in this study.
In contrast to the enzyme assay the capillary GLC method also meets many of the 
analytical requirements mentioned above. The capillary method has the added 
advantage that other polyols and sugars can be determined. The method has been 
continually modified as the factors affecting its performance have been investigated. 
These factors include the nature of the stationary phase, injection technique, sample 
preparation and derivatisation conditions, and methods of calibration.
The best capillary method for sorbitol obtained in our laboratory thus far appears to 
be freeze drying of the sample containing galactitol as internal standard, followed by 
acetate derivatisation, extraction into chloroform with sample concentration and
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injection using splitless with solvent effect onto a capillary column with an immobilised 
non-polar phase with flame ionisation detection. Moreover, neutralisation of the 
perchlorate extract is critical, prior to the recovery of polyols as their acetate 
derivatives, which was found to be maximal at a pH of 9 to 9.5. Additionally, the 
method of generating calibration standards and blind spikes in bulk, in conjuction with 
the above conditions, has produced consistent linear calibrations and excellent 
performance data. Using this method the accuracy for sorbitol determination was +_ 
2.0% with a between day precision for replicate determinations of +_ 10%.
The determination of myo-inositol was found to be less reliable, particularly in diabetic 
samples, where shoulders were seen on either side of the myo-inositol peak (figure 15). 
This effect was less obvious in chromatograms from normal non-diabetic subjects and 
could indicate qualitative differences in the polyol profile between the two groups; 
assuming the interference is due to similar chemical species. However, the capillary 
method developed in this study was able to estimate erythrocyte myo-inositol 
concentrations and in so doing blind spikes were found to be accurate to within _+ 2 %. 
Reproducibility, determined as repeat samples assayed on different days, gave results 
generally within +_ 10% of each other (for diabetic samples from the second Sorbinil 
trial). In contrast poor reproducibility for myo-inositol was found when the samples 
were injected using the PTV injector and this technique is not recommended for such 
determinations.
It is possible that the interference around the myo-inositol retention could be due to 
very closely related inositol isomers. Therefore, for myo-inositol to be accurately 
determined it is recommended that methods capable of separating the closely related 
inositol isomers are investigated. For example; the method of Leavitt and Sherman
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(1982) may be very useful because these authors have successfully resolved D- and L- 
chiro-inositol on a chiral capillary column. If a method such as theirs is used it remains 
to be determined whether differences in inositol isomer composition occur between 
diabetics and normals. Furthermore, if such differences do occur their relationship to 
diabetes will open the possibility for yet further alternative metabolic pathways which 
have not yet been fully appreciated. Evidence that this may be the case is seen in the 
results of capillary GLC analysis of erythrocytes incubated with glucose discussed in 
more detail below.
The capillary GLC method was found to be robust in the sense that the same 
separation could be obtained using equivalent columns (length, diameter and phase 
thickness) supplied from different manufacturers. Additionally, the resuspended hexitol 
acetates are stable for up to three months which facilitates their re-injection if any part 
of the GLC system fails. In practice the only routine maintenance that was regularly 
required was daily changing of the injector septum.
Consistent FID responses to both extracted polyol and unextracted SHA standards was 
also a feature of this method and either calibrants could be used to test the GLC 
analytical conditions or to investigate problems with different stages of the assay 
procedure. Considering the consistent separations and detector response the method 
may be transferable from one laboratory to another. However, the relative cost of the 
equipment and time required for the assay does not make it readily available; 
especially to routine hospital laboratories.
One time saving feature is the use of an automated injector; which allows large 
numbers of samples to be run unattended. Such a system is currently undergoing
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assessment in our laboratory using splitless with solvent effect injection. The C.V. of 
the peak height of the internal standard (galactitol) for a run of 40 samples has been 
found to be 10% which indicates a very consistent recovery reflected throughout all 
stages of the assay. A further time saving feature is the possible use of 
4-dimethylaminopyridine (DMAP) as the catalyst for the acetylation procedue. Initial 
investigations with this catalyst in place of pyridine were found to be promising with 
linear calibrations obtained for standards spiked into both erythrocytes and plasma. It 
is recommended that a full method validation is performed to establish the suitability 
of DMAP in the capillary assay.
The enzymatic and capillary methods were compared by assaying a series of blood 
samples from diabetics using the two techniques. Taking the results overall for assay 
on both the same and different aliquots gave a correlation coefficient of 0.87 when 
subjected to linear regression analysis. The slope of the line was 1.17 (with enzyme as 
y and capillary as x) indicating that the enzyme generally gave a 17% higher value than 
the capillary. Part of this difference may be accounted for by the presence of xylitol 
in the sample which acts as a substrate for the SDH enzyme. Further stability studies 
using a validated method specific for xylitol may help to clarify the contribution this 
polyol makes to the enzyme result. A method comparison between the capillary and 
the newly available purer SDH would also be useful in elucidating the latters 
suitability of the latter for routine use in the sorbitol enzymatic assay.
Apart from the enzyme method for sorbitol analysis the question remains as to what 
improvements can be made to the GLC assay and what alternative methods are 
available? Most analytical procedures can be roughly divided into three or more stages 
which consist of sample collection, sample preparation and the final analytical
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detection often proceeded by a chromatographic separation step. Techniques which 
combine several if not all of these stages together in one step would be the method 
of choice.
In the ideal world there would be available a single specific detector for every single 
component known to exist. Thus, a liquid mixture, such as plasma, whole blood or 
urine, could be collected and a probe, for example ultraspecific for sorbitol, inserted 
and a suitable readout obtained. Another probe specific for myo-inositol can be used 
and so on.
There are probes in existence for the determination of ions in solution such as the 
ion selective electrodes used for serum electrolyte determinations in clinical chemistry 
(Blijenberg et al., 1989). The advantages of this sort of approach are that several 
probes can be inserted in turn into relatively small sample volumes in a very rapid 
automated fashion. However, as yet such systems are not available for the enormous 
variety of compounds encountered in biological matrices but there is much current 
interest in the development of biosensors for their use in analysis. One example is the 
pilot studies of Takei et al., (1985) using a membrane bound alcohol dehydrogenase 
enzyme to measure serum ethanol. The final visualisation is obtained by 
spectrophotometric determination of a coloured dye which presumably eventually will 
be calibrated to obtain readouts on a hand held chart. By analogy there may in the 
future be the possibility of achieving blood sorbitol determinations using immobilised 
SDH but whether this will be specific and sensitive enough remains to be determined.
With highly specific biosensors the need for extensive sample preparation or separation 
steps would be negated although there is still the requirement to maintain the integrity
of the sample upon collection. This latter point is one that can often be overlooked 
when, for example, whole blood is improperly drawn by venepuncture and on arrival 
back in the laboratory is found to be haemolysed and unsuitable for assay. Therefore, 
to a certain extent the analysis begins at the stage of sample collection. Furthermore, 
blood samples generally still require some preparation such as centrifugation to obtain 
the required fraction. And where erythrocytes are concerned their washing in saline 
is obligatory to remove white blood cells and the lipids associated with them all of 
which can be potential sources of interference.
The following comments concerning alternative sample workup procedures are 
primarily directed at chromatographic assays. However, they could equally apply to any 
analytical system (including the sorbitol enzyme assay) used to determine water soluble 
components in biological matrices; such as amino acids, carbohydrates, polar drugs and 
their metabolites, and polyols.
Polyols are highly water soluble, neutral compounds which are ionised at a pH of about 
13 or above. The problem is to isolate them from an aqueous environment for which 
they have complete affinity while leaving behind proteins, lipophilic compounds and 
a multitude of other components. Protein precipitation of biological matrices is the 
most commonly employed method to denature proteinaceous material in the sample. 
A very simple method would be to precipitate the proteins in strong alkali and inject 
the sample directly onto an ion exchange HPLC with amperometric detection such as 
used by Ohsawa et al., (1986) for the determination of xylitol in plasma and saliva. 
However, this method requires filtering before injection, has not yet been attempted 
on red blood cells, and is costly not making it a readily available technique. We have 
discussed with Dionex (the manufacturers of the above ion exchange columns and
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HPLC equipment) the possibility of comparing the capillary GLC analysis for 
erythrocyte polyols with their alternative method but as yet nothing has been 
forthcoming.
An alternative sample preparation procedure is to precipitate the proteins with 
alcohol, methanol or ethanol being a common choice. However, it has to be borne in 
mind that some polyols are only slightly soluble in alcohol for example, erythritol and 
ribitol. Sorbitol while soluble in methanol is sparingly soluble in cold ethanol. 
Precipitation with methanol opens up the possibility of using solid phase sample 
preparation as the next clean up step in the procedure. This has been attempted by 
Valdez and Reier (1987) who used C18 solid phase cartridges to obtain glycols, polyols 
and hydroxyamines in a non-aqueous environment suitable for derivatisation. The C18 
phase was found to be inappropriate for erythritol with recoveries of only 50% which 
is because polyols are not well retained on hydrophobic phases. However, hydrophobic 
phases such as C18 could be used in the reverse situation. This is where the 
aqueous/alcoholic extract is passed through the conditioned column which would retain 
lipophilic components while the polyols would be eluted in the original aqueous 
volume thus providing a simple sample cleanup step. This was attempted in a pilot 
study in our laboratory and the recoveries of an aqueous mix of glucose and polyols 
was found to be 100% there being no retention for them on a C18 cartridge.
It is often stated that if the HPLC conditions are known for a given compound then 
to a certain extent the conditions for solid phase sample preparation are already at 
hand. By analogy the above example of ion exchange HPLC of polyols gives a clue to 
the possible conditions for their solid phase sample preparation. As the polyols are 
ionised at high pH, by for example 0.15 M sodium hydroxide, this solution could be
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used to precipitate proteins and then passed through a solid phase cartridge containing 
a strong anion exchange porous resin. The polyols would be retained, while other 
material was not, and could then be eluted by using a buffer, neutral pH solvent such 
as water or possibly methanol. The usefulness of this sample preparation step should 
be examined for both the GLC and enzymatic assays. Applied to the enzyme assay this 
sample preparation step would avoid the necessity to neutralise the perchloric acid. 
Furthermore, the polyols could be eluted from the ion exchange column with the buffer 
(pH 9) used in the enzyme assay the only problem being strict control of the elution 
volume.
Polyols are insoluble in ether and non-polar solvents so that if solid phase sample 
preparation is not available then straight forward non-polar extraction can be used to 
remove lipophilic substances from the sample. Some workers use combinations of 
immiscible polar and non-polar solvents (such as methanol precipitation followed by 
hexane extraction) to obtain a cleaner sample with the polyols remaining in methanol 
which is then taken to dryness under OFN (Roboz et al., 1984, Jansen et al., 1986 and 
Johnson and Mayersohn, 1984).
The next major problem is to obtain very dry polyol extracts if they are to be 
derivatised which is necessary for GLC and a usual requirement for HPLC detection. 
Drying down under OFN has already been mentioned and two alternatives were tried 
in the current study. The first of these involving vortex evaporation at 70°C under 
vacuum is rapid but Willars et al., (1987) have reported variable loss of myo-inositol 
upon oven drying which could be a problem with vortex evaporation using elevated 
temperatures.
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Freeze drying provides maximum sample integrity (Leenheer 1984) and although very 
time consuming may have to be the compromise between a more rapid but less reliable 
alternative. It is at this stage that the analyst has to make a critical decision as to 
either drying down for derivatisation or turning to an alternative HPLC technique that 
does not require a derivatisation step for detection.
There are alternative HPLC analysis for sugars and polyols such as capillary HPLC 
with laser refractive index (RI) detection (Bornhop et al., 1987) or affinity HPLC 
(Honda et al., 1987). In the former, Bornhop et al., have demonstrated that increased 
sensitivity for sugars can be achieved down to 100 ng amounts for glucose. The column 
consisted of a capillary tube about 0.6 metres long by 0.4 mm internal diameter packed 
with 5 gm diameter C18 spheres. The RI detector in this example is specially designed 
to have an extremely low volume which is achieved by its optical path passing through 
the bottom of the capillary column where the outer polyimide coating is removed. This 
technique while not commercially available at present has enormous possibilities for 
many types of analysis. Not least is the universal nature of the RI detector which to 
date has been limited by its insensitivity. And in addition, the wide selectivity of phases 
and eluent modifications used in HPLC are readily applicable to such a system. As yet 
the system has not been applied to complex biological mixtures or polyols derived from 
biological matrices but there may be combinations of capillary columns alone or 
packed that could achieve the desired separations with the required sensitivity. The 
future for this technique is very promising.
Affinity chromatography had not been applied to the analysis of carbohydrates of small 
molecular weight until Honda et al., demonstrated such separations using affinity 
phases consisting of carbohydrates immobilised on ion exchange resins. The particular
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immobilised carbohydrates employed were glycamines; such as glucamine (1 -amino- 
deoxy-D-sorbitol) and lactamine (4-O-B-D-galactopyranosyl-l-amino-l- 
deoxy-D-sorbitol). The method used post column derivatisation to visualise the 
carbohydrates but the glucamine phase was only able to separate classes of 
carbohydrates such as pentoses from hexoses. However, the versatility of this form of 
separation is in the choice of affinity phase and there are a multitude of different 
carbohydrates or lectins to be investigated as possible alternative phases.
The most useful application of the affinity chromatographic approach is probably as 
a sample separation step for classes of compounds. Although not applied to polyols as 
yet it may prove a useful and rapid sample cleanup procedure especially if the polyols 
can be separated from reducing sugars. This would be particularly useful because there 
is the requirement, especially with in-vitro incubation studies, of characterising just 
the polyol changes. Thus, reducing sugars could be removed and analysed separately 
to the polyols. Indeed using the capillary GLC separation it has become evident that 
there are many components in the sample which still require identification and the 
chances of achieving this are increased if interfering sugars are removed.
Alternatively, the use of an immobilised enzyme such as sorbitol dehydrogenase 
specific for sorbitol as a chromatographic cleanup procedure is possible. Although this 
would be of no benefit if the aim was to measure as many polyols as possible in the 
sample. In addition, there is still the problem of detection with either this or any of the 
above HPLC methods if the compounds do not possess a chromophore in the molecule. 
This is the case with polyols which require derivatisation when a sensitive RI detector 
is not available. Polyols do respond at low wavelength UV but our initial investigations 
with pure dilute aqueous solutions suggested that, for example, at 195 nm there would
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be insufficient detector sensitivity above the background noise. Furthermore, many 
compounds absorb at low wavelength UV and unless they are completely removed 
from the sample interference is a likely possibility.
Polyols require derivatisation to make them volatile for GLC and any of the above 
sample preparation procedures could be applied for sample cleanup at various stages 
of the assay. As already discussed there are numerous possibilities for sample cleanup 
prior to derivatisation. Sample cleanup after derivatisation is a further possibility where 
the derivatives could be passed through, for example, a non-polar solid phase cartridge 
such as C8 or C18. The particular sample cleanup will depend upon the nature of the 
derivative and with polyol acetates the use of a semi-polar solid phase, may be 
possible. This is because acetate derivatives are slightly more polar than the TMS 
variety and may be better retained on mid-polar phases although as yet there is no 
evidence to support this.
The advantage of using solid phase sample preparation, or solvent extraction, after 
derivatisation for the GLC assay is the removal of non-volatile underivatised 
components or unwanted derivatisation by-products. These components if injected onto 
a column, or the injector liners used in capillary GLC, can have non specific adsorption 
effects which can cause components to elute poorly with considerably tailing peaks. 
Consequently the cleaner the final sample the better for GLC analysis.
There are improvements that could be made to the capillary GLC operating conditions 
which may, in conjunction with various solid phase sample preparation procedures, 
confer an added degree of selectivity to the analysis. For example, there is the 
possibility of using thermal desorption as a sample injection technique. This injection
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technique is most commonly used for the analysis of organic volatiles in air which are 
adsorbed on packings contained in stainless steel tubes. With the right choice of 
packing material large solvent volumes, i.e. 100 g\ or possibly more, containing the 
derivatised polyol acetates could be spiked into the tubes and placed on the thermal 
desorption apparatus.
The reasoning behind this approach is the possibility of eradicating the carrier solvent 
through the desorption process while leaving the solutes to be sent to the analytical 
column. If the system were to work then it would also allow the quantitation of low 
molecular weight polyol derivatives such as glyceroltriacetate. In addition, the solutes 
arriving at the analytical column would be free to elute without hindrance from solvent 
flooding effects. It would be very interesting to conduct a small pilot study to 
determine the feasibility of this approach although ultimately thermal desorption is not 
a readily available technique.
As already indicated there are at least 30 unidentified peaks that elute from the 
capillary GLC column most of them before glucose. The possibility of their separation 
from each other may be increased with thermal desorption and slow temperature 
programming. However, some of these components are present in low concentrations 
and not easily detected by the FID. To overcome this detection problem an alternative 
is the possible use of column switching in conjunction with dual detection systems or 
the use of alternative detector orientated derivatisations.
The GLC detectors most commonly used in trace organic analysis are the 
mass-spectrometer, electron capture and FID. The practical range of these detectors 
vary from about 500 pg/ml to 10 jttg/ml for MS, from 500 pg/ml to 100 ng/ml for ECD
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and 0.1 tig/ml to 10 jtxg/ml for FID (de Silva 1978). When GC-MS is not available 
there is the potential of coupling in series ECD followed by FID. This is probably not 
the approach for the polyol analysis because large glucose peaks would swamp the 
ECD and certainly be in concentrations above the linear working range of the 
detector.
If column switching is available then the flow can be directed for earlier parts of the 
chromatogram to the ECD and diverted for the later eluting and more concentrated 
solutes to the FID. However, this requires considerable time and expertise to obtain 
the optimised conditions and ultimately may not be fully justified if alternatives are 
quicker and more reliable. Therefore, the analyst may turn to derivatisation with 
electron capturing reagents such as the halogenated alkyl anhydrides.
The trifluoroacetate derivatives of polyols are more volatile than the acetates and elute 
more quickly on non-polar GLC columns thus speeding up the analysis. They can be 
detected with FID and this alternative should be investigated because it is possible that 
enough sensitivity is achieved without having to resort to ECD. This approach has not 
yet been applied to the analysis of erythrocyte polyols but in doing so it would provide 
a very useful comparison with the existing methods.
There is then a considerable number of approaches that the analyst can adopt to 
improve an assay. Among those mentioned here probably the most useful for polyol 
analysis is at least an ion exchange sample cleanup prior to any further analytical 
procedure. When using the capillary GLC assay freeze drying of the biological extracts, 
prior to derivatisation, although time consuming is the method of choice. Derivatisation 
looks likely to be a requirement for some time to come until alternatives, such as the
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capillary HPLC with laser RI detection, are fully developed and shown to be 
applicable.
The favoured derivatisation is the use of the DMAP catalyst not least because it gives 
rapid acetylations and the feasibility has been established with a biological matrix. 
Capillary GLC as opposed to packed column GLC gives the best polyol separations 
currently available with the required sensitivity for hexitols when using FID. However, 
further work is required to identify the earlier eluting components extracted from 
erythrocytes and because of their low concentration alternative derivatives to the 
acetates will have to be investigated. Ideally the use of mass spectrometry would be the 
detector of choice because it is both sensitive enough and highly specific. The 
considerable price of these detectors and the specialist expertise required to operate 
them do not make them readily available in many laboratories. However, the new 
5890-11 benchtop GC-MS (made by Hewlett-Packard) is priced at a level which is now 
just beginning to be affordable.
Furthermore, the bonded non-polar capillary columns used in these studies did not 
resolve components which were shoulders on the myo-inositol peak. Consequently this 
problem will have to be overcome by the use of alternative phases as discussed above. 
We tried using a Chirasil-Val capillary GLC column to investigate the separations of 
polyol acetates but this was without success. A possible explanation is that the hexitol 
acetates which were the components studied do not elute on non-polar columns below 
about 220°C and the maximum operating temperature of Chirasil-Val is about 200°C. 
The use of Chirasil-Val, or other capillary enantioselective phases, with more volatile 
polyol derivatives, such as the trifluoroacetates, should be in investigated for their 
ability to resolve the inositol isomers.
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Thus, the enormous range of sample preparation procedures in conjunction with 
various separation techniques and available detectors can result in different 
combinations to suit the particular analytical requirements. In terms of other 
applications of these techniques to the analysis of polyols there are many. These 
include the identification of polyols in food, either as their purity as food additives 
(Samarco 1977), or when food is adulterated by their addition to make unsuitable 
products taste better. For example, the clandestine adulteration of immature wines by 
the addition of excessive amounts of xylitol or sorbitol (Estrella et al., 1986). Also the 
identification of polyols originating from Rust fungus has enabled the quality of wheat 
crops to be monitored to guard against this commonly occurring infection (Maclean 
and Scott 1976).
In biochemical applications, for example, Kontrohr and Kocsis (1984) have used 
capillary GLC to identify rare aminohexoses originating from bacterial cell walls as 
their reduced aminoalditol acetate derivatives. This has allowed the rapid identification 
and classification of various pathogenic bacteria. Therefore, methods of polyol analysis 
have been used to investigate a wide range of problems and the particular applications 
that these methods are applied to will only be limited by the amount of available 
funding. The results obtained from the current study in relation to the particular 
problem of diabetes are now discussed.
The enzyme and capillary assays were used to determine erythrocyte sorbitol levels in 
diabetics in two separate clinical trials of Sorbinil. It was found that in both trials the 
levels of sorbitol were reduced upon Sorbinil treatment. This trend was reversed at the 
end of the Sorbinil treatment period, during the wash out phase, with erythrocyte 
sorbitol reverting to high levels.
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The usefulness of a lower dose of Sorbinil (125mg daily compared to 250mg daily) was 
demonstrated for the first time in the second clinical trial where erythrocyte sorbitol 
levels were found to be greatly reduced by 60% within 24 hours after the first daily 
dose. This has important implications considering the known dose related Sorbinil 
intolerance in about 10% of subjects receiving this compound. This result indicates that 
there is the potential to administer a lower Sorbinil dose, which may help to minimise 
any side effects, while still achieving the desired therapeutic aim. This is especially 
required when the possibility is considered of using AR inhibitors for long term 
prophylatic use. Martyn et al., (1987) have since confirmed our erythrocyte sorbitol 
findings in a trial of diabetics receiving a low oral dose of Sorbinil (125mg daily) for 6 
months. However, only a single sorbitol determination was made by them for each 
patient at the 3 month time point. Their results indicate that Sorbinil was well 
tolerated over an extended period of time and that long term therapy with this 
compound may be possible. Thus Sorbinil therapy may be particularly beneficial in 
patients who, when screened, do not shown signs of hypersensitivity to this drug.
In the second clinical trial (using the capillary GLC assay) erythrocyte myo-inositol 
levels in diabetics were found to be unchanged during either Sorbinil or placebo 
therapy but higher than the mean level found in non-diabetics. This finding does not 
fit with the view that in diabetic tissues, particularly animal models, sorbitol is raised 
while myo-inositol is concomitantly lowered. Therefore, it could be concluded that the 
results do not support the widely believed model that changes occurring in less 
accessible tissues are reflected by similar changes in the erythrocyte; where the levels 
of myo-inositol would be expected to be similarity reduced. And, moreover, that 
sorbitol in some way affects myo-inositol metabolism in nerve cells.
202
This view may have to be modified in the light of recent observations by Dyck et al., 
(1988) who used capillary GLC of polyol TMS derivatives derived from biopsy of 
human sural nerve. They found no evidence of deficiency in nerve (biopsy) myo-inositol 
levels or its relationship to the pathogenesis of neuropathy. Raised nerve sorbitol levels 
were, however, strongly associated with the severity of neuropathy. Unfortunately their 
study did not correlate the nerve sorbitol and myo-inositol levels with those of the 
erythrocyte which given the design of the study would have been extremely interesting. 
Furthermore, Sima et al., (1988), using a fluorescence enzymatic sorbitol assay, have 
independently corroborated that human sural nerve sorbitol content is raised in 
diabetics with neuropathy. In addition, both of the above studies showed beneficial 
effects of oral Sorbinil treatment for one year; with reduction in nerve sorbitol content 
and improvement of nerve morphology and physiological function.
Considering the above evidence and the trial results from the current work it is 
possible that the erythrocyte actually models the biochemical events that contribute to 
neuropathy. And that sorbitol alone, rather than in conjunction with myo-inositol, could 
be the primary causative agent. It is recommended that before the role of myo-inositol 
is dismissed completely alternative separations, such as that already mentioned for 
inositol isomer determination, are investigated for their potential application to both 
the erythrocyte model and other tissues affected by diabetes.
In normal non-diabetic subjects the erythrocyte myo-inositol concentrations were found 
to be fairly consistent averaging 9 Mg/ml; equivalent to 50 nmol/ml erythrocyte, and 
is similar to the levels found in diabetics in the second Sorbinil trial. However, the 
interference observed for myo-inositc i retentions in the diabetics may cause the levels
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in this group to be overestimated. Thus, there may be a true difference in myo-inositol 
concentrations between the two groups. It would appear that the analytical conditions 
described herein results in estimates for myo-inositol determinations and underscores 
the need for a more specific assay for inositol isomers.
It was found that the sorbitol concentrations in healthy, non-diabetic volunteers were 
remarkably consistent averaging approximately 1.0 Mg/ml (5.5 nmol/ml) with a 
variation of about _±_ 10%. Moreover, the sorbitol levels were consistent for any one 
individual from day to day over a two week period. This is a new finding and important 
in relation to the levels found in diabetics. The reason for this is that the consistent 
sorbitol levels in healthy, non-diabetic subjects could serve as a target to be achieved 
by diabetics. Ways of achieving this may be by very good glycaemic control or 
alternatively by therapy such as Sorbinil.
In diabetic subjects treated with Sorbinil the erythrocyte sorbitol levels fall and stay 
within this newly defined normal range. This suggests that Sorbinil helps diabetics in 
achieving consistent sorbitol levels similar to that observed in healthy, non-diabetic 
subjects. However, on one occasion the erythrocyte sorbitol level was seen to be 
spuriously high (for one patient in the first trial). This high level has already been 
explained on the basis of very poor glycaemic control but in addition there is the 
possibility that a preceding days dose of Sorbinil was not taken by that particular 
patient. Consequently AR inhibition may be very sensistive to small changes in the 
circulating plasma Sorbinil concentrations which is quickly reflected by the sorbitol 
levels. The speed with which the erythrocyte sorbitol reverts to former levels at the end 
of Sorbinil treatment in diabetics has not been established. It is unfortunate that in the 
second Sorbinil trial, where there was the opportunity to do so, this speed of reversion
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was not investigated. As a consequence it is recommended that in future studies of 
AR inhibition the reversion of sorbitol levels should be closely examined. It is 
important that this be done because there is the possibility that certain therapies may 
suppress the sorbitol levels for prolonged periods of time. If this were the case there 
may be the facility for introducing dosing regimens, for example, on a once a week 
basis.
It is of interest that the concentration of Sorbinil required to inhibit the in-vitro 
accumulation of erythrocyte sorbitol was found to be similar to the plasma Sorbinil 
concentrations found in the clinical trials. It would have been useful to perform an 
in-vitro Sorbinil titration down to the lowest concentration which still gave maximal 
inhibition. This could have provided a simple model for indicating the lowest 
efficacious dose of Sorbinil for in-vivo use. Somewhat surprisingly the erythrocyte model 
for this application has not been investigated by others. It is recommended therefore 
that the in-vitro erythrocyte incubation system developed in this work could serve as 
the initial model for comparing the efficacy of aldose reductase inhibition by different 
compounds. One compound of particular current interest is ascorbic acid (vitamin C) 
which in man, who cannot synthesise it, is required as an essential vitamin.
A recent report by Vinson et al., (1989) has shown that vitamin C given as a dietry 
supplement to diabetics, 2 g/day for 3 weeks, lowered erythrocyte sorbitol levels by 
45%. This finding opens up the possibility of an alternative therapy for treating 
neuropathy which bypasses problems of drug tolerance. However, the analytical 
methodology used by these workers, which was a micro scale enzymatic assay for 
erythrocyte sorbitol, is open to question because no validation data was reported by 
them. The effect needs confirmation by a second analytical technique such as the
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capillary GLC assay. Furthermore, evidence of improvement in nerve morphology and 
physiological fuction need to be obtained. Additionally, the exact relationship between 
ascorbic acid and its modifying effect on sorbitol or the polyl pathway is not known. 
No doubt these questions are currently under investigation.
It was found that erythrocytes from diabetics accumulated sorbitol to a greater extent 
than erythrocytes from healthy non-diabetics when incubated in the presence of 
glucose. The increase was approximately 30% and could be explained by an increased 
aldose reductase activity in the diabetics compared to normals. Using the capillary 
GLC assay it was found that normal erythrocytes from non-diabetics when incubated 
with glucose appear to contain component peaks around the myo-inositol retention 
which are not normally present. The identity of these components has yet to be 
established. It would be very interesting to determine whether the components around 
the myo-inositol retention in normals are the same as already observed in this work 
for diabetics. If they are then there is the suggestion that yet a further metabolic 
pathway for glucose is active in diabetics but not in normals. In this respect 
myo-inositol has been demonstrated to be synthesised from glucose (Niwa et al., 1983). 
Therefore, what is possibly being observed is this conversion in the erythrocyte when 
subjected to enforced hyperglycaemia and that this conversion is occurring in diabetics 
and not in normals. It is recommended that any link between this phenomema and 
neuropathy is further investigated.
Attempts were made to correlate erythrocyte AR activity, by assessing the 
accumulation of sorbitol when incubated with glucose, with the degree of severity of 
neuropathy. The aim was to achieve a simple diagnostic test which would indicate 
which subjects had increased AR activity and therefore the possibility of increased
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susceptibility to neuropathy. No such correlation was found and it could be concluded 
that the erythrocyte model is not a valid reflection of AR activity.
However, this particular investigation was subjected to both logistical difficulties and 
more importantly to probable errors in the experimental incubation conditions 
employed which did not allow for the full expression of AR activity. According to Das 
and Srivastava (1985b) the presence of 0.4M lithium sulphate in the assay mix is 
essential for the full expression of AR activity. Lithium sulphate was not added in the 
assay mix and therefore its effect, if any, on the outcome of the study is not known. 
The repeatability of the AR activity determination for individual diabetics with 
differing degrees of neuropathy is also not known. It would be useful to repeat the 
experiment, with the inclusion of lithium sulphate, before the erythrocyte AR activity 
model is rejected as a possible diagnostic test. Therefore, further work is required to 
establish the erythrocyte AR activity assay conditions and to determine its use as a 
diagnostic aid to neuropathy.
According to Ghahary et al., (1989) there is no convincing data demonstrating that AR 
activity is increased in diabetic tissues. However, they have demonstrated that renal AR 
activity in the streptozotocin-induced diabetic rat is increased and accompanied by 
increased messenger RNA levels coding for aldose reductase. Consequently, in the 
future there is the possibility of using gene probes, in appropriate cells or biopsy 
material, for diagnostic purposes which would replace assessment of AR activity by 
enzymatic assays.
In summary, the enzyme assay has been validated and found to be useful for 
determining the sorbitol levels in diabetic subjects. In particular the assay, at this stage
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of its development, was sensitive enough to determine gross changes in the erythrocyte 
sorbitol levels both in-vivo and in-vitro. Considering the ability of the assay to achieve 
this it may now be of most use as a screening assay for routine hospital laboratory use. 
It would not be difficult to adapt the conditions of the assay to produce a kit that could 
be used under standard conditions. If the new preparation of SDH, mentioned above, 
is truely mono specific for sorbitol it would be the best choice for turning into a 
diagnostic kit. This would provide the clinician with a front line cost effective 
screening test for sorbitol levels as an indicator of aldose reductase activity until more 
refined biochemial diagnostic tests become available. The application of such a test 
would be best utilised at the early stage of diagnosis of diabetes with monitoring of 
individual erythrocyte sorbitol levels perhaps at yearly intervals.
Erythrocyte sorbitol determination used in conjunction with other tests already 
available, such as HbAlc determination, give the best possible chance of aiding the 
physician in detecting the early onset of diabetic complications. This is especially 
needed in the absence of obvious clinical signs of neuropathy. Indeed, when the clinical 
signs of overt neuropathy become apparent it is too late to change the course of 
medical management to avoid the condition. In the ideal world national screening 
programmes would be introduced to screen for AR activity but this is unlikely in the 
present economic climate. By contrast it is recommended that the capillary GLC 
method is the tool of choice for research into the polyol and sugar changes occurring 
in diabetes.
In conclusion, the results of this work support the hypothesis that erythrocyte sorbitol 
levels are raised in diabetics abcve normal. Therapy with Sorbinil does lower diabetic 
erythrocyte sorbitol levels to whhin the normal non-diabetic range and that in normals
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this range is very consistent. Both good glycaemic control of diabetics and whatever 
therapy is currently available to them should be used to achieve consistent erythrocyte 
sorbitol levels similar to normals. It is recommended that sorbitol levels should be 
monitored at an early stage at the onset of initial diagnosis of diabetes. If this is done 
then the long term management of diabetes may help to safegaurd those who are at 
most risk of developing the long term complications associated with this condition.
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